



Padova
CENTRO CONGRESSI,
PADOVA CONGRESS

No boundaries in Infection Research and Care

Con il Patrocinio di



Promosso da



e da

INMI, Istituto Nazionale per le Malattie Infettive
Lazzaro Spallanzani IRCCS

ISS, Istituto Superiore di Sanità

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia

Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle
Malattie Sessualmente Trasmissibili

SITA, Società Italiana per la Terapia Antinfettiva
Antibatterica Antivirale Antifungina

SIV-ISV, Società Italiana di Virologia - Italian Society
for Virology

ANLAIDS, Associazione Nazionale per la Lotta
contro l'AIDS ETS

ARCIGAY, Associazione LGBTQIA+ Italiana APS

ARCOBALENO Aids ODV

ASA, Associazione Solidarietà AIDS-ODV

C.I.C.A., Coordinamento Italiano delle case alloggio
per persone con HIV/AIDS ETS

EpaC, Associazione EpaC ETS

LILA, Lega Italiana per la Lotta contro l'AIDS Onlus

Mario Mieli, Circolo Cultura Omosessuale Mario
Mieli APS

Milano Checkpoint, Associazione Milano
Checkpoint ETS

NADIR, Associazione Nadir ETS

NPS Italia, Network Persone Sieropositive APS

PLUS, Rete persone LGBT+ sieropositive APS

Scientific Program

Seguici su



www.icar2025.it



The 2025 edition of the ICAR Congress dedicates
two special moments to **Giampiero Carosi** and **Massimo Oldrini**
who will be remembered during the Conference days:

Massimo Oldrini on **May 22** at **09.00 a.m.** in Sala Plenaria Mantegna by Alessandra Cerioli
Giampiero Carosi on **May 23** at **09.00 a.m.** in Sala Plenaria Mantegna by Francesco Castelli



Official Journal of the Conference:

Sexually Transmitted Infections

<https://sti.bmj.com/>

will publish an online Supplement containing the ICAR 2025 selected Abstracts, available from June 16, 2025

Sede Congressuale

Padova Congress

Via N. Tommaseo 59, 35131 Padova

Provider e Segreteria Organizzativa

Effetti srl

Via G.B. Giorgini 16, 20151 Milano

Tel. +39 02 3343281 - Fax +39 02 38002105 - icar@effetti.it - @ICARcongress

Seguici su



www.icar2025.it

Endorsement

ISTITUTIONS



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



REGIONE DEL VENETO
Azienda
Ospedale
Università
Padova



UNIVERSITÀ
DEGLI STUDI
DI MILANO



UniSR
Università Vita-Salute
San Raffaele

Sistema Socio Sanitario
Regione
Lombardia
ASST Ovest Milanese



SCIENTIFIC SOCIETIES

AISF, Associazione Italiana per lo Studio del Fegato

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

SIM, Società Italiana di Microbiologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

SIMIT, Società Italiana di Malattie Infettive e Tropicali

SITA, Società italiana per la Terapia Antinfettiva

SIV-ISV, Società Italiana di Virologia - Italian Society for Virology

PATIENTS' AND COMMUNITY ASSOCIATIONS

ANLAIDS, Associazione Nazionale per la Lotta contro l'AIDS ETS

ARCIGAY, Associazione LGBTQIA+ Italiana APS

ARCOBALENO Aids ODV

ASA, Associazione Solidarietà AIDS-ODV

C.I.C.A., Coordinamento Italiano delle case alloggio per persone con HIV/AIDS ETS

Differenza Lesbica, Associazione Arci, culturale laica, antifascista, antirazzista per le donne lesbiche, bisessuali, transessuali

EpaC, Associazione EpaC ETS

Fondazione Villa Maraini ETS, Agenzia Nazionale di Croce Rossa Italiana per la cura delle dipendenze patologiche

Gay Center/Gay Help Line, casa di tutte le persone LGBT+ (lesbiche, gay, bisex e trans)

LILA, Lega Italiana per la Lotta contro l'AIDS Onlus

Mario Mieli, Circolo Cultura Omosessuale Mario Mieli APS

Milano Checkpoint, Associazione Milano Checkpoint ETS

NADIR, Associazione Nadir ETS

NPS Italia, Network Persone Sieropositive APS

PLUS, Rete persone LGBT+ sieropositive APS

ICAR Government Bodies

Direttivo ICAR

President

Antonella Castagna, Milano

Secretary

Nicoletta Frattini, Milano

Members

Andrea Antinori, Roma

Annamaria Cattelan, Padova

Andrea Cossarizza, Modena

Vincenzo Esposito, Napoli

Giuseppina Giupponi, Como

Sergio Lo Caputo, Foggia

Roberto Parrella, Napoli

Barbara Suligoi, Roma

Maurizio Zazzi, Siena

SPC (Scientific Programme Committee)

Goffredo Angioni, Cagliari

Andrea Antinori, Roma

Guido Antonelli, Roma

Matteo Bassetti, Genova

Paolo Bonfanti, Monza

Arnaldo Caruso, Brescia

Antonio Cascio, Palermo

Antonella Castagna, Milano

Francesco Castelli, Brescia

Annamaria Cattelan, Padova

Giovanni Cenderello, Sanremo IM

Massimo Clementi, Milano

Andrea Cossarizza, Modena

Marco Cusini, Milano

Antonella d'Arminio Monforte, Milano

Antonio Di Biagio, Genova

Giovanni Di Perri, Torino

Vincenzo Esposito, Napoli

Antonina Franco, Siracusa

Enrico Girardi, Roma

Andrea Gori, Milano

Chiara Iaria, Palermo

Massimiliano Lanzafame, Trento

Sebastiano Leone, Avellino

Sergio Lo Caputo, Foggia

Paolo Maggi, Enna

Franco Maggiolo, Fabriano

Marina Malena, Rovigo

Elio Manzillo, Napoli

Giulia Carla Marchetti, Milano

Claudio Maria Mastroianni, Roma

Giovanni Mazzola, Caltanissetta

Cristina Mussini, Modena

Giuseppe Nunnari, Catania

Saverio Parisi, Padova

Roberto Parrella, Napoli

Giustino Parruti, Pescara

Carlo Federico Perno, Roma

Stefania Piconi, Lecco

Alessandra Prozzo, Campobasso

Massimo Puoti, Milano

Stefano Rusconi, Legnano MI

Guido Silvestri, Atlanta, USA

Barbara Suligoi, Roma

Marcello Tavio, Ancona

Carlo Torti, Roma

Maurizio Zazzi, Siena

CsC (Community sub-Committee)

Massimiliano Conforti, Roma

Marco Falaguasta, Padova

Massimo Farinella, Roma

Nicoletta Frattini, Milano

Giuseppina Giupponi, Como

Sandro Mattioli, Bologna

Paolo Meli, Bergamo

Ada Moznich, Milano

Stefano Patrucco, Torino

Ilenia Pennini, Padova

Filippo Schloesser, Roma

Comitato Scientifico

Presidenza del Congresso

Annamaria Cattelan, Padova
Paolo Meli, Bergamo
Saverio Parisi, Padova
Stefano Rusconi, Legnano MI

Presidente ICAR

Antonella Castagna, Milano

Coordinatore Abstract

Antonio Di Biagio, Genova

Segreteria Scientifica

Chiara Agrati, Roma
Mara Biasin, Milano
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Alberto Borghetti, Pisa
Andrea Calcagno, Torino
Salvatore Cecere, Bologna
Benedetto Maurizio Celesia, Catania
Antonella Cingolani, Roma
Luna Colagrossi, Roma
Nicola Coppola, Napoli

Gabriella d'Ettore, Roma
Simona Di Giambenedetto, Roma
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Andrea Giacomelli, Milano
Nicola Gianotti, Milano
Giovanni Guaraldi, Modena
Miriam Lichtner, Roma
Giordano Madeddu, Sassari
Fabrizio Maggi, Roma
Paolo Maggi, Enna
Giulia Carla Marchetti, Milano
Maria Mazzitelli, Padova

Valentina Mazzotta, Roma
Valeria Micheli, Milano
Ada Moznich, Milano
Silvia Nozza, Milano
Ilenia Pennini, Padova
Annalisa Perziano, Torino
Roberto Rossotti, Milano
Maria Santoro, Roma
Annalisa Saracino, Bari
Valentina Svicher, Roma
Lucia Taramasso, Genova
Giusy Tiseo, Pisa

Segreteria Corsi pregressuali

Alberto Borghetti, Pisa
Daniele Calzavara, Milano

Maria Aurora Carleo, Napoli
Marta Chiuchiarelli, Roma
Andrea De Vito, Sassari
Alessia Frater, Roma

Alessia Lai, Milano
Mariacristina Poliseno, Bari
Vincenzo Spagnuolo, Milano

Comitato Annuale di Programma (CAP)

Massimo Andreoni, Roma
Andrea Antinori, Roma
Guido Antonelli, Roma
Andrea Cossarizza, Modena
Vincenzo Esposito, Napoli
Marco Falcone, Pisa

Massimo Farinella, Roma
Nicoletta Frattini, Milano
Giuseppina Giupponi, Como
Andrea Gori, Milano
Sergio Lo Caputo, Foggia
Franco Maggiolo, Fabriano TR
Cristina Mussini, Modena
Giuseppe Nunnari, Catania

Roberto Parrella, Napoli
Carlo Federico Perno, Roma
Massimo Puoti, Milano
Loredana Sarmati, Roma
Barbara Suligoi, Roma
Carlo Torti, Roma
Maurizio Zazzi, Siena

Faculty

Chiara Agrati, Roma
Massimo Andreoni, Roma
Paolo Angeli, Padova
Andrea Antinori, Roma
Spinello Antinori, Milano
Guido Antonelli, Roma
Fausto Baldanti, Pavia
Francesco Barbaro, Padova
Monica Basso, Padova
Linda-Gail Bekker, Cape Town ZA
Dario Bernacchia, Legnano MI
Alessandra Maria Bianchi, Milano
Mara Biasin, Milano
Elisa Biliotti, Roma
Teresa Bini, Milano
Cecilia Maria Bonazzetti, Bologna
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Alberto Borghetti, Pisa
Giorgio Bozzi, Milano
Bianca Bruzzone, Genova
Alfonso Cabello Úbeda, Madrid ES
Andrea Calcagno, Torino
Annapaola Callegaro, Milano
Giulia Valeria Calvino, Roma
Leonardo Calza, Bologna
Daniele Calzavara, Milano
Diana Canetti, Milano
Maria Aurora Carleo, Napoli
Dante Carraro, Padova
Enrico Caruso, Milano
Antonio Cascio, Palermo
Antonella Castagna, Milano
Francesco Castelli, Brescia
Annamaria Cattelan, Padova
Francesca Ceccherini Silberstein, Roma
Salvatore Cecere, Bologna
Benedetto Maurizio Cesia, Catania
Alessandra Cerioli, Bologna
Massimo Cernuschi, Milano
Adriana Cervo, Modena
Marta Chiuchiarrelli, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Michela Cinquini, Milano
Nicola Clementi, Milano
Luna Colagrossi, Roma
Massimiliano Conforti, Torino
Nicola Coppola, Napoli

Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Alessandro Cozzi-Lepri, London UK
Davide Croce, Castellanza VA
Antonella d'Arminio Monforte, Milano
Gabriella d'Ettore, Roma
Anita De Rossi, Padova
Andrea De Vito, Sassari
Vito Leonardo del Negro, Roma
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Giovanni Di Perri, Torino
Vincenzo Esposito, Napoli
Stefano Fagioli, Bergamo
Marco Falcone, Pisa
Massimo Farinella, Roma
Benedetta Fioretti, Brescia
Emanuele Focà, Brescia
Alessia Frater, Roma
Nicoletta Frattini, Milano
Francesco Maria Fusco, Napoli
Roberta Gagliardini, Roma
Monica Gandhi, San Francisco USA
Ivan Gentile, Napoli
Anna Maria Geretti, Roma
Simonetta Gerevini, Bergamo
Cristina Gervasoni, Milano
Andrea Giacomelli, Milano
Vania Giacometti, Milano
Nicola Gianotti, Milano
Mario Giobbia, Treviso
Enrico Girardi, Roma
Nicolò Girometti, London UK
Giuseppina Giupponi, Como
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Marco Iannetta, Roma
Maria Rosaria Iardino, Milano
Chiara Iaria, Palermo
Alessia Lai, Milano
Pietro Lampertico, Milano
Adriano Lazzarin, Milano
Agnes Libois, Bruxelles BE
Miriam Lichtner, Roma
Sergio Lo Caputo, Foggia
Francesca Lombardi, Roma
Giordano Madeddu, Sassari
Paolo Maggi, Enna
Fabrizio Maggi, Roma

Franco Maggiolo, Fabriano TR
Giulia Carla Marchetti, Milano
Giulia Martelli, Forlì
Claudio Maria Mastroianni, Roma
Sandro Mattioli, Bologna
Maria Mazzitelli, Padova
Valentina Mazzotta, Roma
Paolo Meli, Bergamo
Marianna Meschiari, Modena
Valeria Micheli, Milano
Luca Miele, Roma
Jovana Milic, Modena
Annalisa Mondì, Roma
Davide Moschese, Milano
Ada Moznich, Milano
Camilla Muccini, Milano
Cristina Mussini, Modena
Silvia Nozza, Milano
Giuseppe Nunnari, Catania
Giancarlo Orofino, Torino
Saverio Parisi, Padova
Stefano Patrucco, Torino
Ilenia Pennini, Padova
Carlo Federico Perno, Roma
Annalisa Perziano, Torino
Daniela Piacentini, Belluno
Paolo Piana, Milano
Matteo Pirro, Perugia
Mariacristina Polisenò, Bari
Anton Pozniak, London UK
Massimo Puoti, Milano
Laura Rancilio, Milano
Diego Ripamonti, Bergamo
Agostino Riva, Milano
Roberto Rossotti, Milano
Stefano Rusconi, Legnano MI
Francesca Russo, Venezia
Francesco Paolo Russo, Padova
Francesco Saladini, Siena
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Lolita Sasset, Padova
Vincenzo Spagnuolo, Milano
Laura Sticchi, Genova
Barbara Suligoi, Roma
Valentina Svicher, Roma
Lucia Taramasso, Genova
Alessandro Tavelli, Milano

Camilla Tincati, Milano
Giusy Tiseo, Pisa
Carlo Torti, Roma
Mario Tumbarello, Siena

Ombretta Turriziani, Roma
Emanuela Vaccher, Aviano PN
Francesca Venturini, Padova
Ilaria Vicenti, Siena

Pietro Vinti, Milano
David Alain Wohl, Chapel Hill CN
Maurizio Zazzi, Siena

Abstract Reviewers

Isabella Abbate, Roma
Chiara Agrati, Roma
Claudia Alteri, Milano
Guido Antonelli, Roma
Daniele Armenia, Roma
Lorenzo Badia, Imola BO
Alessandra Bandera, Milano
Dario Bernacchia, Legnano MI
Mara Biasin, Milano
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Alberto Borghetti, Pisa
Giorgio Bozzi, Milano
Bianca Bruzzone, Genova
Andrea Calcagno, Torino
Annapaola Callegaro, Milano
Antonella Castagna, Milano
Dario Cattaneo, Milano
Manuela Ceccarelli, Enna
Francesca Ceccherini Silberstein, Roma
Salvatore Cecere, Bologna
Benedetto Maurizio Celesia, Catania
Giovanni Cenderello, Sanremo IM
Massimo Cernuschi, Milano
Stefania Cicalini, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Luna Colagrossi, Roma
Federico Conti, Lecco
Nicola Coppola, Napoli
Maria Luisa Cosmaro, Milano

Andrea Cossarizza, Modena
Alessandro Cozzi-Lepri, London UK
Gabriella d'Ettore, Roma
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Marco Falaguasta, Padova
Massimo Farinella, Roma
Carlo Ferrari, Parma
Giorgia Fracca, Milano
Nicoletta Frattini, Milano
Roberta Gagliardini, Roma
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Andrea Giacomelli, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Simone Lanini, Udine
Miriam Lichtner, Roma
Giuseppina Liuzzi, Roma
Sergio Lo Caputo, Foggia
Lucia Lopalco, Milano
Giordano Madeddu, Sassari
Fabrizio Maggi, Roma
Paolo Maggi, Enna
Franco Maggiolo, Fabriano TR
Giulia Carla Marchetti, Milano
Maria Mazzitelli, Padova
Valentina Mazzotta, Roma
Valeria Micheli, Milano

Davide Moschese, Milano
Silvia Nozza, Milano
Giuseppe Nunnari, Catania
Giancarlo Orofino, Torino
Ilenia Pennini, Padova
Annalisa Perziano, Torino
Laura Pezzati, Legnano MI
Carmela Pinnetti, Roma
Pierluca Piselli, Roma
Massimo Puoti, Milano
Diego Ripamonti, Bergamo
Roberto Rossotti, Milano
Francesco Saladini, Siena
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Lolita Sasset, Padova
Vincenzo Spagnuolo, Milano
Nicola Squillace, Monza
Barbara Suligoi, Roma
Valentina Svicher, Roma
Lucia Taramasso, Genova
Camilla Tincati, Milano
Giusy Tiseo, Pisa
Carlo Torti, Roma
Daria Lucia Trabattoni, Milano
Ombretta Turriziani, Roma
Alessandra Vergori, Roma
Ilaria Vicenti, Siena
Maurizio Zazzi, Siena

Care Colleghe e Colleghi,

E' con orgoglio che vi diamo il benvenuto a **Padova** in occasione del **17° Congresso Nazionale ICAR**.

No boundaries in Infection Research and Care è il claim che sostiene questa nuova edizione del Congresso e che caratterizza il programma scientifico, promuovendo un approccio multidisciplinare e collaborativo che vede la sinergia tra ricerca di base e traslazionale per rispondere alle sfide cliniche emergenti in infettivologia.

L'obiettivo è di creare un collegamento tra laboratorio e paziente, per una comprensione più approfondita delle malattie e dei meccanismi che la causano, identificando marcatori genetici o biologici che consentano di guidare trattamenti personalizzati e mirati per ciascun individuo. Inoltre si mira a sviluppare interventi a livello individuale, comunitario e sociale che promuovano strategie preventive aggiornate ed efficaci per migliorare la qualità di vita delle persone. Con questo spirito, intendiamo stimolare il confronto tra le diverse figure della grande comunità che gravita intorno ad ICAR, rappresentata da medici, ricercatori, personale paramedico, operatori di sanità pubblica, associazioni dei pazienti, attivisti e società civile.

Nelle tre giornate congressuali – caratterizzate da un **approccio abstract driven** – vengono affrontate alcune delle principali tematiche infettivologiche di rilevanza globale, con attenzione ad argomenti in materia di qualità della vita, la sostenibilità, il ruolo della società civile e con l'obiettivo di valorizzare la ricerca, far emergere nuove idee e condividere buone prassi. Un'attenzione particolare è rivolta alle nuove generazioni di medici e ricercatori con l'obiettivo di promuovere e valorizzare le loro competenze e favorire il senso di appartenenza alla comunità scientifica al fine di contribuire ad un futuro di eccellenza nella ricerca e cura delle infezioni. In questo contesto, abbiamo lanciato il **Premio TRIS** finalizzato a premiare i migliori manoscritti di autori italiani pubblicati nel 2024 su riviste internazionali indicizzate sulle tematiche proprie del Congresso ICAR.

In tema di prevenzione e salute pubblica, ICAR offre alla cittadinanza la possibilità di effettuare gratuitamente **test rapidi per HIV, HBV, HCV e Sifilide**, durante tutti i giorni del Congresso, in collaborazione con l'Azienda Ospedaliera di Padova, Croce Rossa Italiana e Fondazione Carlo Foresta.

Un ringraziamento speciale va alla Segreteria Scientifica, al Coordinatore Abstract ed ai Revisori, agli Organismi di Governo ICAR, a SIMIT, alle Associazioni Pazienti e di Comunità, alle Istituzioni e Società Scientifiche, agli Studenti, le Scuole e le Giurie del Concorso RaccontART, al Comune di Padova ed, infine, agli Sponsor che ci hanno consentito di ospitare centinaia di partecipanti.

Continuate a seguirci sul **sito** e anche sui **social** per tutti gli aggiornamenti.

Buon Congresso a tutti!

Nice to ICAR you!

I Presidenti



Annamaria
Cattelan



Paolo
Meli



Saverio
Parisi



Stefano
Rusconi

ORARI	SALA PLENARIA MANTEGNA	SALA MANTEGNA MEDIA	SALA CARRARESI	SALA ANTENORE	SALA DONATELLO
14.00 16.30	SPECIAL SESSION RaccontART Contest Awards: incontro con le scuole finaliste e premiazione	PRE-CONFERENCE ADVANCED COURSE Opportunistic infections in HIV: current insights and evolving strategies	PRE-CONFERENCE ADVANCED COURSE From data to care: redefining patient-reported outcomes to measure well-being	PRE-CONFERENCE ADVANCED COURSE Navigating the complexities: clinical and diagnostic challenges in HTE	PRE-CONFERENCE ADVANCED COURSE Stats don't lie! How to believe in numbers
	SALA PLENARIA MANTEGNA				
17.00 18.00	SATELLITE SYMPOSIUM Pioneers in HIV prevention with long-acting in PrEP				
18.00 20.10	ICAR 2025 OPENING SESSION Chairs: A. Cattelan, P. Meli, S. Parisi, S. Rusconi 18.00-18.15 Introducing ICAR 2025: Chairs' welcome addresses 18.15-18.45 Authorities' welcome addresses 18.45-19.00 RaccontART: the three Winners A. Lazzarin Keynote Lectures Chair: A. Castagna 19.00-19.30 Mauro Moroni Memorial Lecture: "HIV suppression for all: against all odds" M. Gandhi Chair: L. Rancilio 19.30-20.00 Giulio Maria Corbelli Memorial Lecture: "Cancer in PWH, from real life to clinical trials: bridging the gaps in science and care" A. Cerioli 20.00-20.10 Closing remarks Chairs: A. Cattelan, P. Meli, S. Parisi, S. Rusconi				

 CONFERENCE SESSIONS	 SYMPOSIUM - EXPERT MEETING	 SPONSORED SESSIONS	 POSTER VIEWING
 ORAL COMMUNICATIONS	 SHORT COMMUNICATIONS	 PARALLEL SESSIONS	

LUNCH TIME 12.30-14.30

ORARI	SALA PLENARIA MANTEGNA	SALA MANTEGNA MEDIA	SALA CARRARESI	SALA ANTENORE	SALA DONATELLO	SALA PETRARCA
09.00 10.00	Keynote Lectures P. Angeli and A. Libois					
10.05 11.05	SATELLITE SYMPOSIUM Shaping the future of HIV: managing the present for revolutionary change				SHORT COMMUNICATIONS HIV 2025: disparities and trajectories	
11.10 12.10	SYMPOSIUM Empowering immunity: breakthroughs in antiviral research	SYMPOSIUM The challenging path towards HBV/HDV cure and the management of MAFLD	SATELLITE EXPERT MEETING-ROUND TABLE Solution for cardio-metabolic management of HIV therapy: the key role of doravirine	ORAL COMMUNICATIONS The statins breakthrough in HIV management	SHORT COMMUNICATIONS ART and comorbidities	
12.15 13.15	SATELLITE SYMPOSIUM Sharing experiences: discussing current hot topics in 2-drug regimens	ORAL COMMUNICATIONS The evolving tale of HIV: shifting patterns, emerging HIV care	SATELLITE EXPERT MEETING Chronic viral hepatitis screening: strategies for early diagnosis and optimal management	SYMPOSIUM Informed consent for HIV testing: it's time for changing	SHORT COMMUNICATIONS Open issues in virology and pharmacology	
	13.20-14.00 Poster Viewing with Authors in the dedicated multimedia areas					
13.30 14.00	SPECIAL SESSION TRIS (Top Researchers ICAR-SIMIT) Awards 2025					
14.05 15.05	SYMPOSIUM Persistent HIV replication: an unsolved issue		ORAL COMMUNICATIONS Long acting PrEP in clinical practice	SYMPOSIUM The HIV cure: where is the research and why don't we have it yet?	14.00-14.30 SPECIAL SESSION DONNA ICAR 2025 e Progetto CARPHA3	
15.10 16.10	SYMPOSIUM Challenges and unmet needs in immunocompromised patients	14.30-15.55 ORAL COMMUNICATIONS Defining immune correlates in the context of ART and vaccination	SATELLITE SYMPOSIUM AND ORAL COMMUNICATIONS Optimizing HIV infection management in Italian clinical practice		14.35-15.05 LECTURE Management of Clostridioides difficile infection	
16.15 17.30	SYMPOSIUM Filling the gaps of antiretroviral therapy: preparing for the future	SPECIAL SESSION Optimising Protection: vaccinations for people living with HIV	ORAL COMMUNICATIONS From virus variability to disease and treatment	ORAL COMMUNICATIONS Beyond viral suppression: rethinking quality of life in HIV care	16.15-17.25 SHORT COMMUNICATIONS Deep insights in two-drug antiretroviral regimen	16.15-17.15 PARALLEL SESSION Investigators' Meeting PrIDE

LUNCH TIME 12.30-14.30

ORARI	SALA PLENARIA MANTEGNA	SALA MANTEGNA MEDIA	SALA CARRARESI	SALA ANTENORE	SALA DONATELLO	SALA PETRARCA
09.00 10.00	Keynote Lectures G. Guaraldi and F. Baldanti					PARALLEL SESSION Fast-Track Cities Meeting
10.05 11.05	SATELLITE SYMPOSIUM Renewed vaccines for a continuous and effective protection		SATELLITE EXPERT MEETING Switch to Bictegravir/ FTC/TAF in persons with HIV on double-drug INSTI-based ART: data from the ICONA Cohort	ORAL COMMUNICATIONS Durability of long-acting ART	GRAND ROUND CLINICAL CASES	PARALLEL SESSION MIYA MIYA, riflessioni da uno scoglio di confine
11.10 12.10	SATELLITE SYMPOSIUM Is the long-acting transformation at the right pace?	ORAL COMMUNICATIONS Building connections across care, prevention and education	SATELLITE EXPERT MEETING Antibiotic therapy: microbiological and clinical challenges		SYMPOSIUM Initiatives on infectious diseases in Low-Middle Income Countries: the Italian experience on cooperation and development	
12.15 13.15	SYMPOSIUM PrEP: a commitment and a challenge	ORAL COMMUNICATIONS Clinical HIV insights	ORAL COMMUNICATIONS The long-acting ART landscape in Italy	SYMPOSIUM Sustainability of antiretrovirals in a landscape of finite economic resources	ORAL COMMUNICATIONS Advances in viral pathogenesis	PARALLEL SESSION GEPO Meeting
	13.20-14.00 Poster Viewing with Authors in the dedicated multimedia areas					
14.00 15.00	SYMPOSIUM HIV across the lifespan: from AIDS to ageing	ORAL COMMUNICATIONS Long-term effectiveness of oral ART	ORAL COMMUNICATIONS Access to prevention in different settings	ORAL COMMUNICATIONS HIV and comorbidities	ORAL COMMUNICATIONS Diagnosis, prevalence and prevention of STIs	PARALLEL SESSION PRESTIGIO Registry Meeting
15.05 16.05	SYMPOSIUM Getting to zero in difficult- to-reach populations	ORAL COMMUNICATIONS ARV drugs from prevention to treatment	ORAL COMMUNICATIONS PrEP issues: adherence and STI	SHORT COMMUNICATIONS From epidemiology to innovation: vaccine coverage and viral pathogenesis	SHORT COMMUNICATIONS Challenges in prevention	
16.10 16.35	SPECIAL SESSION ICAR 2025 Awards and closing remarks					



Padova
CENTRO CONGRESSI,
PADOVA CONGRESS

No boundaries in Infection Research and Care

PRE-CONFERENCE ADVANCED COURSES



**PRE-CONFERENCE ADVANCED COURSE** 14.00-16.30**SALA MANTEGNA MEDIA****Opportunistic infections in HIV: current insights and evolving strategies****Chairs and Discussants:** Maria Aurora Carleo (Napoli), Mariacristina Poliseni (Bari)

The availability of antiretroviral therapies characterized by high efficacy and safety has completely changed the prognosis of HIV infection, allowing good immunological recovery for patients with HIV. Nevertheless, due to the high rate of patients receiving a late-stage diagnosis, the proportion of those presenting with opportunistic diseases, either concurrently with or following diagnosis, has increased over the years. This pre-congress course aims to explore the state of the art regarding opportunistic infections and HIV-related diseases from both an epidemiological and clinical perspective and to provide updated guidelines on diagnosis, treatment, and prophylaxis for these conditions

- | | | |
|-------------|--|--|
| 14.00-14.30 | Opportunistic infections from 1981 to today: has something changed? | A. Mondì, Roma |
| 14.30-15.00 | Updates in the clinical management and prophylaxis of opportunistic infections | G. Bozzi, Milano |
| 15.00-15.30 | The changing face of HIV-associated malignancies: advances, opportunities and future directions | E. Vaccher, Aviano PN |
| 15.30-16.00 | Vaccination in HIV-infected adults could help us to prevent opportunistic infections? | F.M. Fusco, Napoli |
| 16.00-16.30 | Discussion led by Chairs | M.A. Carleo, Napoli; M. Poliseni, Bari |

**PRE-CONFERENCE ADVANCED COURSE** 14.00-16.30**SALA CARRARESI****From data to care: redefining patient-reported outcomes to measure well-being****Chairs and Discussants:** Daniele Calzavara (Milano), Marta Chiuchiarelli (Roma), Alessia Frater (Roma)

As long-term management of people with HIV (PWH) evolves, direct contact with healthcare providers becomes less frequent, risking the neglect of important aspects of the individual's life. Patient-Reported Outcomes (PROs) can bridge these gaps, providing a proactive tool to monitor the quality of life and well-being of PWH. The spread of apps facilitates the use of PROs in clinical practice, turning them into a communication channel that can signal critical issues in real time. This course aims to stimulate a debate to explore how PROs can become increasingly effective, if possible to enhance continuity of care and the centrality of the individual in their healthcare journey.

- | | | |
|-------------|---|---|
| 14.00-14.20 | Understanding patient-centered care: an introduction to PROs, PROMs e QoL | A. Cingolani, Roma |
| 14.20-14.35 | The use of PROs in clinical research: the experience of ICONA Project | A. Tavelli, Milano |
| 14.35-14.50 | PROs at service of PWH. The use of multiface App as an intervention tool | B. Fioretti, Brescia |
| 14.50-15.05 | PROs in real life: clinical cases and implications for practice | J. Milic, Modena |
| 15.05-15.35 | Back to the patient: from the current point of view to the role of the community | G.V. Calvino, Roma; V.L. del Negro, Roma |
| 15.35-16.30 | Discussion led by Chairs | D. Calzavara, Milano; M. Chiuchiarelli, Roma; A. Frater, Roma |


PRE-CONFERENCE ADVANCED COURSE 14.00-16.30

SALA ANTENORE
Navigating the complexities: clinical and diagnostic challenges in HTE
Chairs and Discussants: Alessia Lai (Milano), Vincenzo Spagnuolo (Milano)

In Italy, about 90% of people living with HIV (PWH) on treatment have a suppressed viral load. However, highly treatment-experienced (HTE) PWH, who represent 1-10% of all PWH, are at higher risk of virological failure and clinical progression. In addition, HTE PWH often require complex regimens with multiple drugs and multiple routes of administration, increasing the risk of drug interactions and adverse events. Prolonged ART exposure leads to accumulated toxicities and, in combination with ageing and inflammation, increases the risk of metabolic and oncological comorbidities. This course will review strategies for optimising ART in this population, focusing on the role of resistance testing in guiding treatment decisions. It will also discuss the role of new drugs with novel mechanisms of action that offer promising solutions to overcome resistance and simplify regimens for this challenging population.

14.00-14.20 **Clinical challenges of HTE – How I manage MDR-HIV** R. Gagliardini, Roma

14.20-14.40 **Diagnostic/virological challenges of HTE – Insight on drug resistance to antiretrovirals from new drug classes** F. Saladini, Siena

14.40-15.00 **Current and future perspectives in HIV drug resistance monitoring** N. Clementi, Milano

15.00-15.20 **Suppressed HTE-MDR PWH: a plunge in the HIV-DNA reservoir** F. Lombardi, Roma

15.20-15.40 **Clinical case – How would you manage HIV-MDR? An interactive clinical case** M. Mazzitelli, Padova

An elderly male with long-standing HIV infection presented with viro-immunological stability but extensive multimorbidity, including chronic kidney disease (stage 3b), ischemic heart disease, and osteoporosis. He presented also an HBV coinfection. His antiretroviral history revealed multiple treatment failures, harboring resistance mutations to both NRTIs, INI, and NNRTIs, as well as partial minor to PIs. He was on a complex regimen comprising multiple agents with potential for drug-drug interactions and cumulative toxicity. Due to frailty, polypharmacy, and declining renal function, a regimen simplification was required. After resistance-guided optimization, he was transitioned to a dual therapy with boosted darunavir and lamivudine, achieving sustained viral suppression and improved tolerability. This case highlights the challenge of balancing efficacy and safety in elderly people living with multidrug-resistant HIV and multimorbidity.

15.40-16.30 **Discussion led by Chairs** A. Lai, Milano; V. Spagnuolo, Milano

PRE-CONFERENCE ADVANCED COURSE 14.00-16.30

SALA DONATELLO
Stats don't lie! How to believe in numbers
Chairs and Discussants: Alberto Borghetti (Pisa), Andrea De Vito (Sassari)

The rapid evolution of HIV research requires a solid understanding of advanced statistical methods to interpret complex data accurately. This pre-conference course is designed to deepen researchers' understanding of advanced statistical methods and how they can be applied to drive more robust HIV studies. Through expert-led discussions, attendees will explore the principles of causality, strategies to mitigate bias in observational studies, the risks embedded in clinical trials, and the synthesis of evidence through meta-analyses and systematic reviews. Participants will gain practical insights to elevate their research design and data interpretation, enabling them to make more informed and impactful contributions to the HIV research landscape.

14.00-14.25 **Causality or association? Decoding the links in HIV research** A. Cozzi-Lepri, London UK

14.25-14.35 **Discussion led by Chairs** A. Borghetti, Pisa; A. De Vito, Sassari

14.35-15.00 **Bias beware: strengthening observational studies with the trial emulation strategy** A. Giacomelli, Milano

15.00-15.10 **Discussion led by Chairs** A. Borghetti, Pisa; A. De Vito, Sassari

15.10-15.35 **All that glitters is not gold: the hidden risks in HIV clinical trials** A. Cervo, Modena

15.35-15.45 **Discussion led by Chairs** A. Borghetti, Pisa; A. De Vito, Sassari

15.45-16.10 **Meta-analyses and systematic reviews: synthesizing evidence for stronger HIV research** M. Cinquini, Milano

16.10-16.20 **Discussion led by Chairs** A. Borghetti, Pisa; A. De Vito, Sassari

16.20-16.30 **Final considerations** A. Borghetti, Pisa; A. De Vito, Sassari



No boundaries in Infection Research and Care

SCIENTIFIC PROGRAM



raccont

ART

UNDICESIMO
CONCORSO
ARTISTICO

Arti visive

Fashion
designArti
audiovisiveAltre
espressioni
letterarie

La Giuria Artistica

Nefeli Misuraca, Montatrice e regista di cortometraggi, Roma

Arianna Ninchi, Attrice, Roma

Cristina Piva, Assessora alle Politiche Educative e Scolastiche, Padova

Vincenzo Porcelli, Produttore cinematografico, Roma

Francesco Suriano, Scrittore di teatro, sceneggiatore e regista, Roma

La Giuria Tecnico-Scientifica

Giulia Valeria Calvino, Attivista, Roma

Annamaria Cattelan, Azienda Ospedale, Università degli Studi di Padova, Padova

Francesca Ceccherini Silberstein, Università degli Studi di Roma Tor Vergata, Roma

Massimo Cernuschi, ASA, Milano

Paola Maria Cinque, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano

Maria Luisa Cosmaro, LILA, Milano

Giovanni Del Bene, Esperto di prevenzione, Milano

Antonio Di Biagio, Ospedale Policlinico San Martino, Università degli Studi di Genova, Genova

Massimo Farinella, Circolo di Cultura Omosessuale Mario Mieli, Roma

Nicoletta Frattini, ASA, Milano

Rosario Galipò, ANLAIDS, Roma

Giuseppina Giupponi, LILA, Como

Adriano Lazzarin, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano

Donatella Mainieri, ANLAIDS, Milano

Paolo Meli, CICA - Don Giuseppe Monticelli Società Cooperativa Sociale - Bergamo Fast Track City, Bergamo

Silvia Nozza, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano

Saverio Parisi, Università degli Studi di Padova, Padova

Stefano Patrucco, ARCOBALENO Aids ODV, Torino

Stefano Rusconi, Ospedale Civile di Legnano - ASST Ovest Milanese, Università degli Studi di Milano, Legnano (MI)

Francesca Vichi, Ospedale Santa Maria Annunziata, Bagno a Ripoli (FI)

Donatello Zagato, ASA, Milano



SPECIAL SESSION 14.00-16.30

SALA PLENARIA MANTEGNA

"RACCONTART" CONTEST AWARDS: INCONTRO CON LE SCUOLE FINALISTE E PREMIAZIONE

Chairs: Francesca Ceccherini Silberstein (Roma), Paolo Meli (Bergamo)

Giunto all'undicesima edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV ed Infezioni Sessualmente Trasmesse. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.

14.00-14.30 **Benvenuto dei Presidenti ICAR 2025**

A. Cattelan, Padova; P. Meli, Bergamo
S. Parisi, Padova; S. Rusconi, Legnano MI

14.30-14.40 **Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica**

F. Ceccherini Silberstein, Roma
P. Meli, Bergamo

14.40-16.00 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**

16.00-16.15 **Premiazione dei primi 3 classificati**

A. Lazzarin, Milano

16.15-16.30 **Conclusioni**

F. Ceccherini Silberstein, Roma; P. Meli, Bergamo

Gli Istituti Scolastici finalisti

Liceo Artistico "Andrea Fantoni", Bergamo

ABF - Azienda Bergamasca Formazione, Bergamo

IIS "Caterina Caniana", Bergamo

IIS "Lorenzo Lotto", Trescore Balneario (BG)

ISIS Zenale e Butinone, Treviglio (BG)

Liceo Artistico "Lucio Fontana", Arese (MI)

IISS "M. K. Gandhi", Besana in Brianza (MB)

IPS "Ciro Pollini", Mortara (PV)

IIS "Ettore Majorana", San Lazzaro di Savena (BO)

ISIS "Leonardo da Vinci", Firenze

Liceo Artistico "Caravaggio", Roma

I.I.S. "Volterra Elia", Ancona

Liceo Scientifico "Leonardo Da Vinci", Jesi (AN)

**SATELLITE SYMPOSIUM** 17.00-18.00**SALA PLENARIA MANTEGNA****Pioneers in HIV prevention with long-acting in PrEP**

Chairs: Annamaria Cattelan (Padova), Cristina Mussini (Modena)

With an unrestricted educational grant from ViiV Healthcare

Long-acting pre-exposure prophylaxis (PrEP) marks a significant innovation in HIV prevention, being the first of its kind in the market. Unlike daily oral PrEP, long-acting PrEP offers extended protection with less frequent dosing, addressing adherence challenges and enhancing efficacy. This novel approach is particularly beneficial for individuals who struggle with daily medication due to inconsistent healthcare access, chaotic lifestyles, or stigma. This symposium will explore the clinical implications, safety, and effectiveness of long-acting PrEP, supported by recent studies and real Italian experience, discussing its potential to transform HIV prevention strategies to improve outcomes for high-risk populations.

17.00-17.05	Opening	A. Cattelan, Padova; C. Mussini, Modena
17.05-17.20	The unmet need of PrEP HIV	A. Antinori, Roma
17.20-17.35	The role of Cabotegravir in PrEP	A. Castagna, Milano
17.35-17.55	Roundtable:	Discussants: A. Antinori, Roma;
	The Italian experience with PrEP long-acting	A. Castagna, Milano; A. Gori, Milano
17.55-18.00	Closing and take home messages	A. Cattelan, Padova; C. Mussini, Modena



SPECIAL SESSION 18.00-20.10

SALA PLENARIA MANTEGNA

ICAR 2025 OPENING SESSION

Chairs: Annamaria Cattelan (Padova), Paolo Meli (Bergamo), Saverio Parisi (Padova), Stefano Rusconi (Legnano MI)

18.00-18.15

Introducing ICAR 2025: Chairs' welcome addresses

18.15-18.45

Authorities' welcome addresses

18.45-19.00

RaccontART: the three Winners A. Lazzarin, Milano

19.00-20.00

Keynote Lectures

Chair: Antonella Castagna (Milano)

19.00-19.30 Mauro Moroni Memorial Lecture

"HIV suppression for all: against all odds" M. Gandhi, San Francisco USA

The UNAIDS report for 2024 "AIDS at a Crossroads" discusses how there is a 72% virologic suppression rate among people living with HIV worldwide in 2023. We can and must do better to increase virologic suppression rates for people with HIV globally. There are three ways to do this and we will be discussing each of these interventions in this talk: one is to apply scalable and acceptable adherence interventions to increase adherence to the current INSTI-based regimens; the second is to use long-acting antiretroviral therapy (ART) among those with adherence challenges and viremia; and the third is to screen adequately for INSTI resistance worldwide as surveillance is revealing higher rates than we previously thought. This talk will cover adherence interventions, the exciting field of long-acting ART and INSTI resistance screening with the important goal of eventually getting people with HIV worldwide all virologically suppressed to achieve UNAIDS 95:95:95 targets and beyond.

Chair: Laura Rancilio (Milano)

19.30-20.00 Giulio Maria Corbelli Memorial Lecture

"Cancer in PWH, from real life to clinical trials:**bridging the gaps in science and care"** A. Cerioli, Bologna

Cancers remain a leading cause of morbidity and mortality among people with HIV (PWH), even in the era of combined antiretroviral therapy (cART). Despite this, PWH with cancer are excluded from the majority of innovative cancer clinical trials. As a result, cancer treatments are approved and used in clinical practice without efficacy and safety data specific to PWH. It is urgent to eliminate the serological exclusion criterion based solely on HIV status and replace it with inclusion criteria based on clinical factors, primarily the absence of AIDS, as recommended by the FDA in 2020 but still largely overlooked by clinical trial sponsors. There is a clear need for a systematic shift in current research practices to improve access to care for PWH and those with comorbidities. It is crucial to ensure that representatives from various stakeholder groups collaborate to raise awareness and foster a dialogue that contributes to this change. Concerted efforts and a multidisciplinary approach are essential to prevent inequalities in the treatment of PWH with cancer.

20.00-20.10

Closing remarks A. Cattelan, Padova; P. Meli, Bergamo; S. Parisi, Padova; S. Rusconi, Legnano MI

**KEYNOTE LECTURES** 09.00-10.00**SALA PLENARIA MANTEGNA**09.00-09.05 **In memory of Massimo Oldrini**

A. Cerioli, Bologna

Chair: Nicola Coppola (Napoli)

09.05-09.35 **Management of decompensated cirrhosis in people with HIV**

P. Angeli, Padova

Ascites is the most frequent decompensating event in patients with cirrhosis and HIV. Conditions associated to a transient or false lack of response to medical therapy should be always identified and possibly corrected in order to obtain a correct classification of ascites and optimize its medical management and avoid unnecessary invasive treatment options. Ascites can be classified according to the definitions proposed by the ICA and accepted by the major international guidelines. According to the amount of fluid accumulated in the abdominal cavity, ascites is graded into:

- Grade 1 or mild ascites: only detected by ultrasound
- Grade 2 or moderate ascites: moderate symmetric distension of abdomen
- Grade 3 or large/gross ascites: marked distension of the abdomen.

By applying a treatment-oriented perspective, ascites is classified into:

- Responsive ascites: ascites that can be fully mobilized or limited to grade 1 with diuretic therapy associated or not to moderate dietary sodium restriction or not to long term albumin infusion (LTA)
- Recidivant ascites: ascites that recurs at least on 3 occasions within a 12-month period despite dietary sodium restriction and adequate diuretic dosage
- Refractory ascites: ascites that cannot be mobilized or the early recurrence of which (i.e., after large-volume paracentesis) cannot be satisfactorily prevented by medical therapy
- Tips as well as LTA can be an option for patients with either recidivant or refractory ascites.

Chair: Franco Maggiolo (Fabro TR)

09.35-10.05 **How often to screen STIs in asymptomatic people at risk: challenges on individual and population levels**

A. Libois, Bruxelles BE

This lecture will discuss and challenge the general recommendation for frequent screening of asymptomatic men who have sex with men for *N. gonorrhea* and *C. trachomatis*, particularly PrEP users. It will explore the rationale for frequent testing, the impact on the prevalence and incidence of those infections and the consequences on antibiotic consumption and resistance. Finally, it will propose new recommendation for screening in this population.

**SATELLITE SYMPOSIUM** 10.05-11.05**SALA PLENARIA MANTEGNA****Shaping the future of HIV: managing the present for revolutionary change**

Chairs: Annamaria Cattelan (Padova), Stefano Rusconi (Legnano MI)

With an unrestricted educational grant from Gilead Sciences

HIV remains a significant global health challenge, underscoring the need for an integrated and personalized approach to ending the HIV epidemic. This symposium will address the latest advancements in both HIV prevention and treatment, with a particular focus on the importance of a comprehensive approach to prevention, as well as the crucial role of the genetic barrier and forgiveness in ensuring long-term treatment success for people living with HIV (PLWH). The session will explore how various preventive tools can significantly reduce HIV incidence, especially in high-risk populations, and ultimately contribute to ending the HIV epidemic. A key highlight will be the introduction of a twice-yearly long-acting solution, which has the potential to improve adherence and overcome the barriers associated with current oral preventive therapies. Simultaneously, the symposium will examine critical aspects of optimizing HIV treatment. Special attention will be given to the selection of antiretroviral therapies that provide both a high genetic barrier and forgiveness—key factors in minimizing the risks of virologic failure and the emergence of resistance mutations. By tailoring treatment options to the individual needs of PLWH and ensuring sustained viral suppression, long-term treatment success and improved quality of life can be achieved.

10.05-10.35 **Transforming HIV prevention: a twice-yearly long-acting solution**

L.G. Bekker, Cape Town ZA

10.35-11.05 **Optimizing HIV treatment in virologically suppressed PLWH: the importance of high genetic barrier and forgiveness**

D.A. Wohl, Chapel Hill CN



SHORT COMMUNICATIONS 10.05-11.05

HIV 2025: disparities and trajectories

SALA DONATELLO

Chairs: Massimo Cernuschi (Milano), Laura Rancilio (Milano)

10.05-10.08 **Introduction**

M. Cernuschi, Milano; L. Rancilio, Milano

SC 1 10.08-10.15 Integrating HPV vaccination promotion into community-based sexual health services: an empowerment approach

M. Stizioli¹, M. Barracchia¹, A. Bergomi¹, A. Sala¹, P. Vinti², P. Russo^{2,3}¹Brescia Checkpoint ETS, Brescia, Italy, ²Milano Check Point ETS, Milano, Italy, ³CIG Arcigay Milano, Milano, Italy

SC 2 10.17-10.24 Fast track health path: screening, information and care of fragile people in Rome

P. Sammarco, D. Masci, T. Di Giovanni, G. Rodoquino, E. Rossi, M. Barra

Street Unit and HIV/Infectious Diseases Unit, Villa Maraini Foundation, Italian Red Cross, Rome, Italy

SC 3 10.26-10.33 When Health Services are Hard to Reach: Insights from a mobile HIV/STI programme for migrant sex workers

C. Soligo¹, A. Bianchi¹, D. Zagato¹, E. Toselli², P. Vinti¹, F. Alberton³, M. Strano³, B. Trentacapilli³, C. Bertoni³, A. Sirbelli³, M. Cernuschi^{1,3}¹ASA Associazione Solidarietà AIDS ODV, Milano, Italy, ²Naga ODV, Milano, Italy, ³IRCCS Ospedale San Raffaele, Milano, Italy

SC 4 10.35-10.42 Poor retention in care among transgender women living with HIV(TWLWH): a call for targeted interventions

P.F. Salvo¹, G. Baldin², R.J. Steiner¹, G. Lenzi¹, C. De Vivo¹, G. Cucinotta¹, V. Iannone¹, A. Carbone¹, D. Farinacci², F. Lombardi^{1,2}, S. Di Giambenedetto^{1,2}, C. Torti^{1,2}¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy

SC 5 10.44-10.51 STIs Testing Among Young People: Strategies, Results, and Educational Implications

C. Pellegris¹, I. Mercurio², P. Meli², V. Gotti², D. Meli², E. Zanetti², R. Carissoli³, M. Rizzi⁴, M. Beretta⁴, M. Rizzi⁴¹Associazione Comunità Emmaus, Italy, ²Cooperativa Don Giuseppe Monticelli, Italy, ³Arcigay Bergamo Cives, Italy, ⁴Croce Rossa Italiana - Comitato di Bergamo, Italy

SC 6 10.53-11.00 Promoting Hepatitis and HIV screening in high prevalence populations: the "Test in the City" Project

P. Meli¹, I. Mercurio¹, V. Gotti¹, C. Pellegris¹, L. Saracini², L. Butini³, A. Costantini³, P. Pauri⁴, S. Caucci⁴, M. Cernuschi⁵, D. Zagato⁵, R. Repossi⁵ on behalf of 'Test in the City' Working Group composed by 14 Italian Fast-Track Cities¹Cooperativa Don Giuseppe Monticelli, Bergamo, Italy, ²Opere Caritative Francescane, Ancona, Italy, ³Anlaid Marche, Italy, ⁴Ancona Fast-track City, Italy, ⁵ASA, Milano, Italy11.02-11.05 **Conclusion**

M. Cernuschi, Milano; L. Rancilio, Milano



SYMPOSIUM 11.10-12.10

SALA PLENARIA MANTEGNA

Empowering immunity: breakthroughs in antiviral research

Chairs: Chiara Agrati (Roma), Andrea Cossarizza (Modena)

Highly effective and well-tolerated cART regimens are now available for patients living with HIV. And yet, despite full control over HIV replication, a full immune competence is not recovered in all settings, in turn contributing to (residual) risk of clinical progression, as reported in patients presenting late to the first HIV diagnosis. In this scenario, several aspects related to the dynamics of immune homeostasis over time both in peripheral blood and in the central nervous system still represent open challenges for the present and the future. New available technologies allow us to analyze phenotypic and functional features at single cell level, and represent a formidable tool to fully understand the complex interplay among immune homeostasis, HIV infections and treatments. This symposium aims to address some of these issues, such as defining the immunological and inflammatory dynamics in patients with a late diagnosis, the recruitment of inflammatory cells into the cerebrospinal fluid in patients with viral escape, and the immunological impact of new therapeutic regimens.

11.10-11.25 Immune recovery in late presentation: still far away or almost there?

G.C. Marchetti, Milano

11.25-11.40 Immune activation and damage in the CNS of people with HIV

P. Cinque, Milano

11.40-11.55 Antiretroviral regimens: does immunology matter?

G. Nunnari, Catania

11.55-12.10 Discussion led by Chairs

C. Agrati, Roma; A. Cossarizza, Modena

**SYMPOSIUM** 11.10-12.10**SALA MANTEGNA MEDIA****The challenging path towards HBV/HDV cure and the management of MAFLD**

Chairs: Massimo Puoti (Milano), Valentina Svicher (Roma)

This symposium is aimed at providing new insights on three topics in the field of viral hepatitis and liver diseases. In particular, the first lecture will provide a comprehensive overview on novel anti-HBV drugs, targeting different phases of HBV life cycle, that should go beyond the concept of virological suppression and aim at achieving HBV functional cure. Particular attention will be dedicated to the challenges that virologists and clinicians will have to cope to reach this important end-point. In the same direction, the second lecture will focus on the novel pharmacological approaches that are revolutionizing the management of chronic HDV infection. Finally, the third lecture will be aimed at providing a comprehensive insight and challenges associated with the clinical and therapeutic management of MAFLD particularly in the setting of people living with HIV.

11.10-11.25 **New drugs for HBV: are we ready for functional cure?**

N. Coppola, Napoli

11.25-11.40 **Entry inhibitors and beyond: a new hope for HDV**

P. Lampertico, Milano

11.40-11.55 **MAFLD between life style and new treatment options**

L. Miele, Roma

11.55-12.10 **Discussion led by Chairs**

M. Puoti, Milano; V. Svicher, Roma

**SATELLITE EXPERT MEETING - Round Table** 11.10-12.10**SALA CARRARESI****Solution for cardio-metabolic management of HIV therapy: the key role of doravirine**

Chairs: Andrea Antinori (Roma), Annamaria Cattelan (Padova)
 Discussants: Leonardo Calza (Bologna), Gabriella d'Ettorre (Roma),
 Simona Di Giambenedetto (Roma), Vincenzo Spagnuolo (Milano)

With an unrestricted educational grant from MSD Italy

The purpose of this session is to explore the role of doravirine in clinical practice and assess the potential for integrating this NNRTI into antiretroviral therapy (ART) regimens to enhance long-term patient outcomes. Findings from two randomized clinical trials, DRIVE-FORWARD and DRIVE-AHEAD, highlight doravirine as an effective option for ART, offering significant benefits for the metabolic health of individuals living with HIV due to its outstanding metabolic profile, particularly regarding lipids and body weight. Today, metabolic health is crucial for the management of individuals living with HIV, with studies indicating that up to one in two patients may suffer from cardiometabolic syndrome. This highlights the growing importance of personalizing antiretroviral therapy with choices aimed at improving the comorbidities associated with PWH. Furthermore, metabolic health is more than just the absence of metabolic diseases; it serves as a roadmap to promote a healthy lifestyle. The pathway to improving metabolic health necessitates integrating lifestyle interventions with a proactive approach to antiretroviral therapy, always emphasizing patient-centered care.

**ORAL COMMUNICATIONS** 11.10-12.10**SALA ANTENORE****The statins breakthrough in HIV management**

Chairs: Spinello Antinori (Milano), Teresa Bini (Milano)

11.10-11.15 **Introduction**

S. Antinori, Milano; T. Bini, Milano

OC 1 11.15-11.25 **Achievement of Low-Density Lipoprotein (LDL-C) Targets Based on Individual Cardiovascular Risk in a Cohort of People with HIV (PWH): One-Year Follow-Up Assessment**B. Caloni^{1,2}, G. Carrozzo¹, G. Pozza¹, L. Oreni¹, M.V. Cossu¹, D. Moschese¹, A.L. Ridolfo¹, C. Gervasoni¹, S. Antinori^{1,2}, A. Gori^{1,2,3}, A. Giacomelli^{1,2}¹Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ³Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy**OC 2** 11.27-11.37 **Statin prescription, acceptability and tolerability in a cohort of people living with HIV (PLWH) after updated recommendations on statin therapy**A. Bailoni^{1,2}, M. Sambo^{1,2}, F. Panza^{1,2}, M. Crispo^{1,2}, E. Morelli^{1,2}, M. Zanchi¹, C. Puttini², M. Trezzi², S. Benedetti², F. Montagnani^{1,2}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy

OC 3 11.39-11.49 **Impact of REPRIEVE indications on statin prescription in people with HIV in a real-life setting**
R. Papaioannu Borjesson¹, N. Capra¹, R. Lolatto¹, S. Nozza^{1,2}, D. Canetti¹, E. Bruzzesi^{1,2}, H. Hasson², A. Castagna^{1,2}, V. Spagnuolo¹, C. Muccini¹
¹IRCCS San Raffaele Scientific Institute, Infectious Diseases Department, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

OC 4 11.51-12.01 **Statins reduce frailty in people with HIV**
J. Milic¹, A. Carobbio¹, M. Menozzi², G. Mancini², G. Cuomo², F. Motta¹, C. Musci¹, C. Mussini^{1,2}, P. Raggi³, G. Sebastiani^{4,5}, G. Guaraldi^{1,2}
¹University of Modena and Reggio Emilia, Italy, ²Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ³Department of Medicine and Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada, ⁴Division of Gastroenterology and Hepatology and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada, ⁵Division of Experimental Medicine, McGill University, Montreal, QC, Canada

12.03-12.10 **Conclusion**

S. Antinori, Milano; T. Bini, Milano



SHORT COMMUNICATIONS 11.10-12.10

ART and comorbidities

SALA DONATELLO

Chairs: Benedetto Maurizio Celesia (Catania), Miriam Lichtner (Roma)

11.10-11.13 **Introduction**

B.M. Celesia, Catania; M. Lichtner, Roma

SC 7 11.13-11.20 **Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience**
D. Cattaneo^{1,2}, A.L. Ridolfo³, D. Dalu⁴, C. Pruneri⁴, A. Giacomelli^{3,5}, M.V. Cossu³, C. Fasola⁴, A. Civati³, A. Gori^{3,5}, C. Gervasoni^{2,3}
¹Unit of Clinical Pathology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, ²Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, ³Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, ⁴Department of Oncology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, ⁵Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

SC 8 11.22-11.29 **Neurocognitive impairment over time in people with HIV (PWH) with and without cerebrospinal viral escape (CHVE)**
C. Pinnetti¹, G. Del Duca¹, P. Borrelli², M. Maresca¹, M. Augello³, E. Vuaran⁴, I. Mastrorosa¹, V. Sala³, M. Trunfio⁴, A. Mondì¹, V. Mazzotta¹, L. Borghi³, S. Bonora⁴, A. Calcagno⁴, G. Marchetti³, A. Antinori¹
¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, University "G. d'Annunzio" of Chieti-Pescara, Italy, ³Department of Health Sciences Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁴Department of Medical Sciences, Unit of Infectious Diseases Amedeo di Savoia Hospital, University of Turin, Turin, Italy

SC 9 11.31-11.38 **Comparison between the Frascati criteria and Equivalent Scores for the neurocognitive assessment (NCA) of people living with HIV (PWH)**
G. Del Duca¹, I. Mastrorosa¹, A. Farcomeni², C. Pinnetti¹, A.C. Brita¹, M. Maresca¹, R. Gagliardini¹, V. Mazzotta¹, A. Mondì¹, M. Plazzi¹, M. Fusto¹, J. Paulicelli¹, A. Antinori¹
¹National Institute for Infectious Disease Lazzaro Spallanzani IRCCS, Rome, Italy, ²University of Rome, Tor Vergata, Italy

SC 10 11.40-11.47 **Atherogenic Index of Plasma as a Predictor of Cardiovascular Events in People living with HIV: Evidence from the ICONA Cohort**
N. Squillace¹, S. Lanini², A. Tavelli³, R. Gagliardini⁴, M. Augello⁵, C. Torti⁶, J. Vecchiet⁷, A. Beltrami⁸, A. Castagna⁹, A. Di Biagio¹⁰, G. Madeddu¹¹, A. Bandera¹², G. Guaraldi¹³, S. Lo Caputo¹⁴, A. Antinori¹⁵ on behalf of Icona Foundation Study Group
¹Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori, Monza, Italy, ²Infectious Diseases Clinic, Department of Medicine (DAME), University of Udine, Udine, Italy, ³ICONA Foundation, Milan, Italy, ⁴Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁵Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ⁶UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio", Chieti, Italy, ⁸Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, ⁹Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁰Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Department of Health Science (DISSAL), University of Genova, Italy, ¹¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ¹²Clinic of Infectious Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ¹³Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ¹⁴Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹⁵HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy

SC 11 11.49-11.56 **Critical illness in people with HIV (PWH). Temporal trends, reasons for admission, and mortality of PWH admitted to ICU from 2010 to 2024. The experience of two Italian referral centres**
C. Pinnetti¹, E. La Fata¹, D. Rubino², G. Leanza¹, G. Micheli², F. Frondizi¹, G.V. Stazi², E. Matteini¹, M.G. Caporale³, A. Mondì², M. Chiu-chiarelli¹, V. Mazzotta², D. Livanu⁴, C. Porcelli², C. Torti^{1,2}, A. Antinori², G. De Pascale⁴, M.G. Bocci², A. Cingolani^{1,2}
¹Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²UOC Malattie Infettive - Dipar-

timento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, ³Dipartimento di Scienze Biotechologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Dipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

SC 12**11.58-12.05 Correlation among lipid profile, subclinical atherosclerosis and hepatic steatosis in PLWH: the role of inflammation**

A. Boccia¹, I. Capriglione¹, A. Masiello², V. Iodice², S. Ferrara³, A. Tartaglia⁴, F. Simeone², A. Iodice², P. Maggi²

¹Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy, ²Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ³Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ⁴ASL Foggia, Italy

12.07-12.10 **Conclusion**

B.M. Celesia, Catania; M. Lichtner, Roma

**SATELLITE SYMPOSIUM** 12.15-13.15**SALA PLENARIA MANTEGNA****Sharing experiences: discussing current hot topics in 2-drug regimens**

Chairs: Giulia Carla Marchetti (Milano), Stefano Rusconi (Legnano MI) *With an unrestricted educational grant from ViiV Healthcare*

Two-drug regimens in HIV treatment have garnered substantial evidence from clinical trials and extensive real-world experience. This discussion aims to critically examine key topics concerning these regimens through a peer-to-peer exchange of experiences. First, the talk will explore the management of naïve patients, who often present at a late stage of diagnosis and draw conclusions about the suitability of two-drug regimens for these individuals by comparing different experiences in HIV management strategies. Additionally, the talk will address weight gain related to HIV treatment in the context of an aging HIV population, emphasizing the essential role of early ART intervention and regimen simplification to minimize comorbidities. The talk will foster an open dialogue among peers to share insights and practical experiences, led by chairs who will facilitate a dynamic discussion by posing questions to the speakers and encouraging them to share their own clinical experiences on the selected topics.

12.15-12.20 **Opening**

G.C. Marchetti, Milano; S. Rusconi, Legnano MI

12.20-12.40 **The proof of strength: debating treatment in naïve patients**

A. Cabello Úbeda, Madrid ES; V. Mazzotta, Roma

12.40-12.45 **Discussion led by Chairs**

G.C. Marchetti, Milano; S. Rusconi, Legnano MI

12.45-13.05 **The weight of wait: the role of ARV simplification for long-term health**

G. Guaraldi, Modena; D. Ripamonti, Bergamo

13.05-13.10 **Discussion led by Chairs**

G.C. Marchetti, Milano; S. Rusconi, Legnano MI

13.10-13.15 **Closing and take home messages**

G.C. Marchetti, Milano; S. Rusconi, Legnano MI

**ORAL COMMUNICATIONS** 12.15-13.15**SALA MANTEGNA MEDIA****The evolving tale of HIV: shifting patterns, emerging HIV care**

Chairs: Enrico Girardi (Roma), Ada Moznich (Milano)

12.15-12.20 **Introduction**

E. Girardi, Roma; A. Moznich, Milano

OC 5**12.20-12.30 Progresses in the continuum of care of people living with HIV, using surveillance and cohort data. Italy, 2012-2023**

A. Navarra¹, P. Piselli¹, A. Tavelli², G. De Carli¹, V. Regine³, A. Mammone⁴, L. Timelli⁴, A. Caraglia⁴, L. Pugliese³, L. Rancilio⁵, M. Farinella⁶, S. Leone¹, E. Gennaro¹, M. Nonis¹, F. Vairo¹, A. Antinori², A. d'Arminio Monforte², B. Suligoi³, E. Girardi¹

¹Istituto nazionale per le malattie infettive "L. Spallanzani" – IRCCS, Rome, Italy, ²Fondazione ICONA, Milan, Italy, ³Istituto Superiore di Sanità, Rome, Italy,

⁴Ministero della Salute, Rome, Italy, ⁵Caritas Ambrosiana, Milan, Italy, ⁶Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy

OC 6**12.32-12.42 Disaggregated data on testing activity for HIV in the context of community based voluntary counselling and testing services in the last years in Italy (2019-2023): towards a national registry**

P. Piselli¹, C. Cimaglia¹, E. Gennaro¹, G. Giupponi², L. Cosmaro³, M. Cernuschi⁴, E. Caruso⁴, P. Meli⁵, I. Mercurio⁵, S. Mattioli⁶, N. Frattini⁷, D. Zagato⁷, S. Penon³, M. Farinella⁸, L. Rancilio⁹, I. Pennini¹⁰, S. Patrucco¹¹, M. Stagnitta¹², D. Masci¹³, G. Moi¹⁴, C. Nicoara¹⁵, F. Leseri¹⁶, A. Caioli¹, S. Leone¹, A. Navarra¹¹, A. Caraglia¹⁷, M. Nonis¹, E. Girardi¹ for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"

¹INMI L. Spallanzani, Rome, Italy, ²LILA Como, Como, Italy, ³LILA Milano, Milan, Italy, ⁴Milano Checkpoint, Milan, Italy, ⁵CICA, Bergamo, Italy, ⁶PLUS, Bologna, Italy, ⁷Associazione Solidarietà AIDS (ASA), Milan, Italy, ⁸Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, ⁹CARITAS Ambrosiana, Milan, Italy, ¹⁰Arcigay, Padua, Italy, ¹¹Arcobaleno AIDS, Turin, Italy, ¹²CNCA, Rome, Italy, ¹³Fondazione Villa Maraini, Rome, Italy, ¹⁴Movimento Omosessuale Sardo (MOS), Sassari, Italy, ¹⁵Network Persone Sieropositive (NPS) Italia, Milan, Italy, ¹⁶Checkpoint PLUS Roma, Rome, Italy, ¹⁷Ministero della Salute, Rome, Italy

OC 7 12.44-12.54 **Expanding HIV Screening Beyond Hospital Walls in Milan: 17 years of the "EasyTest" project**
A.R. Raccagni¹, L. Soldini², S. Nozza^{1,2}, G.M. Vidoni³, F. Ferrara⁴, L. Passeri¹, G. Siracusano¹, C. Raddato¹, A. Castagna^{1,2}, M. Locatelli², K. Schlusnus⁵, A. Lazzarin^{1,2}
¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Prevention Department - Reference Centre for HIV and STDs Local Public Health Unit, Milan, Italy, ⁴Centro Diagnostico Italiano, Milan, Italy, ⁵AIRON Communication, Milan, Italy

OC 8 12.56-13.06 **Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?**
A. Mondì¹, A. Roen², G. Micheli¹, L. Taramasso³, I. Lucchetti⁴, V. Mazzotta¹, G. Marchetti⁵, L. Sarmati⁶, A. Gori⁷, G. Lapadula⁸, C. Mussini⁹, A. d'Arminio Monforte⁵, E. Girardi¹⁰, A. Cozzi-Lepri², A. Antinori¹ on behalf of the Icona Foundation Study Cohort
¹Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁴Infectious Disease Clinic, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁵Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ⁶Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Policlinico Tor Vergata of Rome, Rome, Italy, ⁷II Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Department of Biomedical and Clinical Sciences L. Sacco, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy, ⁸Department of Infectious Diseases, IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy, ⁹Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ¹⁰Scientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

13.08-13.15 **Conclusion** E. Girardi, Roma; A. Moznich, Milano



SATELLITE EXPERT MEETING 12.15-13.15

SALA CARRARESI

Chronic viral hepatitis screening: strategies for early diagnosis and optimal management

Chair: Francesco Paolo Russo (Padova)

Sponsored by Gilead Sciences

Chronic viral hepatitis remains a significant global health challenge, requiring innovative screening strategies to ensure early diagnosis and effective management. This expert meeting brings together key perspectives to address gaps in care. Topics include the critical role of in-hospital screening in identifying undiagnosed cases, integrated approaches to managing hepatitis and HIV in fast-track cities, and lessons learned from screening high-prevalence migrant populations, highlighting the Spallanzani Institute's experience. By exploring these diverse settings, the meeting aims to foster actionable insights and collaborative solutions to improve patient outcomes across vulnerable and underserved groups.

12.15-12.35 **In-hospital screening for chronic viral hepatitis: early diagnosis opportunities** S. Fagioli, Bergamo
 12.35-12.55 **Hepatitis and HIV in Fast-Track Cities: addressing care gaps for migrants and people who use drugs (PWUD)** P. Meli, Bergamo
 12.55-13.15 **Screening in high-prevalence migrant populations: the Spallanzani experience** E. Biliotti, Roma



SYMPOSIUM 12.15-13.15

SALA ANTENORE

Informed consent for HIV testing: it's time for changing

Chairs: Maria Rosaria Iardino (Milano), Claudio Maria Mastroianni (Roma)

The topic of written informed consent for the HIV test in Italy is a subject of considerable debate and is still governed by Law 135/90. Initially established as a protective measure for individuals with HIV to mitigate the risk of social stigma, the requirement for written informed consent now poses challenges for public health policies. By eliminating the necessity for written consent, HIV screening could be enhanced, thereby affirming its significance as a vital tool for the healthcare system from both diagnostic and epidemiological viewpoints. This change would effectively position it as a public health intervention, especially in light of the rise in new infection diagnoses reported in 2023. The symposium will address all aspects related to the reformulation of informed consent with the participation of all relevant stakeholders.

12.15-12.25 **Informed consent and HIV testing: approaches and implications for public health** S. Lo Caputo, Foggia
 12.25-12.35 **Current legislation: proposals for change and potential social impact** P. Piana, Milano
 12.35-12.45 **The perspective of people with HIV** M. Farinella, Roma
 12.45-13.15 **Roundtable discussion led by Chairs** M.R. Iardino, Milano; C.M. Mastroianni, Roma
 Discussants: M. Farinella, Roma; S. Lo Caputo, Foggia; P. Piana, Milano

**SHORT COMMUNICATIONS** 12.15-13.15**SALA DONATELLO****Open issues in virology and pharmacology**

Chairs: Bianca Bruzzzone (Genova), Anita De Rossi (Padova)

12.15-12.18 **Introduction**

B. Bruzzzone, Genova; A. De Rossi, Padova

SC 13 12.18-12.25 **Plasma SARS-CoV-2 RNA associates with disease severity during acute infection but not with persistent symptoms***R. Rovito¹, L. Terracciano¹, L. Albertini¹, R. Nardo¹, M. Augello¹, V. Bono¹, A. Santoro¹, V. Sala, C. Tincati¹, F. Bravi², G.C. Marchetti¹*¹Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ²Laboratory of Medical Statistics, Biometry, and Epidemiology "G.A. Maccacaro," Department of Clinical and Community Sciences, University of Milan, Milan, Italy**SC 14** 12.27-12.34 **The potential impact of pharmacogenetics on bulevirtide plasma exposure in the clinical setting***J. Cusato¹, L. Marinaro², M. Antonucci³, A. Palermi¹, M.A. Pavan¹, A. Manca¹, A. De Nicolò¹, A. D'Avolio¹, G. Di Perri², S. Bonora²*¹Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ³Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy**SC 15** 12.36-12.43 **Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide***A. Di Lorenzo^{1,2}, S. D'Anna³, D. Kontogiannis², C. Sorace², A. Crea², E. Teti², V. Malagnino², L. Piermatteo³, I. Grossi³, C. Castelli³, B. Carreri⁴, M. Nezzo⁴, F. Salbuzzi⁴, M. Iannetta^{1,2}, A.M. Geretti^{1,2}, V. Svicher³, R. Salpini³, L. Sarmati^{1,2}*¹Tor Vergata University, Rome, Italy, ²Department of Systems Medicine, Infectious Disease Clinic, Rome, Italy, ³Department of Biology, University of Rome Tor Vergata, Italy, ⁴Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy**SC 16** 12.45-12.52 **Analysis of HIV proviral integration sites in the host genome of PWH with a virus displaying amino acid polymorphism in the integrase C-terminal region***G. Sberna¹, G. Berno¹, C. Gruber¹, G. Rozera¹, L. Fabeni¹, F. Forbici¹, V. Mazzotta¹, R. Gagliardini¹, I. Mastroianni¹, I. Uccella², E. Girardi¹, F. Maggi¹, A. Antinori¹, I. Abbate¹*¹National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome Italy, ²Spaziani Hospital, Frosinone Italy**SC 17** 12.54-13.01 **Performance of a Next-generation Sequencing Test for HIV Drug Resistance Analysis in Proviral HIV-DNA***T.G. Alice¹, F. Cerutti, M.G. Milia, G. Gregori, E. Burdino, A. Ognibene, S. Monteleone, G. Morleo, P. Tremante, E. Scuccimarra, V. Ghisetti*

Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, Italy

SC 18 13.03-13.10 **Long acting cabotegravir and rilpivirine plasma and intracellular pharmacokinetics in the clinical setting after 2-year follow-up***M. Ferrara¹, V. Maccario¹, F. Barrera¹, A. Perinzano¹, A. Pepe¹, E. Drappero¹, M. Tettoni¹, L. Trentini¹, G. Orofino², S. Soloperto³, D. Maiese³, A. De Nicolò³, A. D'Avolio², A. Calcagno¹, S. Bonora¹*¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Unit of Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, Italy, ³Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino, Italy13.12-13.15 **Conclusion**

B. Bruzzzone, Genova; A. De Rossi, Padova

13.20-14.00 Poster Viewing with Authors in the dedicated multimedia areas on the third floor of the Congress Centre

**SPECIAL SESSION** 13.30-14.00**SALA PLENARIA MANTEGNA****TRIS (Top Researchers ICAR-SIMIT) Awards 2025**

Chairs: Massimo Andreoni (Roma), Antonella Castagna (Milano), Maurizio Zazzi (Siena)

This session will reward the three best scientific publications of 2024 related to ICAR topics (HIV, STIs and other Viral infections), published by Italian authors in international indexed journals. The members of the Commission - composed of the ICAR Board and Congress Chairs - individually assessed the various scientific papers on the basis of the following criteria: Originality, Quality of the scientific journal, Methodological rigour, Innovativeness compared to the state of the art on the topic, Relevance to clinical practice.

**TRIS Award for Epidemiology and Social Science**

Awarded by M. Andreoni, Roma

TRIS Award for Basic Science

Awarded by M. Zazzi, Siena

TRIS Award for Clinical Science

Awarded by A. Castagna, Milano

**SPECIAL SESSION** 14.00-14.30**SALA DONATELLO****DONNA ICAR 2025 e Progetto CARPHA3**

Chairs: Annamaria Cattelan (Padova), Vania Giacomet (Milano), Chiara Iaria (Palermo)

ICAR Survey was created with the aim of raising awareness in the scientific and advocacy community on current and burning issues involving PWH with the purpose of sharing at the congress the Italian situation. The second lecture will present the CARPHA3 Project promoted by the Istituto Superiore di Sanità.

14.00-14.20 **DONNA ICAR: Survey on pregnancy, childbirth and breastfeeding**

D. Piacentini, Belluno

14.20-14.30 **Progetto CARPHA3: prevalence and linkage to care of PWH in Italy**

B. Suligoi, Roma

**SYMPOSIUM** 14.05-15.05**SALA PLENARIA MANTEGNA****Persistent HIV replication: an unsolved issue**

Chairs: Ombretta Turriziani (Roma), Maurizio Zazzi (Siena)

Currently available antiretroviral therapy (ART) can suppress active HIV replication, reduce viral load to undetectable levels, and halt disease progression. However, low HIV RNA plasma levels remain persistently or intermittently in some individuals, despite optimal adherence to potent ART. While this may result from virus release from latently infected cells not targeted by ART, other mechanisms can play a role yet remain elusive. The origin and significance of low-level viremia has puzzled HIV experts for years and novel technologies are now expected to shed light on this pending issue. The symposium aims to gain new insights into the nature of HIV-1 persistence, bringing together virology and pharmacology and ultimately assisting the challenging management of low-level viremia in clinical practice.

14.05-14.20 **How to investigate HIV persistence**

I. Vicenti, Siena

14.20-14.35 **The pharmacology of HIV persistence**

A. Calcagno, Torino

14.35-14.50 **How to manage HIV persistence**

A. Saracino, Bari

14.50-15.05 **Discussion led by Chairs**

O. Turriziani, Roma; M. Zazzi, Siena

**ORAL COMMUNICATIONS** 14.05-15.05**SALA CARRARESI****Long acting PrEP in clinical practice**

Chairs: Davide Moschese (Milano), Silvia Nozza (Milano)

14.05-14.10 **Introduction**

D. Moschese, Milano; S. Nozza, Milano

OC 9**14.10-14.20 Preliminary insights into the pharmacokinetics of long-acting Cabotegravir for PrEP: differential blood and seminal fluid concentrations analysis**E. Sabetta¹, A.R. Raccagnì², A. Mattino¹, D. Ferrari³, E. Bruzzesi², V. Lovato⁴, M. Di Gerardo⁵, C. Muccini⁴, A. Castagna^{2,4}, M. Locatelli¹, S. Nozza^{2,4}¹Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy, ²Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy,

³SCVSA Department, University of Parma, Parma, Italy, ⁴Infectious Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy, ⁵Hospital Pharmacy, IRCCS Ospedale San Raffaele, Milan, Italy

- OC 10** **14.22-14.32 Preliminary Results of Long-Acting Injectable PrEP with Cabotegravir at San Raffaele Institute in Milan**
A.R. Raccagni¹, R. Lolatto², N. Capra², E. Bruzzesi¹, C. Muccini², C. Candela¹, A. Baglivi², G. Annichiarico², M. Di Gerardo³, R. Puzzi-ferri³, C. Ferri³, A. Castagna^{1,2}, S. Nozza^{1,2}
¹Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Hospital Pharmacy, IRCCS San Raffaele Scientific Institute, Milan, Italy
- OC 11** **14.34-14.44 Determinants for the start of long-acting injectable cabotegravir as pre-exposure prophylaxis: a case-control analysis**
G. Cavazza^{1,2}, N.B. Bana^{1,2}, C. Baiguera¹, G.J. Burastero¹, L. Rezzonico¹, E. Di Gennaro^{1,2}, E. Caruso³, L. Luzi^{1,2}, M. Cernuschi³, N. Frattini³, M. Puoti^{1,2}, R. Rossotti^{1,3}
¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy, ³Milano Checkpoint, Milan, Italy
- OC 12** **14.46-14.56 Real-world implementation of long-acting PrEP with injectable cabotegravir: preliminary data from an Italian cohort**
V. Mazzotta¹, C. Fusetti², G. Del Duca¹, R. Esvan¹, M.V. Cossu², A. Giacinta¹, G. Terracini¹, S. Lazzarin², F. Caruso², G. Micheli¹, D. Maddalena², V. Barchi¹, G. Frate¹, F. Fama², M. Matone², A. Oliva¹, A. Giacomelli², A. Riva², A. Gori², A. Antinori¹, D. Moschese²
¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- 14.58-15.05 **Conclusion** D. Moschese, Milano; S. Nozza, Milano



SYMPOSIUM 14.05-15.05

SALA ANTENORE

The HIV cure: where is the research and why don't we have it yet?

Chairs: Alessandra Maria Bianchi (Milano), Maria Santoro (Roma)

The possibility of having HIV eradication still appears distant and the expectations are accompanied by a certain "resignation" after having reached a so-called "chronicity" of the disease. Why it has failed so far? What are the most promising research strategies available today? Who and how much is investing to achieve this goal? On the one hand there is evidently a complex problem, on the other there are the expectations of people with HIV, with the dream of being able to definitively overcome the infection, but probably also the hopes of clinicians of being able to offer a therapy program that is an eradicating and therefore definitive cure. Let's try to discuss the future with an immunological approach, a virological one and with the testimony and questions of those who live with the infection.

- 14.05-14.10 **Introduction from the Community** S. Mattioli, Bologna
- 14.10-14.25 **Immunologically based perspectives** A. Cossarizza, Modena
- 14.25-14.40 **Virologically based perspectives** S. Parisi, Padova
- 14.40-15.05 **Roundtable discussion led by Chairs** A.M. Bianchi, Milano; M. Santoro, Roma
- Discussants:* A. Cossarizza, Modena; S. Mattioli, Bologna; S. Parisi, Padova



ORAL COMMUNICATIONS 14.30-15.55

SALA MANTEGNA MEDIA

Defining immune correlates in the context of ART and vaccination

Chairs: Massimo Andreoni (Roma), Camilla Tincati (Milano)

- 14.30-14.35 **Introduction** M. Andreoni, Roma; C. Tincati, Milano
- OC 13** **14.35-14.45 The impact of long-acting injectable cabotegravir plus rilpivirine in PWH on macrophage/mo-nocyte activation and neuronal injury**
M.A. Zingaropoli¹, E. Tortellini¹, M. Guardiani¹, A. Carraro¹, F. Dominelli¹, M. Antonacci¹, C. Del Borgo², R. Marocco², G. Mancarella¹, L. Ansaldo², M.R. Ciardi¹, C.M. Mastroianni¹, M. Lichtner³
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, University of Rome, Rome, Italy

- OC 14** 14.47-14.57 **Changes in CD8+ T-cell activation after switching from suppressive 3-drug to 2-drug cART in people with HIV**
D. Ripamonti^{1,4}, L. Comi¹, V. Bono³, D. Valenti, V. Sala³, G. Marchetti³, C. Tincati³
¹Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ²Bergamo Hospital Research Foundation – ETS (FROM), Bergamo, Italy, ³Clinic of Infectious Diseases, University of Milan, ASST Santi Paolo e Carlo, Milano, Italy
- OC 15** 14.59-15.09 **Impact of long-acting therapy and CMV-coinfection on immune activation and senescence in People with HIV(PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine**
M. Guardiani^{1,4}, E. Tortellini¹, A. Carraro¹, M.A. Zingaropoli¹, L. Ansaldo², A. Grimaldi², P. Pace², F. Dominelli¹, F. Mengoni¹, C. Pasquazzi⁴, O. Turriziani³, M.R. Ciardi¹, V. Vullo¹, C.M. Mastroianni¹, R. Marocco², C. Del Borgo², M. Lichtner⁴
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ⁴Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy
- OC 16** 15.11-15.21 **Long-lasting immunity: smallpox-specific T Cells show distinct memory traits compared to SARS-CoV-2 T Cells**
S. De Biasi¹, D. Lo Tartaro¹, M. Rau², E. Santacroce¹, A.L. Ciobanu¹, F. Bortoli¹, F. Coppi¹, L. Gibellini¹, I. Rubio², G. Candore³, C. Caruso³, A. Cossarizza^{1,4}
¹Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy, ²Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany, ³Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy, ⁴National Institute for Cardiovascular Research, Bologna, Italy
- OC 17** 15.23-15.33 **Two-year neutralizing and T-cell response after MVA-BN vaccination according to HIV infection and CD4 cell count**
V. Mazzotta, G. Matusali, E. Cimini, F. Colavita, J. Paulicelli, R. Esvan, A. Bettini, A. Oliva, F. Cristofanelli, G. Micheli, E. Tartaglia, A. Caioli, E. Girardi, F. Maggi, A. Antinori
 National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- OC 18** 15.35-15.45 **Assessment of the specific cellular immune response to the recombinant herpes zoster vaccine in people living with HIV**
G. Alessio¹, L. Benedetti¹, A.C. Epifani¹, G. Montagnari¹, L. Coppola^{1,2}, G.C. Marchetti³, C. Tincati³, P. Pasculli⁴, C.M. Mastroianni⁴, L. Sarmati^{1,2}, M. Iannetta^{1,2}
¹Tor Vergata University of Rome, Rome, Italy, ²Policlinico Tor Vergata, Rome, Italy, ³San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Italy, ⁴Sapienza University of Rome, Rome, Italy

15.47-15.55 **Conclusion**

M. Andreoni, Roma; C. Tincati, Milano

**LECTURE** 14.35-15.05**SALA DONATELLO****Management of Clostridioides difficile infection: an Italian Delphi consensus**

Chair: Annamaria Cattelan (Padova)

With an unrestricted educational grant from Tillotts Pharma

Despite key advances in therapeutic options, *Clostridioides difficile* infection (CDI), remains challenging for clinicians worldwide a leading cause of nosocomial deaths. This Gram-positive, spore-forming and toxin-producing intestinal bacterium that infects the human gut potentially causing lethal diarrhoea has been designated an 'urgent threat' by the US CDC and it is under surveillance at European and Italian levels. The use of broader spectrum antibiotics, such as vancomycin and metronidazole, can prime the gastrointestinal tract to become more prone to CDI recurrences. Fidaxomicin, a narrow-spectrum antibiotic, has been demonstrated to be superior in preventing recurrence and in preserving the intestinal microbiota. In order to integrate the currently available guidelines on the management of CDI a Delphi methodology was used to achieve consensus on the management of CDI, on the identification of patients at risk of recurrences or severe infection, and on the most appropriate use of fidaxomicin, with the final aim of fostering clinical practice application of treatment algorithms proposed by previous guidelines, in absolute synergy. The Lecture will present the results of the consensus.

14.35-14.55 **Management of Clostridioides difficile infection: an Italian Delphi consensus**

A. Cascio, Palermo

14.55-15.05 **Discussion and final considerations led by Chair**

A. Cattelan, Padova

**SYMPOSIUM** 15.10-16.10**SALA PLENARIA MANTEGNA****Challenges and unmet needs in immunocompromised patients**

Chairs: Miriam Lichtner (Roma), Giordano Madeddu (Sassari)

Immunocompromised hosts are at increased risk for bacterial, viral and fungal infections. Management of these infections may be challenging in this special population, due to a more difficult achievement of clinical cure. Perplexities may rise about the duration of antibiotic treatment and exitancy to antibiotic discontinuation may occur considering this frail population. The prevalence of solid cancer and hematological malignancies is growing in people living with HIV: the management of invasive fungal infections needs for several considerations in these patients. SARS-CoV-2 infection continues to represent a challenge in immunocompromised hosts and the appropriate use of new strategies, including prophylaxis and early antiviral treatment, is crucial to prevent disease progression.

- 15.10-15.25 **The new antibiotic mantra "Shorter Is Better": does it work in immunocompromised hosts?** M. Meschiari, Modena
- 15.25-15.30 **Discussion led by Chairs** M. Lichtner, Roma; G. Madeddu, Sassari
- 15.30-15.45 **When the going gets tough: challenging invasive fungal infections in the immunocompromised host** C.M. Bonazzetti, Bologna
- 15.45-15.50 **Discussion led by Chairs** M. Lichtner, Roma; G. Madeddu, Sassari
- 15.50-16.05 **Modern approach to SARS-CoV-2 infection in immunocompromised subjects: navigating among prophylaxis and early antiviral treatments** M. Falcone, Pisa
- 16.05-16.10 **Discussion led by Chairs** M. Lichtner, Roma; G. Madeddu, Sassari

**SATELLITE SYMPOSIUM
AND ORAL COMMUNICATIONS** 15.10-16.10**SALA CARRARESI****Optimizing HIV infection management in Italian clinical practice**Chairs: Antonio Di Biagio (Genova), Giovanni Di Perri (Torino)
Discussants: Alberto Borghetti (Pisa), Emanuele Focà (Brescia)

With an unrestricted educational grant from Gilead Sciences

The advances in antiretroviral therapy (ART) have radically transformed the modality to treat HIV infection, allowing to achieve viral suppression in the vast majority of people living with HIV (PWH), with a reduced burden of long-term adverse events. However, HIV infection remains a complex disease, requiring addressing clinical challenges such as comorbidities, drug-drug interactions, poor adherence, long-term toxicity, and risk of virologic failure and selection of resistance-associated mutations. In this context, oversimplification of therapeutic strategies could jeopardize virologic suppression and expose PWH to an increased risk of adverse events. Instead, it is necessary to put PWHs at the center of therapeutic decisions, pursuing a therapy optimization that considers all individual characteristics and needs, with the overall quality of life as a goal. This symposium will present the results of 3 different clinical studies that demonstrate how optimizing HIV therapy can assure long-term clinical success.

- 15.10-15.20 **Introduction: HIV treatment optimization in the setting of virological suppression** G. Di Perri, Torino
- OC 19** 15.20-15.30 **Effectiveness of switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from NNRTI-based ART in virologically suppressed HIV-patients: a retrospective analysis (DRIVE-SWITCH Study)**
R. Gagliardini¹, M. Fusto¹, S. Ottou¹, M. Plazzi¹, F. De Zottis¹, R. Bellagamba¹, E. Grilli¹, C. Pinnetti¹, V. Mazzotta¹, R. Caldera², G. Forcina², A. Antinori¹
¹National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, ²Gilead Sciences srl, Milan, Italy
- OC 20** 15.30-15.40 **Switching to BICtegravir in Elderly people living with HIV-1 under virologic control: week 144 results from the BICTEL cohort**
R. Donà, A. Lazzaro, F. Alessi, M. Ridolfi, G. Zacco, A. Pupo, D. Giangiulio, V. Giunta, C.M. Mastroianni, G. d'Ettore
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy
- OC 21** 15.40-15.50 **Effectiveness and safety of switching to BIC/FTC/TAF in second, third and later lines of therapy in virologically suppressed people living with HIV (PWH) on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL STUDY)**
M.V. Cossu¹, A. Giacomelli^{1,2}, M. Matone¹, D. Moschese¹, G. Carrozzo¹, A. Poloni¹, G. Pozza¹, L. Albini³, G. Forcina³, S. Antinori^{1,2}, A. Riva^{1,2}, A. Gori^{1,2,4}
¹Department of Infectious Diseases - ASST FBF SACCO, Italy, ²DIBIC Luigi Sacco, University of Milan, Italy, ³Gilead Sciences S.r.l. - Italy, ⁴Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
- 15.50-16.05 **Discussion led by Discussants** A. Borghetti, Pisa; E. Focà, Brescia
- 16.05-16.10 **Conclusion** A. Di Biagio, Genova

**SHORT COMMUNICATIONS** 15.10-16.10**SALA DONATELLO****Data that matter: epidemiological realities of HIV in the modern era**

Chairs: Salvatore Cecere (Bologna), Adriana Cervo (Modena)

15.10-15.13 **Introduction**

S. Cecere, Bologna; A. Cervo, Modena

SC 19 15.13-15.20 **Incidence of new HIV diagnoses in Italy: a comparison with major Western European countries**V. Regine, L. Pugliese, B. Suligo

Department of Infectious Diseases, National Institute of Health, Rome, Italy

SC 20 15.22-15.29 **Comparison of new HIV diagnosis incidence between Italians and foreigners present in Italy from 2012 to 2023: analysis of the increase post- COVID19 pandemic**R. Iacono, V. Regine, L. Pugliese, B. Suligo

Istituto Superiore di Sanità, Roma, Italy

SC 21 15.31-15.38 **A survey on the continuum of care for HIV in sex-workers in Italy: the contribution of NGOs**E. Gennaro¹, S. Leone¹, A. Camposegna², M. Stagnitta², M. Farinella³, I. Pennini⁴, L. Rancilio⁵, G. Amerio⁶, P. Illicher⁷, P. Meli⁸, D. Masci⁹, B. La Russa¹⁰, G. Giupponi¹¹, N. Frattini¹², M. Masoud¹³, S. Mattioli¹⁴, F. Leseri¹⁵, J. Testa¹⁶, A. Navarra¹, A. Caioli¹, C. Cimaglia¹, M. Nonis¹, A. Caraglia¹⁷, E. Girardi¹, P. Piselli¹ for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"¹INMI L. Spallanzani, Rome, Italy, ²CNCA, Rome, Italy, ³Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, ⁴Arcigay, Padua, Italy, ⁵Caritas Ambrosiana, Milan, Italy, ⁶Caritas Italiana, Rome, Italy, ⁷CDPC APS, Trieste, Italy, ⁸CICA, Bergamo, Italy, ⁹Fondazione Villa Maraini, Rome, Italy, ¹⁰Gruppo Abele Onlus, Turin, Italy, ¹¹LILA Milano, Milan, Italy, ¹²Milano Checkpoint, Milan, Italy, ¹³MIT APS, Bologna, Italy, ¹⁴PLUS, Bologna, Italy, ¹⁵Checkpoint PLUS Roma, Rome, Italy, ¹⁶SIMM, Rome, Italy, ¹⁷Ministero della Salute, Rome, Italy**SC 22** 15.40-15.47 **HBV and HCV Testing in Italy's Marginalized Groups: Advancing WHO's 2030 Elimination Goal**T. Caruso^{1,2}, I. De Giorgi², M. Monti¹, A. Castellaccio³, G. Cavallini², M.L. Manca⁴, S. Lorini¹, S. Marri⁵, L. Petraccia⁶, F. Madia¹, C. Stasi^{7,8}, L. Carraresi⁹, E. Lorefice⁹, S.I. Bonelli³, A. Nerli¹⁰, L. Martini¹, S. Gitto¹, D. Aquilini¹⁰, P. Blanc³, A.L. Zignego¹, L. Gragnani²¹MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, Center for Research and Innovation CRIA-MASVE, University of Florence, Firenze, Italy, ²Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy, ³San Jacopo Hospital, Infectious Disease Unit, Pistoia, Italy, ⁴Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Pisa, Italy, ⁵Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Florence, Italy, ⁶Poison Control Center Unit, Department of Emergency, Anesthesia and Critical Care Medicine, Policlinico Umberto I Hospital - Sapienza, University of Rome, Rome, Italy, ⁷Regional Health Agency of Tuscany, Florence, Italy, ⁸Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy, ⁹San Giuseppe Hospital, Gastroenterology Unit, Empoli, Italy, ¹⁰Santo Stefano Hospital, Infectious Disease Unit Prato, Italy**SC 23** 15.49-15.56 **Characteristics of people living with HIV who were lost to follow-up**L. Comi¹, D. Valenti², R. Teocchi³, P. Meli⁴, I. Mercurio⁴, S. Venturelli¹, D. Ripamonti¹¹Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ²FROM Foundation, Bergamo, Italy, ³Informatics Department, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁴Cooperativa Don Giuseppe Monticelli, Bergamo, Italy**SC 24** 15.58-16.05 **All-Cause Mortality in People with Four-Class Drug-Resistant HIV: A Matched Cohort Analysis with Data from the PRESTIGIO Registry**A. Giacomelli¹, N. Capra², R. Lolatto², R. Gagliardini³, T. Clemente², L. Calza⁴, C. Torti⁵, F. Lagi⁶, C. Fornabaio⁷, G.C. Marchetti⁸, G. Orofino⁹, V. Spagnuolo²¹Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy; ²III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy; ³IRCCS Ospedale San Raffaele, Infectious Diseases Unit, Milan, Italy; ⁴Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; ⁵Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ⁶Infectious Diseases Unit, Agostino Gemelli University Hospital, Rome, Italy; ⁷Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy; ⁸Infectious Diseases Unit, ASST Cremona, Cremona, Italy; ⁹Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy; ¹⁰Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy16.07-16.10 **Conclusion**

S. Cecere, Bologna; A. Cervo, Modena

**SYMPOSIUM** 16.15-17.30**SALA PLENARIA MANTEGNA****Filling the gaps of antiretroviral therapy: preparing for the future**

Chairs: Andrea Antinori (Roma), Nicola Gianotti (Milano)

Thanks to the widespread use and evolution of combination antiretroviral therapy, HIV became a manageable condition. Over the last 10 years, the development of newer compounds, especially 2nd generation integrase inhibitors, and the advent of new drug combinations improved clinical and virological outcomes beyond any expectations, by also addressing the major limitations of previous therapies (toxicities, drug resistance, and drug interactions). Furthermore, the horizon of antiretroviral therapy is constantly expanding with newer drug classes and different modes of delivery. Despite these optimistic achievements, to date several clinical needs in the management of people with HIV remain unmet. Indeed, a significant proportion of people are still diagnosed with advanced HIV disease, a clinical scenario that is still poorly represented in trials exploring new treatment strategies. Furthermore, many people face different challenges that persist despite availability of antiretrovirals, such as adherence issues or disengagement from care, and ageing with an increased burden of comorbidities and comedication. On one hand, this complex landscape emphasizes more and more the need for tailored approaches to each person with HIV, considering all the available antiretroviral drugs and in different combinations—sometimes also as off-label strategies even beyond what is stated by guidelines. On the other hand, it is of crucial importance to adequately compare the currently high standards of treatment with what is expected to emerge in the coming years. In this rapidly evolving and challenging landscape, "new" does not necessarily mean "better," and clinicians will need to carefully and knowingly identify individual needs, by also using social and economic resources wisely.

16.15-16.30	Is advanced disease the most critical unmet need of ART today?	M. Mazzitelli, Padova
16.30-16.45	Maintaining undetectability is the priority: challenges in treatment optimization	A. Borghetti, Pisa
16.45-17.00	Thinking out of the box: beyond treatment guidelines	R. Gagliardini, Roma
17.00-17.15	Filling the gaps of antiretroviral therapy: preparing for the future	A. Pozniak, London UK
17.15-17.30	Discussion led by Chairs	A. Antinori, Roma; N. Gianotti, Milano

**SPECIAL SESSION** 16.15-17.30**SALA MANTEGNA MEDIA****Optimising Protection: vaccinations for people living with HIV**

Chairs: Teresa Bini (Milano), Francesca Russo (Venezia)

Effective immunisation strategies are integral to maintaining optimal standards in HIV care. This symposium will provide a concise overview of the latest immunisation guidelines, highlighting updated recommendations, evidence-based best practices, and applications in adult care. An expert panel will explore challenges, complexities, and emerging research questions, focusing on aspects specific to the Italian context. Through a blend of presentations, case discussions, and Q&A, participants will strengthen their ability to offer informed, evidence-driven immunisation guidance, ultimately enhancing health outcomes and resilience in this potentially vulnerable population.

16.15-16.35	International guidelines on immunisations for adults living with HIV: key highlights from the 2024 update	A.M. Geretti, Roma
16.35-16.50	Overview of the Italian vaccination plan (2023-2025)	A. Di Biagio, Genova
	Debate: how applicable?	
16.50-17.05	Enhancing protection against respiratory infections, a programmatic perspective for Italy	L. Sticchi, Genova
17.05-17.20	Enhancing protection against chronic infections: a clinical perspective for Italy	M. Iannetta, Roma
17.20-17.30	Panel discussion and Q&A led by Chairs	T. Bini, Milano; F. Russo, Venezia

Discussants: A. Di Biagio, Genova; A.M. Geretti, Roma; M. Iannetta, Roma; L. Sticchi, Genova

**ORAL COMMUNICATIONS** 16.15-17.30**SALA CARRARESI****From virus variability to disease and treatment**

Chairs: Nicola Clementi (Milano), Valeria Micheli (Milano)

16.15-16.20	Introduction	N. Clementi, Milano; V. Micheli, Milano
-------------	---------------------	---

OC 22**16.20-16.30 Evaluation of genetic variability and resistance profile in highly treatment-experienced people with HIV-1 with multi-drug resistance enrolled in the PRESTIGIO Registry treated with lenacapavir**M.M. Santoro¹, D. Spalletta¹, V. Spagnuolo², M.C. Bellocchi¹, G. Marchegiani¹, C. Paletti³, R. Lolatto², L. Carioti¹, A. Cervo⁴, A. Di Biagio^{5,6}, R. Gagliardini⁷, M. Ficon⁸, E. Focà^{9,10}, S. Rusconi^{11,12}, M. Zazzi³, F. Saladini³, A. Castagna², F. Ceccherini-Silberstein¹¹University of Rome "Tor Vergata", Rome Italy, ²IRCCS San Raffaele Scientific Institute, Milan, Italy, ³University of Siena, Siena, Italy, ⁴AOU Policlinico di

Modena, Modena, Italy, ⁵San Martino Hospital Genoa, Genoa, Italy, ⁶University of Genoa, Genoa, Italy, ⁷National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, ⁸AULSS 9 Scaligera, Verona, Italy, ⁹University of Brescia, Brescia, Italy, ¹⁰ASST Spedali Civili, Brescia, Italy, ¹¹Legnano General Hospital and DIBC, Milan, Italy, ¹²University of Milan, Milan, Italy

OC 23 16.32-16.42 Evaluation of the viral reservoir in virologically suppressed people with HIV treated with LA Cabotegravir + Rilpivirine regimen

G. Marchegiani¹, F. Antonucci², A. Bertoli^{1,3}, M.C. Bellocchi¹, G. Torre¹, D. Spalletta¹, L. Carioti¹, A. Narducci², O. El Khalili¹, D. Arme-
nia⁴, S. Ferrara², F. Ceccherini-Silberstein¹, S. Lo Caputo², M.M. Santoro¹

¹University of Rome "Tor Vergata", Rome, Italy, ²University of Foggia, Foggia, Italy, ³Polyclinic of Tor Vergata, Rome, Italy, ⁴Saint Camillus International University of Health Sciences "UniCamillus", Rome, Italy

OC 24 16.44-16.54 An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity

L. Piermatteo¹, A. Magnapera¹, G. Torre¹, L. Carioti², S. D'Anna¹, S. Khan², L. Etogo¹, A. Bertoli^{2,3}, P. Paba³, A. Olivero⁴, E. Teti⁵, A. Di Lorenzo⁵, V. Malagnino⁵, M. Iannetta⁵, L. Baiocchi⁶, S. Francioso⁶, I. Lenci⁶, U. Cillo⁷, A. Vitale⁷, G. Brancaccio⁸, G.B. Gaeta⁹, A. Cian-
cia⁴, F. Ceccherini-Silberstein², S. Grelli^{2,3}, L. Sarmati⁵, P. Lampertico¹⁰, M. Rizzetto⁴, G.P. Caviglia⁴, R. Salpini¹, V. Svicher¹

¹Department of Biology, University of Rome "Tor Vergata", Rome, Italy, ²Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ³Unit of Virology, Tor Vergata Polyclinic Foundation, Rome, Italy, ⁴Department of Medical Sciences, University of Turin, Turin, Italy, ⁵Department of Systems Medicine, Infectious Disease Clinic, University of Rome "Tor Vergata", Rome, Italy, ⁶Hepatology Unit, Policlinico Tor Vergata, Rome, Italy, ⁷Hepa-
tobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy, ⁸Infectious Diseases, Link Campus University Rome, Department of Life Sciences, Health and Health Professions, Rome, Italy, ⁹Infectious Disease, University L. Vanvitelli, Naples, Italy, ¹⁰Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

OC 25 16.56-17.06 Evaluation of the SARS-CoV-2 virus genetic barrier to Remdesivir and Nirmatrelvir in vitro and in vivo

I. Varasi¹, L. Fiaschi¹, A. Gidari², S. Bastianelli², S. Pierucci², A. Bergna³, C. Della Ventura³, C. Paletti¹, N. Bartolini¹, C. Biba¹, F. Saladi-
ni¹, A. Lai^{3,4}, M. Zazzi¹, D. Francisci², I. Vicenti¹

¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Department of Medicine and Surgery, University of Perugia, Perugia, Italy, ³De-
partment of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ⁴Laboratory of Medical Microbiology and Virology, University of Insubria, Varese, Italy

OC 26 17.08-17.18 Whole Genome Sequencing of Adenovirus genotypes and clinical implications in pediatric patients

L. Colagrossi¹, L. Forque², V. Fox², R. Scutari², M. Mastropaolo², P. Merli³, V. Fini¹, V.C. Di Maio¹, G. Linardos¹, L. Coltellà¹, S. Ranno¹,
C. Russo¹, A. Villani^{4,5}, C.F. Perno^{1,2}

¹Microbiology and Diagnostic Immunology, Bambino Gesù Children's Hospital, Roma, Italy, ²Multimodal Laboratory Research Unit, Bambino Gesù Children's Hospital IRCCS, Roma, Italy, ³Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital IRCCS, Roma, Italy, ⁴Emergency, Acceptance and General Pediatrics Department, Bambino Gesù Children's Hospital IRCCS, Roma, Italy, ⁵Systems Medicine Departments, Tor Vergata University of Rome, Rome, Italy

17.20-17.30 Conclusion

N. Clementi, Milano; V. Micheli, Milano



ORAL COMMUNICATIONS 16.15-17.30

SALA ANTENORE

Beyond viral suppression: rethinking quality of life in HIV care

Chairs: Alessandra Maria Bianchi (Milano), Antonella Cingolani (Roma)

16.15-16.20 Introduction

A.M. Bianchi, Milano; A. Cingolani, Roma

OC 27 16.20-16.30 Stigma experienced by person with HIV/AIDS in the healthcare settings

L. Sasset¹, E. Lupia², S. Mingardo², C. Cozzolino³, M. Mazzitelli¹, A. Ferrari¹, D. Leoni¹, C. Palmeri³, S. Gardin¹, V. Scaglione¹, A.M. Cattelan^{1,4}

¹Infectious and Tropical Diseases Unit, University Hospital of Padua, Italy, ²Department of Psychiatry, University Hospital of Padua, Italy, ³Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Italy, ⁴Department of Molecular Medicine, University of Padua, Italy

OC 28 16.32-16.42 Challenges in Measuring Health-Related Quality of Life Among Antiretroviral Therapy Experienced People with HIV

M. Menozzi¹, J. Milic², B. Fontana², L. Benassi², M. Ricciardetto², T. Albano², M. Visicaro², F. Calandra², E. Ghidoni², G. Cuomo¹, G. Mancini¹, C. Mussini², G. Guaraldi²

¹Infectious Disease Clinic - Modena HIV Metabolic Clinic, University Hospital of Modena, Modena, Italy, ²Infectious Disease Clinic - Modena HIV Metabolic Clinic - Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

OC 29 16.44-16.54 Poor Treatment Satisfaction and Low Quality of Life in Highly-Treatment Experienced People with HIV PWH: insights from PRESTIGIO Registry

M. Mazzitelli¹, S. Calza², R. Lolatto³, T. Golnaz⁴, B. Menzaghi⁵, A. Cervo⁶, A. di Biagio⁷, R. Papaioannu Borjesson³, F.R. Colombo², D. Minisci⁸, S. Piconi⁹, M.M. Santoro¹⁰, A. Cattelan¹, A. Castagna^{3,4}, E. Focà⁸

¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ²Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ³Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Vita-Salute San Raffaele

University, Milan, Italy, ⁵Infectious Diseases Department, ASST Valle Olona Hospital, Busto Arsizio, Italy, ⁶Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy, ⁷Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ⁸University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁹Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ¹⁰Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

OC 30 16.56-17.06 Neurocognitive Impairment, Sleep Quality, Depression and Anxiety in People Living with HIV: A Cross-Sectional Study

A. Barco¹, M. Sacchetti², F. Rinaldi¹, L. Sgrò², L. Binaschi², O. Bargiacchi¹

¹SC Malattie Infettive, AOU Maggiore della Carità, Novara, Italy, ²S.S.D Psicologia Clinica, AOU Maggiore della Carità, Novara, Italy

OC 31 17.08-17.18 Adherence to electronic monitoring of PROs according with multidimensional biophenotypes (MBP)

E. Matteini¹, A. Delvinio¹, F. Frondizi¹, C. Comandè⁴, A. Luraschi³, G. Tiecco⁷, B. Fioretti⁷, L. Crupi⁵, A. Limongelli⁵, A. Pnevmatikakis⁸, S. Kyriazakos⁸, M.V. De Girolamo³, K. Kostopoulou⁸, M. Chiuchiarrelli¹, A. Di Biagio^{5,6}, E. Quiros Roldan⁷, C. Torti^{1,2}, A. Cingolani^{1,2}
¹Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Italy, ⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS Psicologia, Italy, ⁵Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ⁶Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ⁷Unità di Malattie Infettive, Università degli studi di Brescia, ASST Spedali Civili di Brescia, Italy, ⁸Innovation Sprint, Brussels, Belgium

17.20-17.30 **Conclusion**

A.M. Bianchi, Milano; A. Cingolani, Roma



SHORT COMMUNICATIONS 16.15-17.25

SALA DONATELLO

Deep insights in two-drug antiretroviral regimen

Chairs: Giulia Valeria Calvino (Roma), Giancarlo Orofino (Torino)

16.15-16.18 **Introduction**

G.V. Calvino, Roma; G. Orofino, Torino

SC 25 16.18-16.25 Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2DR or continuing 3DR over a 18-month follow-up

N. Bartolini¹, L. Fiaschi¹, M. Compagno², L. Benedetti², O. El Khalili³, C. Biba¹, C. Paletti¹, I. Varasi¹, M. Iannetta², V. Malagnino², M.M. Santoro³, R. Salpini⁴, V. Svicher⁴, F. Ceccherini-Silberstein³, L. Sarmati², F. Saladini¹, M. Zazzi¹, I. Vicenti¹

¹Department of Medical Biotechnologies, University of Siena, Italy, ²Department of Infectious Diseases, University of Rome Tor Vergata, Rome, Italy, ³Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁴Department of Biology, University of Rome Tor Vergata, Rome, Italy

SC 26 16.27-16.34 Effectiveness of first-line lamivudine-dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort

A. Vergori¹, A. Cozzi-Lepri², S. Lo Caputo³, A. Tavelli^{4,5}, V. Mazzotta¹, E. Schiaroli⁶, G. Orofino⁷, C. Mussini⁸, A. Castagna⁹, A. Cingolani¹⁰, A. Antinori¹, A. d'Arminio Monforte⁴, for ICONA Foundation Study Group

¹Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ⁴Icona Foundation, Milan, Italy, ⁵National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, ⁶Department of Infectious Diseases, University of Perugia, Perugia, Italy, ⁷Division I of Infectious and Tropical Diseases, ASL Città di Torino, Turin, Italy, ⁸Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena; University of Modena and Reggio Emilia, School of Medicine, Modena, Italy, ⁹Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; IRCCS Ospedale San Raffaele Università Vita-Salute, Milan, Italy, ¹⁰Department of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Del Sacro Cuore, Rome, Italy

SC 27 16.36-16.43 Real-world experience with Doravirine in Italy: comparing three-drug and two-drug regimens

A. Cervo¹, A. Giacomelli^{2,3}, R. Rossotti⁴, M. Menozzi¹, B. Fontana¹, E. Martini⁵, G. Menegotto⁵, M. Albertini⁵, A. Rabbì⁶, M. Cossu³, D. Moschese³, C. Gervasoni^{2,3}, C. Mussini^{1,5}, G. Guaraldi^{1,5}

¹Unit of Infectious Diseases, University Hospital of Modena, Italy, ²Department of Biomedical and Clinical Sciences, University of Milan, Italy, ³Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy, ⁴Infectious Diseases Department, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁵University of Modena and Reggio Emilia, Modena, Italy

SC 28 16.45-16.52 Adverse event development in people with HIV on long-acting Cabotegravir + Rilpivirine: timing and clinical insights

G. Colaggi^{1,2}, L. Taramasso², E. Ricci³, S. Ferrara⁴, G. Orofino⁵, E. Pontali⁶, B. Menzaghi⁷, E. Sarchi⁸, G. Cenderello⁹, G. Madeddu¹⁰, G.F. Pellicani¹¹, F. Lagi¹², O. Bargiacchi¹³, T. Bini¹⁴, E. Salomoni¹⁵, L. Calza¹⁶, K. Falasca¹⁷, L. Pusterla¹⁸, S. Rusconi¹⁹, M. Franzetti²⁰, M.A. Carleo²¹, S. Martini²², P. Bonfanti²³, A. Di Biagio^{1,2}

¹DISSAL - University of Genova - Genoa, Italy, ²IRCCS Ospedale Policlinico San Martino - Genova, Italy, ³Fondazione ASIA Onlus, Buccinasco - Milan, ⁴Unit of Infectious Diseases, Department of Clinical and Experimental Medicine - University of Foggia - Foggia, Italy, ⁵Division I of Infectious and Tropical Diseases - ASL Città di Torino, Italy, ⁶Department of Infectious Diseases, Galliera Hospital - Genoa, Italy, ⁷Unit of Infectious Diseases, ASST della Valle

Olona – Busto Arsizio (VA), Italy, ⁸Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital - Alessandria, Italy, ⁹Infectious Diseases Department Sanremo Hospital - Sanremo, Italy, ¹⁰Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy - University of Sassari, Italy, ¹¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino - Messina, Italy, ¹²AOU Infectious and Tropical Diseases, Careggi Hospital - Florence, Italy, ¹³Unit of Infectious Diseases, Ospedale Maggiore della Carità - Novara, Italy, ¹⁴Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences - University of Milan - Milan, Italy, ¹⁵Unit of Infectious Diseases, Santa Maria Annunziata Hospital - Florence, Italy, ¹⁶Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital - "Alma Mater Studiorum" University of Bologna - Bologna, Italy, ¹⁷Clinic of Infectious Diseases, Department of Medicine and Science of Aging - G. d'Annunzio University, Chieti-Pescara - Chieti, Italy, ¹⁸Division of Infectious Diseases, ASST Lariana - Como, Italy, ¹⁹Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese - Legnano, and DIBIC, University of Milan, Italy, ²⁰UOC Malattie Infettive, ASST Ovest-Milanese, Ospedale Nuovo di Legnano, Legnano, Italy, ²¹Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli - Naples, Italy, ²²Infectious Diseases Unit, University of Campania, Luigi Vanvitelli - Naples, Italy, ²³Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori - University of Milano-Bicocca, Monza, Italy

SC 29 16.54-17.01 **Reasons for declining Long-Acting-Injectable therapy in eligible PLWH: insights from the WHY-Not study**

L. Pagnucco¹, D. Ripamonti², G. Sangaletti¹, L. Comi², L. Baldassari³, R. Gulminetti¹

¹Infectious Diseases Unit UOC, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy, ²Infectious Diseases Unit UOC, ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy, ³School of Medicine - Infectious Diseases, University of Milano-Bicocca, Monza, Italy

SC 30 17.03-17.10 **Real-World Discontinuation and Virological Outcomes of Long-Acting Cabotegravir + Rilpivirine in virologically suppressed adults living with HIV: A Multicenter Observational Study in Tuscany (LAHIV)**

F. Lagi¹, G. Formica², M. Fabbiani³, B. Rossetti⁴, M. Piccica⁵, A. Pampaloni⁶, B. Menichini⁷, S. Costarelli⁸, E. Riguccini⁹, G. Sarteschi¹⁰, M. De Gennaro¹¹, E. Francalanci¹², L. Pisano¹², G. Gasparro², M. Fognani², P. Corsi¹, M. Pozzi¹, G. Sterrantino², M. Tumbarello³, D. Messeri⁷, C. Costa⁵, B. Adriani⁶, C. Nencioni⁴, D. Tacconi⁹, S. Sani⁸, A. Vincenti¹⁰, N. Pimpinelli¹², A. Bartoloni¹

¹SOD Malattie Infettive, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy, ²Dipartimento di medicina sperimentale e clinica, Università degli studi di Firenze, Italy, ³Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena, Italy, ⁴UO Malattie Infettive, Ospedale di Grosseto, Azienda USL Toscana Sud Est, Italy, ⁵SOC Malattie Infettive, Ospedale Santa Maria Annunziata, USL Toscana Centro, Italy, ⁶UO Malattie Infettive, Azienda Ospedaliera Prato, USL Toscana Centro, Italy, ⁷SOS Malattie Infettive, Azienda Ospedaliera Pistoia, USL Toscana Centro, Italy, ⁸UO Malattie Infettive, Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest, Italy, ⁹UOC Malattie Infettive, Azienda Ospedaliera Arezzo, USL Toscana Sud-Est, Italy, ¹⁰UO Malattie Infettive, Nuovo Ospedale Apuane, USL Toscana Nord-Ovest, Italy, ¹¹UO Malattie Infettive, Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest, Italy, ¹²S.C. Dermatologia, P.O. Piero Palagi, Usl Toscana Centro, Italy

SC 31 17.12-17.19 **Durability, Adherence, and Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A 96-Week Real-World Study**

D. Moschese¹, M. Matone¹, A. Giacomelli¹, C. Fusetti¹, A. Riva^{1,2}, A. Gori^{1,2}, M.V. Cossu¹

¹Dept of Infectious Diseases, ASST Fatebenefratelli Sacco, Italy, ²Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Italy

17.21 - 17.25 **Conclusion**

G.V. Calvino, Roma; G. Orofino, Torino



PARALLEL SESSION 16.15-17.15

SALA PETRARCA

Investigators' Meeting PrIDE (Prevention ICONA Dedicated Ensemble)

Chairs: Valentina Mazzotta (Roma), Silvia Nozza (Milano)

Presentazione

Organigramma

Presentazione del Protocollo

Stato di avanzamento dei centri e caratteristiche principali della CRF

Sito PrIDE e ingresso nella coorte

Modalità di presentazione proposte di lavoro

**KEYNOTE LECTURES** 09.00-10.00**SALA PLENARIA MANTEGNA**09.00-09.05 **In memory of Giampiero Carosi**

F. Castelli, Brescia

Chair: Paolo Maggi (Enna)

09.05-09.35 **Make people with HIV experience healthy aging. Empower the community, build public health strategies**

G. Guaraldi, Modena

The Decade of Healthy Ageing (2021-2030), proclaimed by the United Nations, represents a crucial opportunity to reshape the future of people living with HIV. Advances in antiretroviral therapy have extended life expectancy, but healthy aging remains a challenge due to multimorbidity, frailty, and stigma. The WHO's framework of intrinsic capacity and functional ability highlights the need to move beyond disease management toward comprehensive well-being. Empowering the HIV community is essential to overcoming systemic barriers, ensuring equitable access to care, and fostering age-friendly environments. Public health strategies must integrate social determinants of health, intergenerational support, and tailored long-term care. Combatting ageism within HIV care is key to dismantling the stigma cascade that limits opportunities for older individuals. This lecture will explore how multistakeholder collaboration, inclusive policies, and innovative interventions can drive real change. By centering human dignity and community engagement, we can transform aging with HIV into a positive, empowered experience. The goal is clear: make people with HIV experience healthy aging, empower the community, and build sustainable public health strategies.

Chair: Fabrizio Maggi (Roma)

09.35-10.05 **Whole genome sequencing: diagnostics, monitoring and tracking of viral infections**

F. Baldanti, Pavia

During the COVID-19 pandemics, next generation sequencing (NGS) technology became widespread in many laboratories due to the need of tracking and monitoring emergence and spread of SARS-CoV-2 variants. Five years after an event who stressed to its limit the clinical and diagnostic Health Care System of our Country, a positive legacy can be recognized in the democratization of NGS that, before the pandemic was available only in highly specialized labs. As a result, a better and deeper surveillance system is now available in Italy, especially for monitoring emerging (and re-emerging) respiratory viral infections as well as for variants tracking and understanding of vaccine efficacy. On the other hand, whole genome sequencing (WGS) has since then becoming more extensively used for analyzing markers of antibiotic resistance in multiple bacterial species, as well as for determining of other virulence factors. Finally, metagenomic approaches are now possible in diagnosis and surveillance of uncommon and even unknown pathogens leading the frontier of molecular diagnostic to an unprecedented level of efficacy.

**PARALLEL SESSION** 09.00-10.00**SALA PETRARCA****Fast-Track Cities Meeting**

Chairs: Franco Maggiolo (Fabro TR), Paolo Meli (Bergamo)

Aggiornamento sulle dinamiche globali delle FTCL e sulle iniziative rispetto all'Europa

B. Audoin, Paris FR

L'esperienza di Test in The City, primo progetto condiviso tra le FTC italiane per lo Screening e il Linkage to Care proattivo per HBV, HCV e HIV, il valore aggiunto della condivisione di buone prassi e strategie di intervento

P. Meli, Bergamo

Discussione generale:

Le prospettive per il futuro, tra possibili ulteriori progettualità comuni e il tema della sostenibilità anche alla luce del nuovo "Piano Nazionale d'azione per porre fine all'HIV, alle epatiti virali e alle infezioni sessualmente trasmissibili (PNA HIV-EPIST)"

**SATELLITE SYMPOSIUM** 10.05-11.05**SALA PLENARIA MANTEGNA****Renewed vaccines for a continuous and effective protection**

Chairs: Chiara Agrati (Roma), Stefano Rusconi (Legnano MI)

With an unrestricted educational grant from GSK

Vaccines are fundamental weapons for protecting people from worrisome diseases. This is what they are designed for, but more recently the vaccine strategy has been implemented to prevent diseases in people with a wide variety of immunodeficiencies. This symposium will shed light on the cross-talk between vaccines and protection against incident bacterial infections. The activity of vaccines versus Respiratory Syncytial Virus and Varicella Zoster Virus in the adult immunocompromised population will also be discussed.

10.05-10.25 **Vaccines as a shield against antimicrobial resistance**

G.C. Marchetti, Milano

Adult immunisation - from theory to clinical practice:10.25-10.40 **Focus on Respiratory Syncytial Virus (RSV) vaccine**

A. Riva, Milano

10.40-10.55 **Focus on Varicella Zoster Virus (VZV) vaccine**

D. Canetti, Milano

10.55-11.05 **Discussion led by Chairs**

C. Agrati, Roma; S. Rusconi, Legnano MI

**SATELLITE EXPERT MEETING** 10.05-11.05**SALA CARRARESI****Switch to Bictegrovir/FTC/TAF in persons with HIV on double-drug INSTI-based ART: data from the ICONA Cohort**Chairs: Antonella d'Arminio Monforte (Milano),
Giordano Madeddu (Sassari)

With an unrestricted educational grant from Gilead Sciences

Switch from double to triple regimens and reasons for switch have been poorly investigated in the real-life setting in the INSTI era. We have therefore analysed the ICONA Cohort to identify frequency and reasons for switching from 2DR INSTI-based regimens to BIC/FTC/TAF, and to evaluate the clinical outcome after switch.

10.05-10.10 **Introduction**

A. d'Arminio Monforte, Milano

10.10-10.15 **Study rationale**

A. Tavelli, Milano

10.15-10.25 **Study results**

A. De Vito, Sassari

Discussants:10.25-10.35 **Switch while on suppressive 2DR-ART**

R. Rossotti, Milano

10.35-10.45 **Switch from 2DR-ART while on detectable viral load**

S. Lo Caputo, Foggia

10.45-11.00 **General discussion led by Chairs**

A. d'Arminio Monforte, Milano; G. Madeddu, Sassari

11.00-11.05 **Conclusions**

G. Madeddu, Sassari

**ORAL COMMUNICATIONS** 10.05-11.05**SALA ANTENORE****Durability of long-acting ART**

Chairs: Stefano Bonora (Torino), Francesca Ceccherini Silberstein (Roma)

10.05-10.10 **Introduction**

S. Bonora, Torino; F. Ceccherini Silberstein, Roma

OC 32 10.10-10.20 **Effectiveness and Safety of Long-Acting Cabotegravir and Rilpivirine in Older People with HIV: Insights from the GEPO Cohort**

E. Focà¹, A. Riva², S. Calza³, B. Fioretti¹, S. Gardin⁴, J. Milic⁵, B.M. Celesia⁶, G. Orofino⁷, A. De Vito⁸, G.V. De Socio⁹, M.V. Cossu², F. Barrera¹⁰, M. Mazzitelli⁴, S. Nozza¹¹, G. Guaraldi⁴, A. Calcagno¹⁰

¹Division of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ²Third Division of Infectious Diseases, University of Milan, Ospedale L. Sacco, Milan and University of Milan, Milan, Italy, ³Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ⁴Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁵Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁶ARNAS 'Garibaldi' UOC Malattie Infettive Catania, Catania, Italy, ⁷Unit of Infectious Diseases, «Division A», Ospedale Amedeo di Savoia, Turin, Italy, ⁸Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, ⁹Department of Medicine, Infectious Diseases Unit, Azienda Ospedaliera di Perugia and University of Perugia, Santa Maria Hospital, Perugia, Italy, ¹⁰Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Torino, Italy, ¹¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 33 10.22-10.32 Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCohLART StudyG. Loi¹, N. Capra², R. Lolatto², M. Negri¹, G. Catalano¹, F. Passini¹, N. Moschetta¹, S. Nozza^{1,2}, A. Castagna^{1,2}, C. Muccini²¹Vita-Salute San Raffaele University, Milan, Italy, ²Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy**OC 34 10.34-10.44 Durability of long acting cabotegravir and rilpivirine in a multicenter real-life cohort of people with HIV**M. Mazzitelli¹, C. Cozzolino², D. Yaacoub³, A. Pieri³, E. Erne³, C. Puzzolante⁴, B. Fontana⁴, M. Giglia⁵, C. Rigamonti⁵, M. Cordoli⁶, C. Zanchi⁶, G. Fasan⁶, E. Lattuada⁷, M. Lanzafame⁷, G. Battagin⁸, S. Nicolè⁸, M. Malena⁹, M. Rossi¹⁰, D. Piacentini¹¹, F. Raumer¹², L. Calza⁵, C. Mussini⁴, A. Cattelan¹¹Unità Operativa Malattie Infettive e Tropicali, Azienda Ospedale Università di Padova, Italy, ²Dipartimento di Scienze Cardiovascolari e Toraciche, Università di Padova, Italy, ³Unità Operativa Malattie Infettive e Tropicali di Bolzano, Italy, ⁴Unità Operativa Malattie Infettive e Tropicali di Modena, Italy, ⁵Unità Operativa Malattie Infettive e Tropicali, Università degli Studi di Bologna, Italy, ⁶Unità Operativa Malattie Infettive e Tropicali di Verona, Italy, ⁷Unità Operativa Malattie Infettive e Tropicali di Trento, Italy, ⁸Unità Operativa Malattie Infettive e Tropicali di Vicenza, Italy, ⁹Unità Operativa Malattie Infettive e Tropicali di Rovigo, Italy, ¹⁰Unità Operativa Malattie Infettive e Tropicali di Treviso, Italy, ¹¹Unità Operativa Malattie Infettive e Tropicali, Ospedale San Martino, Belluno, Italy, ¹²Unità Operativa Malattie Infettive e Tropicali di Santorso, ULSS7 Pedemontana, Italy**OC 35 10.46-10.56 Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohLART study**C. Muccini¹, N. Capra¹, R. Lolatto¹, V. Spagnuolo¹, D. Canetti¹, S. Bossolasco¹, S. Bagaglio¹, P. Striglia¹, S. Nozza^{1,2}, A. Castagna^{1,2}¹Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy10.58-11.05 **Conclusion**

S. Bonora, Torino; F. Ceccherini Silberstein, Roma

**CLINICAL CASES** 10.05-11.05**SALA DONATELLO****Grand Round Clinical Cases**

Chairs and Discussants: Ivan Gentile (Napoli), Cristina Mussini (Modena), Carlo Federico Perno (Roma)

The "Grand Round Session" devoted to Clinical Cases on HIV and STI and Viral infections in the immunocompromised host will represent a unique opportunity for interactive discussion led by Experts with young researchers and to support the exchange of knowledge among the scientific community. A Committee formed by the ICAR Presidents and Governing Board selected three clinical cases from all those received from "Call for Clinical Cases" based on the following criteria: a) Relevance of the topic; b) Clarity (precision, organization, and structure) of the case; c) Identification of key messages relevant for clinical practice and research.

CC 1 10.05-10.25 Syphilis maligna rupia: an atypical presentation of "the great pretender"N.B. Bana^{1,2}, E. Di Gennaro^{1,2}, G. Cavazza^{1,2}, L. Luzi^{1,2}, C. Baiguera¹, G.J. Burastero¹, L. Rezzonico¹, A. Raimondi¹, F. D'Aloia², L. Mezzadri², M. Puoti^{1,2}, R. Rossotti¹¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Malignant syphilis is a rare vasculitic form of secondary syphilis typically observed in immunocompromised patients but occasionally reported in immune-competent individuals. A 38-year-old man diagnosed with HIV in 2013 presented recurrent, atypical skin lesions resembling his previous episode in 2013, alongside fever and general malaise. Clinical findings and serologic data confirmed malignant syphilis rupia, and a three weeks treatment led to significant clinical improvement. Despite a slow serologic response, constitutional symptoms resolved rapidly. Diagnosis relies on characteristic skin morphology, high serologic titre, and response to antibiotics, with Jarisch-Herxheimer reaction prophylaxis recommended. Malignant syphilis should be suspected in patients at risk of sexually transmitted infections presenting atypical skin lesions.

CC 2 10.25-10.45 A PML Fighter: two-year follow-up of a viro-immunologically suppressed 29-year-old man living with HIV and active Progressive Multifocal Leukoencephalopathy receiving JC Virus-Specific T-Cell Therapy and human recombinant interleukin 7G. Catalano¹, R. Vercesi², I. Mainardi², McC. Garcia Martearena¹, R. Papaioannu Borjesson², A. Danise², M. Guffanti², P. Vezzulli², P. Comoli³, A. Castagna^{1,2}, P. Cinque²¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Cell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Progressive Multifocal Leukoencephalopathy (PML) is a severe demyelinating condition caused by JC polyomavirus (JCV), predominantly affecting individuals with weakened immune systems. Immune reconstitution remains the primary effective approach. This case discusses a 29-year-old male with perinatally acquired HIV who experienced a PML relapse despite virological suppression. Treatment efforts resulted in partial clinical and radiological improvements, including reduced lesion size and improved motor function. However, JCV-DNA levels persisted with evidence of evolving viral mutations. These findings underscore the complexity of managing PML and highlight the promise of innovative approaches in addressing its challenges.

CC 3 10.45-11.05 Pharmacokinetic paradox in HIV management: when low plasma levels defy virological logic in the era of long-acting artM. Trizzino¹, C. Gioè¹, L. Pipitò², B. Catania², A. Cascio²¹Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, ²Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy

Case highlights the challenges of managing HIV in a 54-year-old male with severe inflammatory bowel disease (IBD), which impaired oral antiretroviral therapy (ART) absorption. Despite low levels of long-acting drugs, virological suppression was achieved, raising questions about conventional pharmacokinetic thresholds. The patient's clinical condition improved significantly, with resolution of symptoms and stable nutritional status. This case underscores the potential of long-acting antiretroviral therapy to overcome absorption limitations in patients with severe gastrointestinal pathology and suggests a need to reassess therapeutic drug monitoring (TDM) cut-offs and explore individualized dosing strategies for complex cases.

**PARALLEL SESSION** 10.05-11.05**SALA PETRARCA****MIYA MIYA, riflessioni da uno scoglio di confine**

"Miya Miya", in arabo, significa "va tutto bene". Una frase che diventa simbolo di speranza nonostante il mare, le barche sovraffollate, la paura e il dolore, perché quelle parole rappresentano il desiderio di credere in un futuro migliore, per chi arriva e per chi accoglie. Questo libro è un diario collettivo, nato dall'esperienza di giovani medici specializzandi di Malattie Infettive di Bari, impegnati sul molo Favalaro di Lampedusa; racconta l'incontro tra chi approda, segnato da viaggi impossibili, e chi tende una mano con solidarietà e con cura. Le pagine si riempiono di emozioni, riflessioni e testimonianze intense, mostrando il volto umano della migrazione. Un volto fatto di paura e resilienza, di gesti semplici e potenti, di lingue diverse che si incontrano per trovare un significato comune. Accompagnate da immagini evocative, queste storie parlano non solo di chi arriva, ma anche di chi sceglie di restare accanto. "Proteggere persone, non confini", recita una scritta sul molo. Il libro ci invita proprio a questo: riflettere su ciò che ci unisce oltre le differenze, oltre il mare. Un inno alla vita che resiste nonostante tutto e un messaggio universale di speranza e di grande umanità.

**Presentazione del Libro**

G. Putoto, Padova

Dialogo con gli Autori

M. Cibelli, Bari; A. Saracino, Bari

**SATELLITE SYMPOSIUM** 11.10-12.10**SALA PLENARIA MANTEGNA****Is the long-acting transformation at the right pace?**

Chairs: Paolo Bonfanti (Monza), Sergio Lo Caputo (Foggia)

With an unrestricted educational grant from ViiV Healthcare

The adoption of long-acting regimens is revolutionizing the management of HIV, offering significant benefits to a broad and diverse patient population. In addition, substantial clinical benefits have been observed, such as long-term adherence, fewer DDIs or positive impacts in metabolic parameters and inflammation markers. This event is organized to delve into the advantages of these treatments, discuss market transformations, and outline current strategies to maximize the impact of these innovations.

11.10-11.15	Opening	P. Bonfanti, Monza; S. Lo Caputo, Foggia
11.15-11.45	The long-acting benefits for a broad and diverse population	Discussants: A. Di Biagio, Genova; C. Muccini, Milano; G. Nunnari, Catania
11.45-12.05	Long-acting market transformation: what are we doing to achieve it?	Discussants: S. Di Giambenedetto, Roma; G. Orofino, Torino
12.05-12.10	Closing and take home messages	P. Bonfanti, Monza; S. Lo Caputo, Foggia

**ORAL COMMUNICATIONS** 11.10-12.10**SALA MANTEGNA MEDIA****Building connections across care, prevention and education**

Chairs: Ilenia Pennini (Padova), Annalisa Perziano (Torino)

11.10-11.15	Introduction	I. Pennini, Padova; A. Perziano, Torino
OC 36	11.15-11.25 Anlaids School - Through a positive and inclusive view of Sexuality, our STI prevention training R. Galipò ^{1,3} , M. Campanella ⁴ , P. Costa ⁶ , S. De Balzo ² , A. De Faveri ⁸ , S. Negri ⁵ , A. Palummieri ¹ , L. Butini ^{1,7} ¹ Anlaids ETS, Roma, Italy ² Anlaids Campania, Napoli, Italy, ³ Anlaids Lazio, Roma, Italy, ⁴ Anlaids Liguria, Genova, Italy, ⁵ Anlaids Lombardia, Milano, Italy, ⁶ Anlaids Mantova, Mantova, Italy, ⁷ Anlaids Marche, Ancona, Italy, ⁸ Anlaids Torino, Torino, Italy	
OC 37	11.27-11.37 Proactive testing for sexually transmitted and endemic diseases at an open access clinic for migrants: a one year update R. Ligresti ^{1,2} , S. Pettenuzzo ² , A. Cordori ¹ , G. Ciaccioli ² , E. Ferrante ² , C. Tincati ² , T. Bini ² , G. Marchetti ² ¹ Università degli studi di Milano, Ospedale Luigi Sacco, Milano, Italy, ² Università degli studi di Milano, Ospedale San Paolo, Milano, Italy	

- OC 38** 11.39-11.49 **NGO role in Continuum of Care (CoC): An opportunity not to be missed**
A. Camposeragna¹, M.L. Cosmaro², M. Farinella³, I. Pennini⁴, L. Rancilio⁵, G. Amerio⁶, L.A. Gbedo⁷, P. Meli⁸, M. Stagnitta¹, D. Masci⁹, B. La Russa¹⁰, G. Giupponi¹¹, N. Frattini¹², M. Masoud¹³, S. Mattioli¹⁴, F. Leserri¹⁵, J. Testa¹⁶, E. Gennaro¹⁷, S. Leone¹⁷, A. Navarra¹⁷, A. Caioli, C. Cimaglia¹⁷, M. Nonis¹⁷, A. Caraglia¹⁸, E. Girardi¹⁷, P. Piselli¹⁷ for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"
¹CNCA, Rome, Italy, ²LILA Milano, Milan, Italy, ³Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, ⁴Arcigay, Padua, Italy, ⁵Caritas Ambrosiana, Milan, Italy, ⁶Caritas Italiana, Rome, Italy, ⁷CDCP APS, Trieste, Italy, ⁸CICA, Bergamo, Italy, ⁹Fondazione Villa Maraini, Rome, Italy, ¹⁰Gruppo Abele Onlus, Italy, ¹¹LILA Como, Como, Italy, ¹²Milano Checkpoint, Milan, Italy, ¹³MIT APS, Bologna, Italy, ¹⁴PLUS, Bologna, Italy, ¹⁵Checkpoint PLUS Roma, Italy, ¹⁶SIMM, Rome, Italy, ¹⁷INMI L. Spallanzani, Rome, Italy ¹⁸Ministero della Salute, Rome, Italy
- OC 39** 11.51-12.01 **Chemsex and MDPV: the experience of a community-based chemsex service with increasingly severe and complex clients**
A. Bianchi¹, P. L. Vinti¹, A. Antonino¹, C. Soligo¹, P.M. Testoni¹, M. Manfredini¹, G. Fracca¹, D. Zagato¹, M. Cernuschi^{1,2}
¹ASA Onlus ODV, Milano, Italy, ²San Raffaele Hospital, Milano, Italy

12.03-12.10 **Conclusion**

I. Pennini, Padova; A. Perziano, Torino

**SATELLITE EXPERT MEETING** 11.10-12.10**SALA CARRARESI****Antibiotic therapy: microbiological and clinical challenges****Chairs:** Giusy Tiseo (Pisa), Mario Tumbarello (Siena)

With an unrestricted educational grant from Menarini

Bacterial infections represent the major emergency in the field of infectious diseases. This is due to the increased incidence of nosocomial infections, which places a burden on care in terms of mortality and disability and on the economy in terms of healthcare costs. The availability of new antimicrobial therapies is changing the management of gram-negative infections by offering new therapeutic opportunities for the management of increasingly 'difficult' strains. On the other hand, from the point of view of antibiotic sensitivity, the availability of long-acting drugs is changing the treatment strategies for gram-positive infections, reducing the duration of hospitalisations.

- 11.10-11.30 **How to manage nosocomial infections caused by Carbapenemases-Producing Enterobacteriaceae (CPE)** M. Falcone, Pisa
- 11.30-11.50 **Gram+: innovative options in ABSSSI treatment**
- Clinical and real-life evidences with long-acting antibiotics** M. Puoti, Milano
- 11.50-12.10 **Discussion led by Chairs** G. Tiseo, Pisa; M. Tumbarello, Siena

**SYMPOSIUM** 11.10-12.10**SALA DONATELLO****Initiatives on infectious diseases in Low-Middle Income Countries: the Italian experience on cooperation and development****Chairs:** Don Dante Carraro (Padova), Francesco Castelli (Brescia)

Cooperation in Low-Middle Income Countries (LMIC) is essential for the long-term success of any health initiative and is part of the moral duty of countries with a high income. Transversal projects are beneficial for both sides and lessons can be learned in countries with a wide range of resources. Infectious disease management is the ideal arena for effectively testing such a strategy. This symposium will present different experiences in LMIC with a multilateral partnership.

- 11.10-11.25 **HIV in the Shinyanga rural community, Tanzania: experiences and results over a 5-year project** G. Martelli, Forlì
- 11.25-11.30 **Discussion led by Chairs** Don D. Carraro, Padova; F. Castelli, Brescia
- 11.30-11.45 **Management of non-malaria fever episodes in Inhambane Province, Mozambique** F. Castelli, Brescia
- 11.45-11.50 **Discussion led by Chairs** Don D. Carraro, Padova; F. Castelli, Brescia
- 11.50-12.05 **Tools and skills on how to build a successful project in Low-Middle Income Countries** M. Giobbia, Treviso
- 12.05-12.10 **Discussion led by Chairs** Don D. Carraro, Padova; F. Castelli, Brescia

**SYMPOSIUM** 12.15-13.15**SALA PLENARIA MANTEGNA****PrEP: a commitment and a challenge**

Chairs: Valentina Mazzotta (Roma), Ilenia Pennini (Padova)

Discussant: Silvia Nozza (Milano)

The rationale for organizing a symposium focused on pre-exposure prophylaxis (PrEP) and sexually transmitted infections (STIs) is rooted in the urgent need to address rising infection rates and improve public health outcomes. STIs continue to pose significant health challenges globally, impacting individuals' physical and mental well-being. With the advent of PrEP as a preventative measure, there is a critical opportunity to enhance education and awareness among healthcare providers and the public. This symposium aims to bring together experts from various fields to share research findings, best practices, and innovative strategies for integrating PrEP into comprehensive sexual health programs. By fostering dialogue and collaboration, the event seeks to reduce stigma surrounding STIs and promote open discussions about sexual health. Furthermore, it provides a platform for advocates to voice their experiences and challenges, ensuring that diverse perspectives inform future interventions. Ultimately, the symposium strives to empower communities with knowledge and resources to improve access to PrEP.

12.15-12.30 **Community-based approach to reach key populations**

S. Mattioli, Bologna; P. Vinti, Milano

12.30-12.45 **Perspectives on PrEP: where it is going and where it can go**

N. Girometti, London UK

12.45-13.00 **Recognizing and managing PrEP failure: a real problem that needs to be addressed**

L. Taramasso, Genova

13.00-13.15 **Discussion**

V. Mazzotta, Roma; S. Nozza, Milano; I. Pennini, Padova

**ORAL COMMUNICATIONS** 12.15-13.15**SALA MANTEGNA MEDIA****Clinical HIV insights**

Chairs: Monica Basso (Padova), Cristina Gervasoni (Milano)

12.15-12.20 **Introduction**

M. Basso, Padova; C. Gervasoni, Milano

OC 40 12.20-12.30 **Incidence of non-AIDS-related cancers in people with HIV in the period 2000-2023: a single center retrospective study**G. Pozza¹, G. Carrozzo¹, B. Caloni¹, M. Matone¹, M.V. Cossu¹, D. Moschese¹, A.L. Ridolfo¹, C. Gervasoni¹, L. Oreni², S. Antinori^{1,2}, A. Gori^{1,2,3}, A. Giacomelli^{1,2}¹Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ³Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy**OC 41** 12.32-12.42 **Treatment interruptions among PWH on INSTI: virologic failure and other reasons for switching therapy in a real-life cohort**N. Squillace¹, B. Menzaghi², E. Ricci³, L. Taramasso⁴, G. Orofino⁵, S. Piconi⁶, G. Pellicanò⁷, E. Sarchi⁸, G. Madeddu⁹, G.V. De Socio¹⁰, R. Gulminetti¹¹, E. Salomoni¹², B.M. Cesia¹³, A. Bandera¹⁴, E. Pontali¹⁵, S. Ferrara¹⁶, G. Cenderello¹⁷, A. Di Biagio⁴, P. Bonfanti¹¹Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy, ²Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), Italy, ³Fondazione ASIA Onlus, Buccinasco (MI), Italy, ⁴Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy, ⁵Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, ⁶Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ⁷Infectious Diseases, G. Martino Hospital -University of Messina, Messina, Italy, ⁸Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ⁹Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, ¹⁰Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ¹¹Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ¹²Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, ¹³Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹⁴Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ¹⁵Infectious Diseases Unit, Galliera Hospital, Genoa, Italy, ¹⁶Infectious Diseases Unit, Ospedali Riuniti, Foggia, Italy, ¹⁷Infectious Diseases, Department of Graduated Medical Care, Sanremo Hospital, Sanremo, Italy**OC 42** 12.44-12.54 **Key predictors of optimal viro-immunological response in primary HIV infection**A. Mondì¹, A. Navarra², R. Gagliardini¹, V. Mazzotta¹, I. Abbate³, G. Micheli¹, R. Esvan¹, C. Pinnetti¹, M. Camici¹, G. Rozera³, M.M. Plazzi¹, M. Fusto¹, L. Fabeni³, E. Girardi⁴, F. Maggi³, A. Antinori¹¹Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ³Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁴Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy**OC 43** 12.56-13.06 **Body composition and pharmacokinetics of long-acting antiretroviral therapies in a cohort of people living with HIV**S. Arsuffi¹, S. Rapino¹, M. Manenti¹, S. Calza², F.R. Colombo¹, B. Fioretti¹, D. Minisci¹, G. Tiecco¹, S. Bonora³, A. Calcagno³, A. D'Avolio⁴, C. Anzoni¹, I. Polesini¹, F. Castelli¹, E. Quiros-Roldan¹, E. Focà¹¹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy, ²Unità di Biostatistica e Biomatematica e Unità di

Bioinformatica, Dipartimento di Medicina Molecolare e Traslazionale, Università degli Studi di Brescia, Italy, ³UO Malattie Infettive, AO Amedeo di Savoia e Università degli Studi di Torino, Italy, ⁴Laboratorio di Farmacologia clinica e Farmacogenetica, Ospedale Amedeo di Savoia e Università di Torino, Italy

13.08-13.15 **Conclusion**

M. Basso, Padova; C. Gervasoni, Milano



ORAL COMMUNICATIONS 12.15-13.15

SALA CARRARESI

The long-acting ART landscape in Italy

Chairs: Leonardo Calza (Bologna), Nicola Gianotti (Milano)

12.15-12.20 **Introduction**

L. Calza, Bologna; N. Gianotti, Milano

OC 44 12.20-12.30 Virologic outcomes of long acting cabotegravir and rilpivirine in viraemic and poorly adherent PLWH

G. Cavazza¹, N.B. Bana¹, A. Raimondi², G. Burastero², L. Rezzonico², E. Di Gennaro¹, F. D'Aloia¹, L. Mezzadri¹, L. Luzi¹, F. Peracchi¹, L. Chianura², C. Moiola², M. Puoti², R. Rossotti²

¹School of Medicine and Surgery, University Bicocca, Milan, Italy, ²Department of Infectious Diseases – ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

OC 45 12.32-12.42 Switching to Long-Acting CAB/RPV: A Real-World Analysis in People Living with HIV

L. De Martino¹, L. Maddaloni¹, A. Lazzaro¹, R. Donà¹, G. Bugani¹, L. Santinelli¹, A. D'Auria¹, I. Mezzaroma², C. Fimiani¹, M. Falciano¹, C. Andreoni¹, C. Scagnolari¹, C.M. Mastroianni¹, G. d'Ettore¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, ²Department of Translational and Precision Medicine; Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy

OC 46 12.44-12.54 Effectiveness and patient reported outcomes (PROs) of long-acting ART with cabotegravir/rilpivirine: the Long-Ikona study

R. Gagliardini¹, A. Giacomelli², S. De Benedittis³, A. Tavelli³, V. Mazzotta¹, R. Esvan¹, V. Bono⁴, N. Bobbio⁵, G. Carrozzo², E. Schiaroli⁶, G. Orofino⁷, G. Marchetti⁸, A. Cingolani⁸, A. Antinori¹, A. d'Arminio Monforte³ on behalf of Long-Ikona Study Group

¹National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, ²III Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC Luigi Sacco, Università degli Studi di Milano, Milan, Italy, ³ICONA Foundation, Milan, Italy, ⁴Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy, ⁵Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ⁶Department of Medicine, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Italy, ⁷Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, ⁸UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, Italy

OC 47 12.56-13.06 Patient-reported outcomes (PROs) as a measure of satisfaction with Long-Acting therapy in PWH

G. Del Duca¹, I. Sperduti², M. Maresca¹, M. Fusto¹, R. Gagliardini¹, E. Grilli¹, S. Ottou¹, R. Bellagamba¹, F. De Zottis¹, I. Mastroianni¹, A. Antinori¹

¹National Institute for Infectious Disease Lazzaro Spallanzani IRCCS, Rome, Italy, ²Regina Elena Cancer National Institute IRCCS, Rome, Italy

13.08-13.15 **Conclusion**

L. Calza, Bologna; N. Gianotti, Milano



SYMPOSIUM 12.15-13.15

SALA ANTENORE

Sustainability of antiretrovirals in a landscape of finite economic resources

Chairs: Paolo Bonfanti (Monza), Saverio Parisi (Padova)

Discussants: Andrea Antinori (Roma), Davide Croce (Castellanza VA), Paolo Meli (Bergamo), Cristina Mussini (Modena), Francesca Venturini (Padova)

The landscape of antiretroviral therapy is constantly evolving with the introduction of new drugs and innovative strategies of administration and needs continuous updates. In addition, a reorganization of both human and economic resources is warranted. In this context, collaboration among various stakeholders will be crucial to develop clinical pathways that ensure the sustainability of the system. In parallel, providing equal access to care and ensuring equity in the management of individuals living with HIV is mandatory. During this symposium, the following topics will be addressed in a roundtable discussion with the participation of various actors involved in the process:

- Sustainability Beyond Economics: access to drugs in EU
- Care Pathways as a Tool for Clinical Governance
- Equal Access to Care: Regional Disparities
- Equity: Comprehensive Patient Engagement
- Responsibility of Infectious Disease Clinicians

**ORAL COMMUNICATIONS** 12.15-13.15**SALA DONATELLO****Advances in viral pathogenesis**

Chairs: Massimiliano Conforti (Torino), Loredana Sarmati (Roma)

12.15-12.20 **Introduction**

M. Conforti, Torino; L. Sarmati, Roma

OC 48 12.20-12.30 **HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential**
S. D'Anna¹, L. Piermatteo¹, A. Di Lorenzo², L. Carloti³, G. Brancaccio⁴, E. Teti², I. Grossi¹, C. Castelli¹, A. Magnapera¹, V. Malagnino², M. Iannetta², C. Pasquazzi², U. Cillo⁶, A. Vitale⁶, E. Gringeri⁶, M. Magrofuoco⁶, L. Baiocchi⁷, S. Francioso⁷, I. Lenci⁷, A. Koffas⁸, A.M. Geretti², M. L. Abate⁹, A. Olivero⁹, G. B. Gaeta¹⁰, L. Sarmati², M. Rizzetto⁹, U. Gill⁸, P. Kennedy⁸, G. P. Caviglia⁹, V. Svicher¹, R. Salpini¹

¹Department of Biology, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ³Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ⁴Infectious Diseases, Link Campus University Rome, Department of Life Sciences, Health and Health Professions, Rome, Italy, ⁵Sant'Andrea Hospital, Rome, Italy, ⁶Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, ⁷Hepatology Unit, Policlinico Tor Vergata, Rome, Italy, ⁸Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁹Department of Medical Sciences, University of Turin, Turin, Italy, ¹⁰Infectious Disease Unit, University L. Vanvitelli, Naples, Italy

OC 49 12.32-12.42 **Plasma JCV-DNA changes as prognostic marker in Progressive Multifocal Leukoencephalopathy**
I. Mainardi¹, A. Tarantino², R. Vercesi¹, G. Catalano¹, MdC. Garcia Martearena¹, M. Guffanti¹, A. Danise¹, H. Hasson¹, M. Faraci³, A. Gallo⁴, M. Cerri⁵, A. Castagna¹, P. Cinque¹

¹IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Manima Not-for-Profit Healthcare and Assistance, Milan, Italy, ³IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁴University of Campania "Luigi Vanvitelli", Napoli, Italy, ⁵Lodi ASST Ospedale Delmati, Sant'Angelo Lodigiano, Italy

OC 50 12.44-12.54 **Baseline viral load impacts the aging process in infants with perinatally acquired HIV enrolled in the EARTH cohort**

M.R. Petrara¹, E. Ruffoni¹, G.R. Pascucci², E. Morrocchi², F. Carmona¹, C. Giaquinto³, N. Cotugno¹, P. Rossi¹, S. Giunco⁴, P. Palma², A. De Rossi^{1,4}, within the EPIICAL Consortium

¹Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, ²Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ³Department of Women's and Children's Health, University of Padova, Division of Pediatric Infectious Diseases, Padova, Italy, ⁴Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy

OC 51 12.56-13.06 **Expression of HCMV-encoded miRNAs in co-infected PLWH and relationships with inflammation/immune activation**

E. Lazzari, G. Rozera, R. Esvan, R. Gagliardini, V. Mazzotta, L. Federici, E. Girardi, A. Antinori, F. Maggi, I. Abbate
 National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy

13.08-13.15 **Conclusion**

M. Conforti, Torino; L. Sarmati, Roma

**PARALLEL SESSION** 12.15-13.15**SALA PETRARCA****GEPP0 Meeting** (GEriatric Patients living with HIV/AIDS: a Prospective multidimensional assessment of an ageing cOhort & community)

Chair: Andrea Calcagno (Torino)

Update status coorte**Presentazione studi prospettici:**

- ALERTS e INTERVENTIONS
- GEPP0 003
- GEPP0 004

Idee e proposte - discussione di gruppo

13.20-14.00 Poster Viewing with Authors in the dedicated multimedia areas on the third floor of the Congress Centre

**SYMPOSIUM** 14.00-15.00**SALA PLENARIA MANTEGNA****HIV across the lifespan: from AIDS to ageing**

Chairs: Simona Di Giambenedetto (Roma), Sergio Lo Caputo (Foggia)

In recent years, HIV co-morbidities, initially associated with ART side effects, have evolved to include pathological conditions more commonly associated with ageing, residual inflammation and immune activation. People with HIV (PWH) have an estimated risk of atherosclerotic cardiovascular disease, including myocardial infarction and stroke, that is up to twice that of the general population. In addition, in the context of ageing, degenerative diseases of the central nervous system should be screened for, diagnosed at an early stage and considered in the differential diagnosis with central nervous system AIDS-defining diseases such as PML.

14.00-14.30 **Cardiovascular risk in people with HIV. From REPRIEVE and beyond:****The infectious disease specialist point of view**

P. Bonfanti, Monza

The area specialist point of view

M. Pirro, Perugia

14.30-15.00 **From PML to cerebrovascular disease. Clinical spectrum and innovative approaches:****The infectious disease specialist point of view**

P. Cinque, Milano

The area specialist point of view

S. Gerevini, Bergamo

**ORAL COMMUNICATIONS** 14.00-15.00**SALA MANTEGNA MEDIA****Long-term effectiveness of oral ART**

Chairs: Annalisa Saracino (Bari), Carlo Torti (Roma)

14.00-14.05 **Introduction**

A. Saracino, Bari; C. Torti, Roma

OC 52 14.05-14.15 **Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study**

A. d'Arminio Monforte¹, A. Tavelli^{1,2}, R. Gagliardini³, S. Rusconi⁴, L. Taramasso⁵, A. Cervo⁶, R. Marocco⁷, V. Mazzotta³, A. Costantini⁸, G. Burastero⁹, A. Giacomelli¹⁰, A. Saracino¹¹, S. Nozza¹², S. Lo Caputo¹³, A. Antinori³ on behalf of Icona Foundation Study Group

¹Icona Foundation, Milan, Italy, ²National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, ³Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁴Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, and DIBIC, Università degli Studi di Milano, Milan, Italy, ⁵Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁶Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ⁷Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy, ⁸Clinical Immunology Unit, Azienda Ospedaliero-Universitaria delle Marche - Università Politecnica delle Marche, Ancona, Italy, ⁹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁰III Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC Luigi Sacco, Università degli Studi di Milano, Milan, Italy, ¹¹Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy, ¹²Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹³Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy

OC 53 14.17-14.27 **Observational effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment experienced people with HIV across age groups: 24-month results from the Italian BICSTaR cohort**

D. Canetti¹, G. Marchetti², S. Rusconi³, V. Esposito⁴, E. Quiros-Roldan⁵, B. Candelaresi⁶, A. Saracino⁷, V. Malagnino⁸, A. Antinori⁹, A. Marongiu¹⁰, L. Albini¹¹, R. Caldera¹¹, G. Forcina¹¹, G. Di Perri¹²

¹Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, "ASST Santi Paolo e Carlo", Milan, Italy, ³Infectious Diseases Unit, ASST Ovest Milanese - University of Milan, Milan, Italy, ⁴Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital-A.O. dei Colli, Naples, Italy, ⁵Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia, Italy, ⁶Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, ⁷Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Italy, ⁸Department of Systems Medicine, University of Rome Tor Vergata, Italy; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, Italy, ⁹HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, ¹⁰Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK, ¹¹Gilead Sciences Srl, Milan, Italy, ¹²Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy

OC 54 14.29-14.39 **Ten years results on the effectiveness and safety of DTG+3TC as a switch regimen in the ODOACRE cohort**

A. Ciccullo¹, G. Baldin^{2,3}, A. Cervo⁴, L. Oreni⁵, M. Mazzitelli⁶, F. Lagi⁷, M. Menozzi⁴, F. Lombardi^{2,3}, F. Bassani⁸, A. Giacomelli⁵, M. Fabbiani⁹, A. Cattelan⁶, A. Borghetti¹⁰, S. Antinori⁵, C. Mussini⁴, S. Di Giambenedetto^{2,3}

¹Infectious Diseases Unit, Ospedale San Salvatore, L'Aquila, Italy, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Roma, Italy, ³Catholic University of the Sacred Heart, Department of Healthcare Surveillance and Bioethics, Section of Infectious Diseases, Rome, Italy, ⁴Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy, ⁵III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, ⁶Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁷Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁸Ospedale Civile di Legnano ASST Ovest Milanese, University of Milan, Legnano, Italy, ⁹Department of Medical Biotechnologies, University of Siena, Siena, Italy; Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, ¹⁰Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

OC 55 14.41-14.51 **Long-term durability of dolutegravir/lamivudine dual regimen in a real-world setting (Dolu3TC study)**
D. Ripamonti¹, L. Comi¹, S. Venturelli¹, A. Repishti², T. Spaccaferro², D. Valenti³, A. Francavilla³
¹ASST Papa Giovanni XXIII, Bergamo, Italy, ²University of Milano-Bicocca, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ³FROM - Fondazione per la Ricerca Ospedale di Bergamo – ETS, Bergamo, Italy

14.53-15.00 **Conclusion**

A. Saracino, Bari; C. Torti, Roma



ORAL COMMUNICATIONS 14.00-15.00

SALA CARRARESI

Access to prevention in different settings

Chairs: Giuseppina Giupponi (Como), Valentina Mazzotta (Roma)

14.00-14.05 **Introduction**

G. Giupponi, Como; V. Mazzotta, Roma

OC 56 14.05-14.15 **Rising chemsex trends among PrEP users in Milan: a 2024-2025 study**
C. Fusetti¹, E. Caruso², F. Petri¹, R. Repossi², A. Giacomelli¹, N. Frattini², M.V. Cossu¹, P. Vinti², F. Caruso¹, A. Riva¹, A. Gori¹, M. Cernuschi¹, D. Moschese^{1,2}
¹Department of Infectious Diseases, Luigi Sacco Hospital, ASST FBF Sacco, Milan, Italy, ²Milano Checkpoint ETS, Milan, Italy

OC 57 14.17-14.27 **TelePrEP: New data on a best practice in HIV prevention**
M.L. Cosmaro¹, S. Penon¹, F. Falzetta¹, A.R. Raccagni², C. Candela², S. Nozza^{2,3}
¹Fondazione ILLA Milano ETS, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 58 14.29-14.39 **Is PrEP knowledge a privilege? The unequal access to PrEP Information for cis and trans women and gender non-conforming individuals at HIV testing sites**
C. Del Giudice¹, M. Barracchia², B. Botros Abd El Malek², R. Pignata², M. Stizioli²
¹Anlaids Torino, Torino, Italy, ²Brescia Checkpoint, Brescia, Italy

OC 59 14.41-14.51 **Facilitators and Barriers HIV/STI Information and Services Among LGBTQI+ Immigrants in Italy**
Y.S. Ranjit¹, M. Barracchia², M. Costacurta³, M. Mazzitelli⁴, M. Falaguasta⁵
¹Department of Communication, University of Missouri, U.S.A., ²Europubhealth, European Public Health Master, ³Department of Social and Political Sciences, Università degli Studi di Milano, Milan, Italy, ⁴Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁵Anlaids sez. Padova APS, Italy

14.53-15.00 **Conclusion**

G. Giupponi, Como; V. Mazzotta, Roma



ORAL COMMUNICATIONS 14.00-15.00

SALA ANTENORE

HIV and comorbidities

Chairs: Vincenzo Esposito (Napoli), Lucia Taramasso (Genova)

14.00-14.05 **Introduction**

V. Esposito, Napoli; L. Taramasso, Genova

OC 60 14.05-14.15 **Long-Term Success of Combined Kidney-Liver Transplantation in People with HIV: Evidence from a Real-World Cohort**
A. Cervo¹, I. Baldisserotto², M. Albertini², F. Casari², E. Ghidoni², V. Todisco², J. Milic², P. Guerrini³, G. Mori⁴, B. Catellani³, G. Donati^{2,4}, F. De Benedetti^{2,3}, C. Mussini^{1,2}, G. Guaraldi^{1,2}
¹Infectious Diseases Clinic, University Hospital of Modena, Modena, Italy, ²Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena, Modena, Italy, ⁴Nephrology, Dialysis and Kidney Transplant Unit, University Hospital of Modena, Modena, Italy

OC 61 14.17-14.27 **HIV-to-HIV Organ Transplantation: A Comparative Analysis of Liver and Kidney Transplant Outcomes in People with HIV Receiving Organs from donors without HIV infection**
A. Cervo¹, I. Baldisserotto², M. Albertini², F. Casari², E. Ghidoni², V. Todisco², G. Mori³, F. Damiano³, B. Catellani⁴, S. Di Sandro^{2,4}, F. De

Benedetto^{2,4}, G. Donati^{2,3}, C. Mussini^{1,2}, G. Guaraldi^{1,2}

¹Infectious Diseases Clinic, University Hospital of Modena, Modena, Italy, ²Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Nephrology, Dialysis and Kidney Transplant Unit, University Hospital of Modena, Modena, Italy, ⁴Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena, Modena, Italy

OC 62 14.29-14.39 Tobacco and Alternative Nicotine Product Use Among People With HIV: Should We Be Concerned?

A. De Vito¹, A. Giacomelli^{2,3}, M. Mazzitelli⁴, G. Balducci⁵, M. Fabbiani^{7,8}, A. Colpani¹, M. Galimberti², A. Carbone^{5,6}, A. Civati², A. Cattelan⁴, S. Di Giambenedetto^{5,6}, G. Madeddu¹

¹Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan, Italy, ³Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, Milan, Italy, ⁴Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁵Unit of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Catholic University of the Sacred Heart, Rome, Italy, ⁷Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁸Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy

OC 63 14.41-14.51 Hypertriglyceridemia and Gender Differences in the Risk of Major Adverse Cardiovascular Events in People with HIV: A Single Center Retrospective Longitudinal Study

A. Siribelli¹, N. Capra², R. Lolatto², C. Bertoni¹, R. Papaioannu Borjesson², C. Muccini², V. Spagnuolo^{1,2}, G. Morsica², A. Castagna^{1,2}, H. Hasson²

¹Vita-Salute San Raffaele University, Italy, ²IRCCS San Raffaele Scientific Institute, Italy

14.53-15.00 **Conclusion**

V. Esposito, Napoli; L. Taramasso, Genova



ORAL COMMUNICATIONS 14.00-15.00

SALA DONATELLO

Diagnosis, prevalence and prevention of STIs

Chairs: Francesco Maria Fusco (Napoli), Stefano Patrucco (Torino)

14.00-14.05 **Introduction**

F.M. Fusco, Napoli; S. Patrucco, Torino

OC 64 14.05-14.15 Clinical evaluation of gonococcal-specific culture test for rectal gonorrhea diagnosis

F. Passini¹, A.R. Raccagni¹, R. Lolatto², N. Capra², M.F. Lucente¹, C. Candela², C. Muccini², E. Bruzzesi¹, M. Negri¹, V. Lovato², A. Castagna^{1,2}, S. Nozza^{1,2}

¹Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 65 14.17-14.27 Progressive Increase of New Syphilis Diagnoses among MSM with HIV Infection: A 30-Year Report from Rome STI Reference Center

C. Stingone, M. Zaccarelli, M. Giuliani, L. Gianserra, M.G. Donà, E. Giuliani, A. Latini
IST & HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy

OC 66 14.29-14.39 High-Risk HPV Other than HPV16 Are Common in Advanced Anal Precancerous Lesions in MSM Living With HIV

E.N. Cavallari¹, M. Ridolfi¹, A. Lazzaro¹, F. Alessi¹, C. Eberspacher², D. Mascagni², A. Pierangeli³, O. Turriziani³, C.M. Mastroianni⁴, G. D'Ettore⁴

¹Department of Infectious Diseases Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome Italy, ²Department of Surgical Sciences "Sapienza" University of Rome, Italy, ³Department of Molecular Medicine "Sapienza" University, Rome, Italy, ⁴Department of Public Health and Infectious Diseases "Sapienza" University, Rome, Italy

OC 67 14.41-14.51 The actual need of doxyPEP might not be as large as expected

R. Rossotti^{1,2}, D. Calzavara¹, E. Caruso¹, A. De Bona^{1,3}, D. Moschese^{1,4}, C. Muccini^{1,5}, D. Tesoro^{1,3}, P. Vinti¹, M. Cernuschi¹, A. Tavelli⁶, A. d'Arminio Monforte⁶, G. Lapadula^{1,7}

¹Milano Checkpoint, Milan, Italy, ²ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ³ASST Santi Paolo e Carlo, Milan, Italy, ⁴ASST Fatebenefratelli Sacco, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶ICONA Foundation, Milan, Italy, ⁷Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

14.53-15.00 **Conclusion**

F.M. Fusco, Napoli; S. Patrucco, Torino



PARALLEL SESSION 14.00-15.00

SALA PETRARCA

PRESTIGIO Registry Meeting

Chair: Antonella Castagna (Milano)

Current situation of the Registry

A. Castagna, Milano

Delfino trial and ongoing research proposals

V. Spagnuolo, Milano

New eCRF/Samples/regulatory process

E. Carini, Milano; R. Lolatto, Milano; G. Piromalli, Milano

**SYMPOSIUM** 15.05-16.05**SALA PLENARIA MANTEGNA****Getting to zero in difficult-to-reach populations**

Chairs: Nicoletta Frattini (Milano), Barbara Suligoi (Roma)

Although the strategies available to move towards the end of the HIV epidemic are many and are being progressively implemented at a global level, the existence of fragile populations into which these strategies have difficulty penetrating make the end of the HIV epidemic not yet attainable, both at a global level but also in countries such as Italy, where access to prevention and treatment is apparently universal. The emergence of these populations and the tailoring of interventions on them represent the key to making prevention and treatment strategies more efficient at a population level. In this symposium, attention will be focused on hard-to-reach populations in Italy, the barriers to their access to various levels of the healthcare system from a legal and regulatory perspective, and an assessment of community-based settings will be carried out in an attempt to identify how far these populations can be reached.

- 15.05-15.20 **Difficult-to-reach populations: who they are and how they can be reached** E. Girardi, Roma
- 15.20-15.35 **Legal and regulatory barriers to universal access to care in Italy** M.L. Cosmaro, Milano
- 15.35-15.50 **I am in the field: community-based experience of hard-to-reach populations** E. Caruso, Milano
- 15.50-16.05 **Discussion led by Chairs** N. Frattini, Milano; B. Suligoi, Roma

**ORAL COMMUNICATIONS** 15.05-16.05**SALA MANTEGNA MEDIA****ARV drugs from prevention to treatment**

Chairs: Andrea Calcagno (Torino), Lolita Sasset (Padova)

- 15.05-15.10 **Introduction** A. Calcagno, Torino; L. Sasset, Padova

- OC 68** **15.10-15.20 The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry**
T. Clemente¹, N. Capra¹, V. Malagnino^{2,3}, R. Lolatto¹, S. Lo Caputo⁴, L. Comi⁵, A. Giacomelli^{6,7}, G. Cenderello⁸, M. Colafigli⁹, S. Rusconi^{6,10}, M. Zazzi¹¹, A. Castagna^{1,12} on behalf of the PRESTIGIO Study Group

¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ³Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, Italy, ⁴A.O.U. Policlinico Foggia, Università di Foggia, Foggia, Italy, ⁵Infectious Diseases Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy, ⁶Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, ⁷III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, ⁸Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, ⁹Struttura Complessa di Malattie Infettive, Ospedale regionale "Umberto Parini" di Aosta, Aosta, Italy, ¹⁰Ospedale Civile di Legnano ASST Ovest Milanese, University of Milan, Legnano, Italy, ¹¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ¹²Vita-Salute San Raffaele University, Milan, Italy

- OC 69** **15.22-15.32 Risk of developing low-level viral rebound (LLVR) among people with HIV (PWH) with current HIV-RNA ≤ 50 copies/mL receiving 2DR vs 3DR: a case control study**

A. Vergori¹, A. Cervo², A. Roen³, R. Gagliardini¹, T. Clemente⁴, V. Mazzotta¹, E. Quiros-Roldan⁵, M.C. Polisen⁶, L. Sarmati⁷, F. Ceccherini-Silberstein⁸, F. Maggiolo⁹, C. Mussini², C.F. Perno¹⁰, A. Antinori¹, A. Cozzi-Lepri³, On Behalf Of The ICONA Foundation Study Group

¹Clinical Infectious Diseases Department, Viral Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Infectious Diseases Clinic, University Hospital of Modena, Modena, Italy, ³Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom, ⁴Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy, ⁵Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia, Brescia, Italy, ⁶Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Jonian Area (DiMePreJ), A.O.U.C. Policlinic di Bari, Bari, Italy, ⁷Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Policlinico Tor Vergata of Rome, Rome, Italy, ⁸Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy, ⁹Infectious diseases' specialist Freelance, None, Fabro, Italy, ¹⁰IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy

- OC 70** **15.34-15.44 Advancing HIV care in pregnancy: trends in virological suppression, mother-to-child transmission and postpartum retention over two decades**

F. Casari¹, A. Cervo², C. Puzzolante², M. Digaetano², G. Guaraldi^{1,2}, C. Mussini^{1,2}

¹Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Infectious Diseases Clinic, University Hospital of Modena, Modena, Italy

- OC 71** **15.46-15.56 Predictors of linkage to prevention services after HIV Post-Exposure Prophylaxis (PEP): a retrospective analysis from 2019 to 2024**

R. Esvan, G. Micheli, A. Giacinta, A. Caioli, V. Barchi, A. Oliva, A. D'Agostino, R. Schiavone, A. Lener, E. Gennaro, A. Antinori, V. Mazzotta
 National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

- 15.58-16.05 **Conclusion** A. Calcagno, Torino; L. Sasset, Padova

**ORAL COMMUNICATIONS** 15.05-16.05**SALA CARRARESI****PrEP issues: adherence and STI**

Chairs: Francesco Barbaro (Padova), Dario Bernacchia (Legnano MI)

15.05-15.10 **Introduction**

F. Barbaro, Padova; D. Bernacchia, Legnano MI

OC 72 15.10-15.20 **Comparison of users accessing PrEP in hospital-based or community-based settings: first picture from the PRIDE cohort**

V. Mazzotta¹, A. Tavelli², T. Masoero², E. Caruso³, A. Lucchini⁴, D. Tesoro⁵, D. Moschese⁶, F. Leserri⁷, M. Farinella⁸, R. Esvan¹, N. Frattini³, A. De Bona⁵, C. Fusetti⁹, L. Del Negro², G. Del Duca¹, L. Taramasso⁹, F.M. Fusco¹⁰, M. Menozzi¹¹, E. Milano¹², R. Rossotti¹³, F. Barbaro¹⁴, A. Giacinta¹, S. Cerere¹⁵, M. Giglia¹⁶, S. Venturelli¹⁷, M. Ridolfi¹⁸, M. Ceccarelli¹⁹, M. Cernuschi³, A. d'Arminio Monforte², A. Castagna²⁰, A. Antinori¹, S. Nozza²⁰

¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, ²ICONA Foundation, Milano, Italy, ³Milano Checkpoint ETS, Milano, Italy, ⁴Azienda Sanitaria Locale "Città di Torino", Torino, Italy, ⁵ASST Santi Paolo e Carlo, Milano, Italy, ⁶Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ⁷Checkpoint PLUS Roma, Roma, Italy, ⁸Circolo di Cultura Omosessuale Mario Mieli, Roma, Italy, ⁹IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ¹⁰AORN Ospedali dei Colli, Napoli, Italy, ¹¹Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ¹²University Hospital Polyclinic, University of Bari, Bari, Italy, ¹³ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁴University Hospital of Padova, Padova, Italy, ¹⁵BLQ Checkpoint, Bologna, Italy, ¹⁶IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ¹⁷ASST Papa Giovanni XXIII, Bergamo, Italy, ¹⁸Sapienza University of Rome, Roma, Italy, ¹⁹School of Medicine and Surgery, "Kore" University of Enna, Enna, Italy, ²⁰IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy

OC 73 15.22-15.32 **Comparing Self-Reported and Pharmacy-Based Monitoring Adherence rates in individual accessing HIV Pre-Exposure Prophylaxis (PrEP): An 18-Month Retrospective Analysis**

R. Brunoro¹, D. Mengato¹, E. Giunco¹, F. Barbaro², A.M. Cattelan², F. Venturini¹

¹Hospital Pharmacy - University Hospital of Padua, Padua, Italy, ²Infectious and Tropical Diseases Unit - University Hospital of Padua, Padua, Italy

OC 74 15.34-15.44 **STI occurrence among PrEP users: a six-year follow-up study from the Bergamo centre**

S. Venturelli¹, L. Baldassari², L. Comi¹, F. Borghi¹, A. Francavilla³, D. Ripamonti¹

¹Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, ³Bergamo Hospital Research Foundation - ETS (FROM), Bergamo, Italy

OC 75 15.46-15.56 **PrEP and STIs screening policies: one size fits all?**

E. Schlitzer¹, S. Cecere¹, S. Mattioli¹, L. Del Negro², F. Leserri²

¹Plus aps, Bologna, Italy, ²Plus Roma aps, Rome, Italy

15.58-16.05 **Conclusion**

F. Barbaro, Padova; D. Bernacchia, Legnano MI

**SHORT COMMUNICATIONS** 15.05-16.05**SALA ANTENORE****From epidemiology to innovation: vaccine coverage and viral pathogenesis**

Chairs: Guido Antonelli (Roma), Gabriella d'Ettorre (Roma)

15.05-15.08 **Introduction**

G. Antonelli, Roma; G. d'Ettorre, Roma

SC 32 15.08-15.15 **Implementation of a monitoring system for immunization coverage in people living with HIV in the Lombardy region**

M. Maffeo^{1,2}, A. De Monte³, S. Villa³, S. Scarioni^{1,2}, C. R. Borriello^{1,2}, G. Del Castillo², M. Mezzatesta⁴, G. Preziosi⁴, N. Paniconi⁴, B. Opauski⁴, D. Cereda²

¹ASST Fatebenefratelli Sacco, University Hospital, Milan, Italy, ²Directorate General for Health, Lombardy Region, Milan, Italy, ³Department Biomedical Sciences for Health, University of Milan, Milan, Italy, ⁴ARIA S.P.A., Milan, Italy

SC 33 15.17-15.24 **Implementing the National Vaccination Plan in People with HIV (PWH): a national survey among ICONA centers**

A. Russo¹, A. Giacomelli², A. De Vito³, M. Mazzitelli⁴, M. Ceccarelli⁵, S. De Benedittis⁶, A. Tavelli^{6,14}, M. Cernuschi⁷, L. Taramasso⁸, M. Lichtner⁹, V. Mazzotta¹⁰, E. Girardi¹¹, C. Mussini¹², S. Lo Caputo¹³, A. d'Arminio Monforte⁶ on behalf of Icona Foundation Study Group

¹AOU "Luigi Vanvitelli", Unit of Infectious Disease Malattie, Naples, Italy, ²III Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC Luigi Sacco, Università degli Studi di Milano, Milan, Italy, ³Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ⁴Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁵Unit of Infectious Diseases, School of Medicine and Surgery, "Kore" University of Enna, Enna, Italy, ⁶ICONA Foundation, Milan, Italy, ⁷A.S.A. Onlus - Association of Solidarity 'AIDS, Italy, ⁸Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁹Clinical Infectious Diseases, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy, ¹⁰Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ¹¹Scientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ¹²Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ¹³Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹⁴National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy

- SC 34** **15.26-15.33 Generation of a novel and safe viral-based neutralization assay for monitoring Flavivirus emerging and re-emerging zoonoses**
A. Gallinaro¹, C. Falce¹, I. Farina², Z. Michelin¹, M.F. Pirillo¹, M. Borghi², A. Canitano¹, A. Amendola², D. Lelli³, G. Pezzoni³, R. Suzuki⁴, G. Venturi², D. Negri², A. Cara¹
¹National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, ²Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy, ³Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, IZSLER, Brescia, Italy, ⁴National Institute of Infectious Diseases, Tokyo, Japan
- SC 35** **15.35-15.42 Incidence and Risk Factors of HPV-16 Clearance at the Anal Site in MSM with HIV**
E. Bruzzesi^{1,2}, M. Negri¹, N. Capra², R. Lolatto², C. Candela¹, A.R. Raccagni¹, G. Ponta¹, A.M. Tamburini³, E. Criscuolo⁴, R. Burioni⁴, A. Castagna^{1,2}, S. Nozza^{1,2}
¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Gastrointestinal Surgery Unit, San Raffaele Scientific Institute, Milan, Italy, ⁴Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
- SC 36** **15.44-15.51 G-Quadruplexes are Molecular Switches in HIV-1 Latency Regulation**
E. Ruggiero¹, M. Terreni¹, B. Tosoni¹, R. Perrone^{1,2}, P. Soldà¹, I. Frasson¹, M. Nadai¹, L. Sasset³, M. Mazzitelli³, A. Garzino-Demo^{1,4}, A.M. Cattelan^{1,3}, S.N. Richter^{1,3}
¹University of Padova, Padova, Italy, ²Buck Institute for Research on Aging, Novato, CA, USA, ³Padova University Hospital, Padua, Italy, ⁴University of Maryland Baltimore School of Medicine, Baltimore, Maryland, USA
- SC 37** **15.53-16.00 Low-level viremia during antiretroviral treatment is not associated with impaired immunological recovery in the second-generation INSTI era**
T. Clemente¹, N. Capra¹, R. Lolatto¹, G. Catalano², M. Negri², G. Torkjazi², D. Canetti¹, S. Bossolasco¹, E. Messina¹, S. Nozza^{1,2}, V. Spagnuolo¹, A. Castagna^{1,2}
¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy
- 16.02-16.05 **Conclusion** G. Antonelli, Roma; G. d'Ettore, Roma



SHORT COMMUNICATIONS 15.05-16.05

SALA DONATELLO

Challenges in prevention

Chairs: Annapaola Callegaro (Milano), Luna Colagrossi (Roma)

- 15.05-15.08 **Introduction** A. Callegaro, Milano; L. Colagrossi, Roma
- SC 38** **15.08-15.15 Predictors of STI reinfection in a monocentric cohort of high-risk men who have sex with men**
P.F. Salvo¹, A. Vella², R.J. Steiner¹, G. Cucinotta¹, G. Lenzi¹, V. Iannone¹, C. De Vivo¹, A. Carbone¹, D. Farinacci³, F. Lombardi^{1,3}, S. Di Giambenedetto^{1,3}, C. Torti^{1,3}, G. Balzin^{1,3}
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, ³Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- SC 39** **15.17-15.24 Mpox vaccination and natural immunity: a comparative serological study**
D. Maddalena, M. Cutrera, F. Caruso, A. Mancon, C. Fusetti, A. Rizzo, M.V. Cossu, B. Argentero, A. Giacomelli, A. Riva, A. Gori, D. Mileto, D. Moschese
 ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- SC 40** **15.26-15.33 Macrolide-resistant Mycoplasma genitalium: epidemiological insights from a clinical study in high-risk populations**
G. Ciaccioli¹, D. Tesoro¹, L. Biasoli¹, G. Ancona¹, E. Zaninetta¹, T. Bini¹, L. Nekrasova², O. Turri², D. Campisi², E. Borghi², C. Tincati¹, A. De Bona¹, G. Marchetti¹
¹Clinic of Infectious Diseases, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, ²Department of Laboratory Diagnostic Technologies, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy
- SC 41** **15.35-15.42 One-year experience in HIV non-occupational post-exposure prophylaxis (nPEP) management at Jenner 44 STI clinic - Luigi Sacco Hospital, Milan, Italy: focus on adherence**
L. Cordier¹, V. Di Cristo¹, A. Grisolia¹, M. Morosi¹, A. Lombardi³, A. Rizzo³, E. Villa¹, A. Gori², A. Capetti¹
¹SSD Fragilità e Prevenzione, Jenner 44 - Infectious Diseases Department - Luigi Sacco Hospital - Milan, Italy, ²Director Department of Infectious Diseases, Head Infectious Disease Unit - Luigi Sacco Hospital - Milan, Italy, ³Laboratory of Clinical Microbiology, Virology and Bioemergencies - Luigi Sacco Hospital - Milan, Italy
- SC 42** **15.44-15.51 Burden of Anal High Grade Dysplasia is High Among an Under-screened Population Such as Women Living With HIV**
E.N. Cavallari¹, F. Tanzi², A. Federica¹, A. Lazzaro¹, M. Ridolfi¹, A. Pernazza³, I. Palaia², V. Di Donato², C.M. Mastroianni⁴, G. d'Ettore⁴
¹Azienda Ospedaliera-Universitaria Policlinico Umberto I, Rome, Italy, ²Department of Gynecology "Sapienza" University, Rome, Italy,

³Department of Radiological Oncological and Pathological Sciences "Sapienza" University, Rome, Italy, ⁴Department of Public Health and Infectious Diseases "Sapienza" University, Rome, Italy

SC 43

15.53-16.00 Is DoxyPEP Being Overused? Insights from a PrEP Clinic Cohort

F. Caruso^{1,2}, C. Fusetti¹, F. Petri¹, D. Maddalena^{1,2}, R. Fattore^{1,2}, M. Cossu¹, A. Gori^{1,2}, D. Moschese¹

¹Department of Infectious Diseases, Luigi Sacco Hospital, Milan, Italy, ²Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy

16.02-16.05 **Conclusion**

A. Callegaro, Milano; L. Colagrossi, Roma

**SPECIAL SESSION** 16.10-16.35**SALA PLENARIA MANTEGNA****ICAR 2025 Awards and closing remarks**

Chairs: Annamaria Cattelan (Padova), Paolo Meli (Bergamo), Saverio Parisi (Padova), Stefano Rusconi (Legnano MI)

ICAR support and reward the young excellences of Italian research with special prizes announced and awarded during this Session.

16.10-16.15

ICAR 2025 Scientific Committee Awards

Annamaria Cattelan (Padova), Paolo Meli (Bergamo), Saverio Parisi (Padova), Stefano Rusconi (Legnano MI)

Three prizes for the best **Clinical, Basic and Social Science Abstracts**.



16.15-16.20

The Editorial Prize at ICAR 2025
Sexually Transmitted Infections Journal (BMJ Group)

A.M. Geretti, Roma

A prize for the oral presentation that best reflects the scope, aims and themes of the journal. The winner will receive a 1-year mentored position as an editorial member of Perspectives, a regular journal section, providing an excellent introduction to editorial responsibilities.

Sexually Transmitted Infections

16.20-16.30

ICAR Call for Research 2025-2026

A. Castagna, Milano

ICAR-SIMIT launches an Open Call to select biomedical Research Projects that aims to address some of the main health challenges currently faced and best reflect ICAR themes. The fundamental aim of this call is to foster groundbreaking and relevant research projects that lead to the advancement of knowledge and offer solutions related to some of the most significant health problems linked to HIV/AIDS.



16.30-16.35

Closing remarks and ICAR 2026 announcement

Antonella Castagna (Milano), Annamaria Cattelan (Padova), Paolo Meli (Bergamo), Saverio Parisi (Padova), Stefano Rusconi (Legnano MI)



No boundaries in Infection Research and Care

POSTER EXHIBITION and CLINICAL CASES



All posters can be viewed through dedicated multimedia areas, on the third floor of the Congress Centre, during all Conference days. On 22 and 23 May, from 13.20 to 14.00, there will be Poster Viewing with the Authors, as follows:

Multimedia area 1

Clinical HIV • Hepatitis and Liver Diseases

Multimedia area 2

HIV: Antiretroviral therapy • Infections in the Immunocompromised Host

Multimedia area 3

Epidemiology • Social Science, PROs

Multimedia area 4

Ageing • Basic Science-Immunology • PrEP • STIs • Vaccines • Virology and Pharmacology

Presenting Authors are requested not to exceed 5 minutes for the presentation of their work, to give everyone the opportunity to present their Poster.



Ageing

- P 1 Ageing in HIV from a gender perspective: results from a survey assessing needs and provisions of care**
M. Cascio^{1,2}, R. Iardino³, A. d'Arminio Monforte^{2,4}, S. Lo Caputo^{2,5}, S. Nozza^{2,6}, N. Policek^{1,2,7}, S. Negri^{2,8}, L. Brogonzoli³, S. Mattioli⁹, L. del Negro¹⁰, E. Sala¹¹
¹European AIDS Treatment Group (EATG), Brussels, Belgium, ²HIV Outcomes Italy, Milan, Italy, ³Fondazione The Bridge, Milan, Italy, ⁴Fondazione Icona, Milan, Italy, ⁵University of Foggia, Foggia, Italy, ⁶IRCCS-Ospedale S. Raffaele, Milan, Italy, ⁷NPS Italia Onlus, Milan, Italy, ⁸ANLAIDS Lombardia ETS, Milan, Italy, ⁹Plus APS, Bologna, Italy, ¹⁰Plus Roma, Rome, Italy, ¹¹University of Pavia, Pavia, Italy
- P 2 Attitudes toward ageing and HIV-related stigma in elderly people with HIV**
S. Gardin¹, M. Mazzitelli¹, L. Sasset¹, D. Leoni¹, A. Ferrari¹, V. Scaglione¹, F. Colombo¹, A. Cattelan^{1,2}
¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ²Department of Molecular Medicine, Padua University, Padua, Italy
- P 3 The Glasgow Manifesto in Italy: A platform for change**
N. Policek, A. Kalogiannis, C. Longhi, M. Cascio
European AIDS Treatment Group, Brussels, Belgium

Basic Science - Immunology

- P 4 Elevated levels of interleukin-15 in naïve PLWH normalize earlier for those treated in the primary phase of infection**
G. Bozzi¹, M. Centazzo^{2,3}, S. Scaglioni^{2,3}, G.M. Butta^{2,4}, P. Saltini^{1,3}, A. Liparoti^{1,3}, A. Gori³, A. Bandera^{1,3}, L. Manganaro^{2,3}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²National Institute of Molecular Genetics, Rome ed Enrica Invernizzi, Milan, Italy, ³UNIMI Università degli Studi di Milano, Milan, Italy, ⁴Icahn School of Medicine at Mount Sinai, New York City, USA
- P 5 Evaluation of T cell-mediated immune response after dengue infection: a comparison between people living with HIV and HIVnegative individuals**
P.F. Salvo¹, F. Lombardi^{1,2}, G. Baldin², V. Campolattano¹, I. Aversa³, A. Abatino³, S. Di Giambenedetto^{1,2}, C. Palmieri³, C. Torti^{1,2}
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, ³Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi Magna Grecia, Catanzaro, Italy
- P 6 Immunomodulatory effects of HIV Tat's N-terminal sequence on CD8+ T cells**
E. Tassani, M. Martino, B. Dallan, D. Proietto, V. Albanese, S. Pacifico, A. Caputo, R. Gavioli, E. Torreggiani, F. Nicoli
University of Ferrara, Ferrara, Italy
- P 7 The opposite trend of neurotrophins NGF and BDNF during HIV pathogenesis**
L. Maddaloni¹, P. Rosso², E. Fico², A. Lazzaro³, M. Ridolfi³, F. Alessi³, M. Fracella¹, G. Ferraguti⁴, C. Scagnolari¹, M. Fiore², G. d'Ettore³
¹Department of Molecular Medicine, University of Rome La Sapienza, Rome, Italy, ²Institute of Biochemistry and Cell Biology, National Research Council (CNR), Rome, Italy, ³Department of Public Health and Infectious Diseases, University of Rome La Sapienza, Rome, Italy, ⁴Department of Experimental Medicine, University of Rome La Sapienza, Rome, Italy

Clinical HIV

- P 8 Anal cancer screening in Italy: a pilot survey**
M.G. Donà¹, A. Pellegrini², F. Rollo³, A. Latini¹, E. Giuliani¹, V. Laquintana³, M. Benevolo³ on behalf of the ITACA working group
¹San Gallicano Dermatological Institute IRCCS, Rome, Italy, ²Società Italiana di Citologia (SICI), Rome, Italy, ³IRCCS Regina Elena National Cancer Institute, Rome, Italy
- P 9 Anal cancer screening uptake in a cohort of women with HIV**
M. Mazzitelli¹, D. Leoni¹, C. Cozzolino², C. Ruffolo³, M. Scarpa³, S. Ferrari³, G. Spolverato³, L. Franchin⁴, L. Sasset¹, A. Ferrari¹, V. Baldo², A. Cattelan¹
¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ²Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Italy, ³General Surgery, 3rd division Padua University Hospital, Padua, Italy, ⁴Microbiology and Virology Unit, Padua University Hospital, Padua, Italy

- P 10 Bempedoic Acid and Evolocumab in People Living with HIV: A Real-World Strategy for Achieving LDL Targets in Statin-Intolerant or Reluctant Patients**
M. Menozzi¹, M. Manicardi², G. Cuomo¹, G. Mancini¹, A. Pugliese³, J. Milic⁴, L. Benassi⁴, F. Romani⁴, S. Ambrosio⁴, G. Guaraldi⁴, C. Mussini⁴
¹Infectious Disease Clinic – Modena HIV Metabolic Clinic, University Hospital of Modena, Modena, Italy, ²Cardiology Clinic, AOU Policlinico di Modena, Modena, Italy, ³Pharmaceutical Department, AOU Policlinico di Modena, Modena, Italy, ⁴Infectious Disease Clinic - Modena HIV Metabolic Clinic - Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy
- P 11 Beyond viral suppression: navigating the polypharmacy maze in elderly people with HIV on antiretroviral therapy**
C. Gioè¹, M. Trizzino¹, F. Zimmerhofer², A. Cicero², L. Pipitò², A. Cascio²
¹Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, ²Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy
- P 12 Cardiovascular management in PLWH: poor adherence to blood pressure and LDL-C targets**
F. Chiappini, C. Ucciferri, K. Falasca, J. Vecchiet
Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy
- P 13 Carotid and femoral intima media thickness (c-IMT and f-IMT): risk stratification for cardiovascular events in PLWH**
G.B. Martone¹, I. Capriglione¹, A. Boccia¹, V. Iodice², A. Masiello², F. Simeone², A. Iodice², P. Maggi²
¹Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy, ²Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy
- P 14 Challenging retention in care in HIV-vertically acquired people: a real life experience**
A. D'Angelillo¹, G. Lorenzetti², V. Iannone¹, D. Farinacci³, A. Bertoli⁵, M. Santoro⁵, S.F. Ceccherini⁵, L. Colagrossi⁴, C.F. Perno⁴, S. Di Giambenedetto^{1,3}, S. Bernardi²
¹Catholic University of Sacred Heart, Department of Healthcare Surveillance and Bioethics, Section of Infectious Diseases Rome, Italy, ²Perinatal and Complex Infectious Disease Unit, Bambino Gesù Children's Hospital, Rome, Italy, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy – Dipartimento di Scienze Mediche e Chirurgiche – UOC Malattie Infettive, Rome, Italy, ⁴Microbiology and Diagnostic Immunology, Bambino Gesù Paediatric Hospital, Rome, Italy, ⁵University of Rome Tor Vergata, Rome, Italy
- P 15 Changes in bone mineral density and bone turnover markers in antiretroviral therapy-naïve people with HIV starting bicitgravir/emtricitabine/tenofovir alafenamide or doravirine/lamivudine/tenofovir disoproxil fumarate**
L. Calza¹, M. Giglia¹, C. Rigamonti¹, A. Zuppiroli¹, D. Marzolla¹, I. Bon², P. Viale¹
¹Unit of Infectious Diseases, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy, ²Unit of Microbiology I, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy
- P 16 Changes in glucose homeostasis in people living with HIV naïve to antiretroviral therapy and starting dolutegravir/lamivudine or bicitgravir/emtricitabine/tenofovir alafenamide**
L. Calza, M. Giglia, A. Zuppiroli, D. Marzolla, C. Rigamonti, S. Cretella, P. Viale
Unit of Infectious Diseases, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy
- P 17 Changes in lipid profile and cardiovascular risk after switching to long-acting cabotegravir/rilpivirine**
A. Carraro¹, R. Marocco², L. Ansaldo², G. Mancarella², S. Corazza³, A. Grimaldi³, S. De Maria³, A. Gasperin³, C. Del Borgo², M. Lichtner⁴
¹Infectious diseases Unit Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy, ²Infectious diseases Unit Santa Matia Goretti Hospital, Sapienza University of Rome, Latina, Italy, ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ⁴Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy
- P 18 Comorbidities predict longitudinal cognitive changes in People with HIV**
E. Vuaran¹, S. Calza², S. Miglietta¹, M. Trunfo^{1,3}, D. Vai⁴, C. Tettoni¹, G. Guastamacchia⁵, M. Agnesone⁴, S. Bonora¹, A. Calcagno¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ³HIV Neurobehavioral Research Program, Departments of Neurosciences and Psychiatry, University of California San Diego, San Diego, USA, ⁴Psicologia Aziendale, ASL "Città di Torino", Turin, Italy, ⁵Unit of Neurology, "Maria Vittoria" Hospital, ASL "Città di Torino", Turin, Italy
- P 19 Correlation between lipid profile, subclinical atherosclerosis and hepatic fibrosteatosis in PLWH: comparison between TAF/FTC/BIC and TDF/3TC/DOR**
I. Capriglione¹, A. Boccia¹, G.B. Martone¹, V. Iodice², A. Masiello², F. Simeone², A. Iodice², P. Maggi²
¹Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy, ²Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy
- P 20 Disparities in cardiovascular risk management for PLWH: a comparison of ESC and EACS guidelines**
F. Chiappini¹, C. Ucciferri¹, K. Falasca¹, J. Vecchiet¹, R. Tommasi², I. Odeshchak²
¹Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, ²University Cardiology Division, Heart Department, Policlinico "SS Annunziata", Chieti, Italy
- P 21 Evolution of liver fibrosis in a cohort of people living with HIV without active hepatitis co-infections**
M. Crispo^{1,2}, F. Panza^{1,2}, A. Bailoni^{1,2}, E. Morelli^{1,2}, M. Zanchi², G. Giuliano², F. Pippi², M. Sambo^{1,2}, F. Montagnani^{1,2}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy
- P 22 Glucose homeostasis in People Living With HIV starting long-acting antiretroviral therapy**
A. Zuppiroli, M. Giglia, C. Rigamonti, D. Marzolla, S. Cretella, L. Calza, P. Viale
Infectious Diseases Unit, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy
- P 23 HIV & MASLD burden: longitudinal changes, predictive factors and prognostic impact in people living with HIV from Southern Italy**
E. Zappulo¹, A. Iuliano¹, F. Spada¹, D. Pietrolungo¹, L. Liguori¹, S. Mercinelli¹, L. Bianco¹, M. Cotugno¹, G. Di Filippo¹, I. Gentile¹
¹Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University of Naples Federico II, Naples, Italy, ²Azienda Ospedaliero Universitaria San Giovanni di Dio Ruggi d'Aragona, Salerno, Italy
- P 24 HIV indicator conditions prior to late presentation: a ten-year analysis in a major clinical center—implications for addressing missed opportunities in one of Italy's top five most affected cities**
G. Bo¹, G.C. Orofino², T. De Blasi², M. Guastavigna², A. Ianniello³, C. Bobba¹, M. Quaranta¹, G. Calleri²
¹Medical Science Department, University of Turin, Turin, Italy, ²Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ³Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy
- P 25 HIV Still Hiding in Reservoirs: Four Cases of Symptomatic CSF Escape with Tenofovir Alafenamide/Emtricitabine/Bictegravir**
C. Pinnetti¹, C. Lipani², A. Perinzano², I. Mastrorosa¹, F. Romano², V. Mazzotta¹, R. Bosio², R. Gagliardini¹, C. Calitri², S. Bonora², A. Antinori¹, A. Calcagno²
¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino - Ospedale Amedeo di Savoia, Italy
- P 26 Implementation of Statin Therapy in an HIV-Positive Cohort: Real-World Challenges and Insights from the REPRIEVE Trial**
C. Muscatello, C. Grillo, A. Narducci, F. Ieva, M.G. Nyenyeri, S. Ferrara, S. Lo Caputo
Infectious Disease Unit, Department of Medical and Surgical Science, University of Foggia, Foggia, Italy

- P 27 Lost to follow-up: what's happened? A single center analysis**
C. Grillo, F.R.P. Ieva, R. Papale, A. Narducci, F. De Gregorio, M. Niglio, C. Muscatello, M.G. Nyenyeri, S. Ferrara, S. Lo Caputo
Division of Infectious Diseases, AOU Policlinico Riuniti Foggia, Italy
- P 28 Management of pregnancy in women living with HIV: a two-week neonatal prophylaxis and breastfeeding experience**
D. Piacentini¹, L. Cosimi², G. Nicolini³, G. Piccolini⁴, D. Bugana⁵, R. Scaggiante¹, M. Lanzafame⁶
¹Infectious Diseases Unit, Specialistic Area Department, S. Martino Hospital, Belluno, Italy, ²Clinical Department of Medical, Surgical and Health Sciences, University of Udine, Italy, ³Pediatric and Neonatal Pathology Unit, Medical Area Department, S. Martino Hospital, Belluno, Italy, ⁴Laboratory Analysis Unit, Laboratory and Pathology Diagnostic Department, S. Martino Hospital, Belluno, Italy, ⁵Obstetrics and Gynecology Unit, Surgical Area Department, S. Martino Hospital, Belluno, Italy, ⁶Infectious Diseases Unit, Province Agency for Health Services, S. Chiara Hospital, Trento, Italy
- P 29 Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects in Italy**
F. Romano¹, I. Getuli², M. Ridolfi¹, A. Lazzaro¹, F. Alessi¹, C.M. Mastroianni¹, L. Tarsitani², G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, ²Department of Human Neuroscience, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy
- P 30 Metabolic impact of switching TAF/FTC/RPV to BIC/TAF/FTC in a real-life setting**
L. Pagnucco, A. Arcuri, R. Gulminetti
Infectious Diseases Unit UOC, Department of Medical Science, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
- P 31 Multidimensional Scale for the Detection of Health Needs in People with HIV: Preliminary Results From the MUSA study**
A. Calcagno¹, E. Sala², L. Petrolini³, M. Polisenio⁴, M. Mazzitelli⁵, B.M. Ceslasia⁶, A. Saracino⁷, A. Cattelan⁸, G. Marchetti⁹, P. Cinque¹⁰, M.V. Cossu¹¹, C. Torti¹², S. Di Giambenedetto¹³, G. Madeddu¹⁴, M. Giacomini¹⁵, R. Iardino¹⁶, L. Brogonzoli¹⁷
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, ²Department of Political and Social Sciences, University of Pavia, Pavia, Italy, ³Clinic of Infectious Diseases, DiMePre-J, Università di Bari, Bari, Italy, ⁴Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ⁵Garibaldi Hospital, Catania, Italy, ⁶Department of Health Sciences, Clinic of Infectious Diseases, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, ⁷Unit of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁸Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, ⁹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, ¹⁰Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ¹¹Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, Italy, ¹²Fondazione The Bridge, Milan, Italy
- P 32 Predictors of Hospitalization in HIV Patients: Identifying Key Risk Factors**
L. Moffa¹, C. Tana², C. Ucciferri¹, J. Vecchiet¹, K. Falasca¹
¹Ospedale SS. Annunziata, Clinica di Malattie Infettive e Tropicali, Chieti, Italy, ²Ospedale SS. Annunziata, Clinica di Medicina Interna e Geriatria, Chieti, Italy
- P 33 Prevalence and predictors of increased creatine phosphokinase (CPK) levels in a cohort of People Living With HIV (PLWH) treated with modern antiretroviral regimens**
F. Panza^{1,2}, E. Conticini^{3,4}, E. Morelli^{3,4}, S. Grazzini^{3,4}, A. Bailoni^{1,2}, M. Crispo^{1,2}, L. Visi¹, M. Sambo^{1,2}, F. Montagnani^{1,2}, B. Frediani^{3,4}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy, ³Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁴Rheumatology Unit, Siena University Hospital, Siena, Italy
- P 34 Prevalence, predictors and outcomes of poor immunological recovery in PLWH on effective c-ART: a retrospective study from a tertiary University center in Italy**
E. Zappulo¹, M. Sarno^{1,2}, L. Liguori¹, F. Spada¹, D. Pietrolungo¹, D. Diana¹, G. Di Filippo¹, M. Cotugno¹, S. Mercinelli¹, I. Gentile¹
¹Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University of Naples Federico II, Naples, Italy, ²U.O.S.V.D. Infectious Disease P.O. A. Cardarelli, Campobasso, Italy
- P 35 Previous COBI-including regimen is the major determinant of lipid profile modification in a cohort of PWH on stable TAF treatment switching to dual treatment**
N. Squillace¹, L. Taramasso², E. Ricci³, B. Menzaghi⁴, G. De Socio⁵, G. Orofino⁶, B.M. Ceslasia⁷, E. Sarchi⁸, G. Madeddu⁹, S. Piconi¹⁰, G. Pellicano¹¹, L. Attala¹², A. Di Biagio¹³, P. Bonfanti¹⁴, for the CISA Study Group
¹Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy, ²Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy, ³Fondazione ASIA Onlus, Buccinasco (MI), Italy, ⁴Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, ⁵Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁶Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, ⁷Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ⁸Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ⁹Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, ¹⁰Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ¹¹Infectious Diseases, G. Martino Hospital - University of Messina, Messina, Italy, ¹²Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy
- P 36 Re-CALL, Re-TURN, Re-start: a clinical project for retention in HIV care**
B. Trentacapilli¹, R. Lolatto², N. Capra², G. Ponta², S. Nozza^{1,2}, C. Muccini², E. Bruzzesi¹, V. Spagnuolo², A. Castagna^{1,2}, D. Canetti²
¹Vita-Salute San Raffaele University, Italy, ²Division of Infectious Diseases, IRCCS Ospedale San Raffaele, Italy
- P 37 Screening with GAD-2 in a real-life outpatient setting in Milan. High prevalence of anxiety, associated factors and acceptance of psychological assessment**
G. Bozzi¹, A. Pastena^{1,2}, A. Liparoti^{1,2}, S. Negri³, V. Castelli¹, B. Mariani¹, A. Muscatello¹, A. Bandera^{1,2}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²UNIMI Università degli Studi di Milano, Milan, Italy, ³Anlaidi Lombardia, Milan, Italy
- P 38 Statin use in people living with HIV without apparent cardiovascular risk factors: observational study of an outpatient cohort**
V. D'Aquila¹, D. Zaccà¹, D. Kontogiannis¹, C. Aguglia¹, I. Fato¹, N. Braccialarghe¹, G. Alessio¹, F. Barreca², M. Zordan², A. Di Lorenzo², L. Ansaldo¹, D. Checchi², G. De Simone², T. Mulas², M. Compagno², E. Teti², V. Malagnino¹, M. Iannetta¹, L. Sarmati¹, A.M. Geretti¹
¹Tor Vergata University, Rome, Italy, ²Tor Vergata Hospital, Rome, Italy
- P 39 Temporal trends, clinical correlates and prognostic potential of advanced disease in naïve PLWH and impact of COVID-19 pandemic: preliminary results of a 20-year retrospective cohort study**
E. Zappulo, G. Festa, D. Pietrolungo, L. Liguori, F. Spada, F. Cuccurullo, G. Di Filippo, S. Mercinelli, M. Cotugno, I. Gentile
Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University of Naples "Federico II", Naples, Italy
- P 40 The role of inflammatory and atherogenic markers in a group of young men living with HIV with erectile dysfunction: a cross-sectional study**
G. Tiecco¹, M. Riva², F. Cesanelli¹, L. Rossi¹, C. Colangelo¹, S.A. Reale¹, F. Gottardi¹, A. Delbarba³, C. Cappelli³, E. Focà¹, F. Castelli¹, E. Quiros-Roldan¹
¹Department of Clinical and Experimental Sciences, Unit of Infectious Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ²Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, ³Unit of Endocrinology and Metabolism, Department of Medicine, ASST Spedali Civili di Brescia, Brescia, Italy
- P 41 Transgender people with HIV: challenges in the ART management**
P. Pasculli¹, M.A. Zingaropoli¹, F. Dominelli¹, S. Iaquinandi¹, M. Guardiani¹, M. Antonacci¹, Y. Fosso¹, M. Lichtner², C.M. Mastroianni¹, M.R. Ciardi¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy

Epidemiology

- P 42 A walk on the wild side: an observational retrospective single center study on a cohort of Trans* women coming from Latin America accessing clinics for HIV and STIs in a teaching hospital in Rome**
A. Destro¹, M. Ridolfi², A. Lazzaro², F. Alessi², F. Ciccone¹, G. d'Ettore¹
¹"Sapienza" University of Rome, Italy, ²Policlinico "Umberto I" Rome, Italy
- P 43 An HIV Clinic in Bouar, Central African Republic: the cure moves where medical care is missing**
M. Strano^{1,2}, F. Alberton¹, A. Sala³, T. Danazomo³, C. Berton^{1,2}, T. Pozzi³, A. Castagna^{1,2}, G. Gaiera¹
¹IRCCS Istituto Scientifico San Raffaele, Unità Operativa di Malattie Infettive, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Italy, ³Centre Saint Michel, Bouar, Central African Republic
- P 44 Antiretroviral therapy in pregnant women living with HIV: real-life data from a tertiary center catering to the greater Milan area, 2019-2025**
G. Bozzi¹, M. Pernich^{1,2}, A. Liparoti^{1,2}, V. Castelli¹, B. Mariani¹, A. Muscatello¹, B. Tassis¹, E. Sina^{1,2}, C. Tagliabue¹, G. Di Pietro¹, C. Pietrasanta¹, I. Cetin^{1,2}, P. Marchisio^{1,2}, M. Fumagalli^{1,2}, A. Bandera^{1,2}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²UNIMI Università degli Studi di Milano, Milan, Italy
- P 45 Association of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio values with mortality and the occurrence of non-AIDS and AIDS events**
V. Spagnuolo¹, A. Cozzi-Lepri², A. Cervo³, G. Madeddu⁴, A. Bandera⁵, V. Mazzotta⁶, G. D'Ettore⁷, G. Orofino⁸, L. Sarmati⁹, L. Calza¹⁰, A. Mondì¹¹, A. Di Biagio¹¹, A. Cingolani¹², C. Mussini³, A. Antinori¹, A. Castagna¹ on behalf of the Icona Foundation Study Group
¹Unit of Infectious Diseases; IRCCS San Raffaele Hospital, Milan, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ⁴Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ⁵Clinic of Infectious Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ⁶Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁷Department of Public Health and Infectious Diseases, Umberto I Hospital, Sapienza University of Rome, Rome, Italy, ⁸Division I of Infectious and Tropical Diseases, ASL Città di Torino, Turin, Italy, ⁹Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Policlinico Tor Vergata of Rome, Rome, Italy, ¹⁰Infectious Diseases Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ¹¹Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Department of Health Science (DISSAL), University of Genova, Italy, ¹²UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, Italy
- P 46 Characteristics and clinical outcomes of individuals with HIV and late diagnosis in a healthcare setting in eastern Sicily over the past 15 years**
B.M. Celesia, B. Bellocchi, M.S. Paternò Raddusa, C. Gullotta, G. Bruno, R. Bruno, N. Villari, E. Pistarà, V. Moscat, M.G. Coco, F. Cosentino, A. Franzò, A. Marino, B.S. Cacopardo, G. Nunnari
Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi Catania, Italy
- P 47 Clinical characteristics and molecular dynamics of Dengue Cases occurring in Liguria in 2024**
G. Garzillo¹, M. Lucente², C. Fracalvieri², B. Galano², M. Ogliastrò², A. Lai³, V. Paolozzi¹, F. Moroni³, G. Zehender²
¹Department of Health Science (DISSAL), University of Genoa, Genoa, Italy, ²Hygiene Unit, Policlinico San Martino Hospital, Genoa, Italy, ³Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- P 48 Cluster of primary HIV infections sustained by CRF02_AG in intravenous drug users in Milan**
G. Bozzi¹, C. Alteri^{1,2}, M. Pernich^{1,2}, A. Liparoti^{1,2}, V. Castelli¹, B. Mariani¹, S. Uceda Renteria¹, L. Morelli³, V. Micheli³, A. Callegaro¹, A. Muscatello¹, A. Bandera^{1,2}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²UNIMI Università degli Studi di Milano, Milan, Italy, ³ASST Fatebenefratelli Sacco, Milan, Italy
- P 49 Co-circulation and co-infection with different influenza viruses in the 2024-2025 FLU season**
G. Garzillo¹, F. Stefanelli², G. Guarona¹, B. Galano², R. Qosja², V. Chessa², V. Paolozzi¹, V. Ricucci², A. Lai³
¹Department of Health Science (DISSAL), University of Genoa, Genoa, Italy, ²Hygiene Unit, San Martino Hospital, Genoa, Italy, ³Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- P 50 Correlation of self-test for HIV bought by pharmacies and regional incidence of HIV in Italy: 2018-2023**
S. Leone¹, P. Piselli¹, E. Gennaro¹, B. Suligoi², A. Caraglia³, A. Antinori¹, E. Girardi¹ for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"
¹Istituto Nazionale per le Malattie Infettive L. Spallanzani IRCCS, Rome, Italy, ²Istituto Superiore di Sanità, Rome, Italy, ³Ministero della Salute, Rome, Italy
- P 51 Drug resistance mutations among ART-naïve individuals in Lecco**
F. Conti, N. Gemignani, M. Bottanelli, V. Morena, L. Bradanini, A. Chiesa, C. Molteni, A. Pandolfo, S. Pontiggia, G. Valsecchi, S. Volpi, S. Piconi
Infectious diseases unit – Alessandro Manzoni Hospital, ASST Lecco, Italy
- P 52 Epidemiology of Enteroviruses in Liguria: Analysis of Data from January 2024 to February 2025**
G. Guarona², C. Fracalvieri¹, M. Lucente¹, M. Ferraris¹, B. Galano¹, R. Qosja¹, B. Giusto¹, S. Varesano¹, V. Ricucci¹
¹Hygiene Unit, Policlinico San Martino Hospital, Genoa, Italy, ²Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
- P 53 Expanding HCV screening in hospitalized patients: preliminary data of a single centre experience in Monza, Italy**
G. Ghilardi¹, V. Brogna¹, N. Corti¹, F. Artelli¹, E. Colella², I. Caramma², M. Faltoni², M. Locatelli², V. Cogliandro², L. Bisi², A. Rugova², A. Soria², P. Bonfanti¹
¹Università Milano-Bicocca, Monza, Italy, ²Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- P 54 HIV infection in migrants from Sub-Saharan Africa in the North East of Italy**
A. Ferrari¹, M. Cola¹, L. Sasseti¹, C. Cozzolino², M.C. Rossi³, F. Rigo⁴, V. Del Punta⁵, A. Londero⁶, M. Lanzafame⁷, S. Panese⁸, E. Erne⁹, D. Piacentini¹⁰, M. Malena¹¹, V. Manfrin⁴, A.M. Cattelan¹
¹Tropical and Infectious Diseases Clinic, Padua University Hospital, Padua, Italy, ²Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padua, Italy, ³Infectious Diseases Unit, Treviso Hospital, Treviso, Italy, ⁴Infectious Diseases Unit, Vicenza Hospital, Vicenza, Italy, ⁵HIV Outpatient Clinic, Verona, Italy, ⁶Infectious Diseases Unit, University Hospital, Udine, Italy, ⁷Infectious Diseases Unit, Trento Hospital, Trento, Italy, ⁸Infectious Diseases Unit, Mestre-Venice Hospital, Venice, Italy, ⁹Infectious Diseases Unit, Bolzano Hospital, Bolzano, Italy, ¹⁰Infectious Diseases Unit, Belluno Hospital, Belluno, Italy, ¹¹Infectious Diseases Unit, Rovigo Hospital, Rovigo, Italy
- P 55 HIV testing in Italy: preliminary data from three pilot regions of the PRONTI study, 2018-2023**
F. Centrone¹, V.A. Orlando², M. Puglia³, G. Cruschelli⁴, C. Pasqualini^{5,6}, C. Galli⁷, V. Regine⁸, A. Caraglia⁹, M. Farinella¹⁰, L. Pugliese⁸, L. Rancilio¹¹, L. Tavoschi⁴, F. Voller⁵, B. Suligoi⁹, M. Chironna²
¹Hygiene Unit, Policlinic of Bari, Bari, Italy, ²Interdisciplinary Department of Medicine, University of Bari, Bari, Italy, ³Tuscany Regional Health Agency, Florence, Italy, ⁴Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ⁵Piedmont Regional Service for the Epidemiology of Infectious Diseases (SeREM), Alessandria, Italy, ⁶Research and Innovation Department (DAIRI), "SS Antonio e Biagio e C. Arrigo" University Hospital, Alessandria, Italy, ⁷PRONTI project team, independent researcher, ⁸AIDS operations center, Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy, ⁹Former General Directorate of Health Prevention, Ministry of Health, Rome, Italy, ¹⁰Mario Mieli, LGBTQIA+ Culture Center, Rome, Italy, ¹¹Caritas Ambrosiana, Milano, Italy

- P 56 Interventions to support breastfeeding among mothers living with HIV: a systematic review and meta-analysis**
F. Di Gennaro¹, F.V. Segala^{1,2}, N. Veronese³, N. Sugandhi⁴, C. Dugdale⁵, I. Kasirye⁶, A. Saracino¹
¹Clinic of Infectious Diseases, DIMEPREJ, University of Bari, Italy, ²Doctor with Africa CUAMM, ³Unicamillus Rome, Italy, ⁴WHO HIV Department, Geneva
- P 57 Investigation on the Continuum of Care in people who inject drug in Italy: the Italian NGOs contribution**
S. Leone¹, E. Gennaro¹, A. Camposeragna², M. Stagnitta², M. Farinella³, I. Pennini⁴, L. Rancilio⁵, G. Amerio⁶, L.A.H. Gbedo⁷, P. Meli⁸, D. Masci⁹, B. La Russa¹⁰, G. Giupponi¹¹, N. Frattini¹², M. Masoud¹³, S. Mattioli¹⁴, F. Leserri¹⁵, J. Testa¹⁶, A. Navarra¹, A. Caioli¹, C. Cimaglia¹, M. Nonis¹, A. Caraglia¹⁷, E. Girardi¹, P. Piselli¹ for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"
¹INMI L. Spallanzani, Rome, Italy, ²CNCA, Rome, Italy, ³Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, ⁴Arcigay, Padua, Italy, ⁵Caritas Ambrosiana, Milan, Italy, ⁶Caritas Italiana, Rome, Italy, ⁷CDCP ONLUS, Trieste, Italy, ⁸CICA, Bergamo, Italy, ⁹Fondazione Villa Maraini, Rome, Italy, ¹⁰Gruppo Abele Onlus, Turin, Italy, ¹¹LILA Como, Como, Italy, ¹²Milano Checkpoint, Milan, Italy, ¹³MIT APS, Bologna, Italy, ¹⁴PLUS Bologna, Bologna, Italy, ¹⁵Checkpoint PLUS Roma, Rome, Italy, ¹⁶SIMM, Rome, Italy, ¹⁷Ministero della Salute, Rome, Italy
- P 58 Low adherence to Post-Exposure Prophylaxis for HIV in people who underwent sexual assault: implementation of a re-call strategy**
G. Bozzi¹, A. Liparoti^{1,2}, A. Pastena^{1,2}, M. Pernich^{1,2}, V. Castelli¹, N. Iannotti¹, A. Lombardi^{1,2}, B. Mariani¹, A. Muscatello¹, A. Bandera^{1,2}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Infectious Diseases, Milano, Italy, ²Unimi - Università degli Studi di Milano, Milano, Italy
- P 59 Measles Outbreak in Liguria: Molecular Surveillance and Transmission Dynamics in 2024-2025**
S. Fracalvieri¹, N. Randazzo¹, G. Garzillo², M. Lucente¹, B. Giusto¹, S. Ferrari¹, V. Faccio³, V. Frumento³, A. Orsi²
¹Hygiene Unit, Policlinico San Martino Hospital, Genoa, Italy, ²Department of Health Science (DISSAL), University of Genoa, Genoa, Italy, ³ASL 2 Savonese, Savona, Italy
- P 60 Near full-length sequencing is able to ensure a more accurate HIV-1 subtyping: comparison with commonly used methods**
F. Smoquina, G. Bero, F. Forbici, G. Sberna, G. Rozera, I. Abbate, E. Lazzari, V. Mazzotta, A. Antinori, E. Girardi, F. Maggi, L. Fabeni
National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy
- P 61 Occupational and sexual exposures: analysis of post-exposure prophylaxis (PEP) prescription and surveillance program in a large hospital, Northern Italy**
S. Arsuffi¹, S.F. Bertolotti², D. Minisci¹, B. Fioretti¹, I. Polesini¹, V. Castelanelli¹, F. Gaffurini¹, I. Izzo¹, E. Quiros-Roldan¹, F. Castelli¹, E. Focà¹
¹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy, ²Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Italy
- P 62 Prevalence and incidence trends of AIDS events in people newly diagnosed with HIV infection before and after COVID-19 pandemic: experience from the Pisan cohort**
M. Cesaretti, F. Greco, M. Polidori, L. Del Bono, R. Iapoce, S. Colomboaioni, A. Borghetti, M. Falcone
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Pisa, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
- P 63 Respiratory pathogen profile and its association with hospitalization risk in paediatric patients with acute respiratory infection (ARI): Inpatient and outpatient comparison**
R. Scutari¹, V.C. Di Maio², M. Mastropalo¹, B. Lucignano², V. Cortazzo², M. Del Carmen Pereyra Boza², M. Onori², L. Colagrossi², M. Pisani³, T. D'Urbano², G. Ferri², F. Di Leva², A. Villani³, P. Bernaschi², C.F. Perno^{1,2}
¹Multimodal Laboratory Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ²Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ³General Pediatrics and ED 2nd Level, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
- P 64 Testing for HIV and other sexual transmitted diseases offered in the context of community based voluntary counselling and testing services in the last years in Italy (2019-2023)**
A. Caioli¹, E. Gennaro¹, C. Cimaglia¹, G. Giupponi², M. Farinella³, I. Pennini⁴, S. Patrucco⁵, M. Cernuschi⁶, L. Rancilio⁷, P. Meli⁸, M. Stagnitta⁹, D. Masci¹⁰, N. Frattini¹¹, G. Mai¹², C. Nicora¹³, S. Mattioli¹⁴, F. Leserri¹⁵, S. Leone¹, A. Navarra¹, A. Caraglia¹⁶, M. Nonis¹, E. Girardi¹, P. Piselli¹ for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"
¹INMI L. Spallanzani, Rome, Italy, ²LILA Milano, Milan, Italy, ³Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, ⁴Arcigay, Padua, Italy, ⁵Arcobaleno AIDS, Turin, Italy, ⁶Associazione Solidarietà AIDS (ASA), Milan, Italy, ⁷CARITAS Ambrosiana, Milan, Italy, ⁸CICA, Bergamo, Italy, ⁹CNCA, Rome, Italy, ¹⁰Fondazione Villa Maraini, Rome, Italy, ¹¹Milano Checkpoint, Milan, Italy, ¹²Movimento Omosessuale Sardo (MOS), Sassari, Italy, ¹³Network Persone Sieropositive (NPS) Italia, Milan, Italy, ¹⁴PLUS, Bologna, Italy, ¹⁵Checkpoint PLUS Roma, Rome, Italy, ¹⁶Ministero della Salute, Rome, Italy

Hepatitis and Liver Diseases

- P 65 A model of screening and cascade of care for chronic viral hepatitis in asylum seekers and refugees in Rome**
G. Quartini^{1,3}, E. Biliotti¹, F. Faraglia¹, S. Vita¹, A. D'Abramo¹, S. Rosati¹, N. Bevilacqua¹, D. Kontogiannis², S. Pantanella¹, E. Boschiavo¹, G. Tarabu¹, A. Lamonaca¹, A. Caioli¹, D. Francisci³, G. D'Offizi¹, E. Nicastri¹
¹National Institute for Infectious Disease "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²Department of Systems Medicine, Tor Vergata University, Rome, Italy, ³Infectious Diseases Clinic, University of Perugia, Perugia, Italy
- P 66 Bulevirtide treatment in people living with HIV/HBV/HDV coinfection**
C. Giuliani, L. Pagnucco, G. Sangaletti, A. Celsi, A. Arcuri, M. Gerola, R. Gulminetti
Infectious Diseases Unit UOC, Department of Medical Science, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
- P 67 Characterization of a cohort of liver transplant patients for HBV and/or HBV/HDV related complications: results of a Campania multicenter study**
G. Stornaivolo¹, L. Salmoni², A. Russo², D. Angrisani³, A. Santonicola⁴, G. Valente⁵, F. Longobardi^{2,6}, F. Morisco⁷, M. Persico⁸, M. Stanzione¹, C. Sagnelli², M. Pisaturo², N. Coppola²
¹AOU Vanvitelli, Naples, Italy, ²Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, ³Senior Medical Officer, Complex Operational Unit of Hepatology, AORN Cardarelli, Naples, Italy, ⁴Gastrointestinal Unit Department of Medicine Surgery and Dentistry, University of Salerno, Salerno, Italy, ⁵Hepatic Pathophysiology SATTE, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁶Complex Operational Unit of Internal Medicine and Hepatology, Gragnano Hospital, Naples, Italy, ⁷Chief of Liver and Biliary diseases Unit, University of Naples Federico II, Naples, Italy, ⁸Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Salerno, Italy
- P 68 Clinical and instrumental changes of liver function after one year of bulevirtide treatment in Chronic Hepatitis Delta with advanced hepatic disease: insight from a Monocentric Cohort study**
A. Zuppiroli, L. Badia, P. Viale
Unit of Infectious Diseases, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy
- P 69 Clinical and virological features of chronic HBV infected patients with genotype E**
M. Alberti¹, G. Tiecco¹, M.A. De Francesco², L. Zeneli¹, F. Gottardi¹, S. Zaltron³, A. Spinetti³, F. Castelli¹, E. Quiros-Roldan²
¹Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ²Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia-ASST Spedali Civili, Brescia, Italy, ³SC of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy

- P 70 Comparative investigation on the implementation of the national screening program for HCV in Italian regions**
I. Gardini, M. Conforti, M. Bartoli, F. Silvia, A. Cavallaro
Associazione EpaC - ETS, Monza, Italy
- P 71 Evaluating integrated healthcare pathways for HCV elimination: a pilot study from a large Italian region**
E. De Vita, L. Tivoschi
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
- P 72 Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history and careful monitoring of viral markers**
M. Menozzi¹, A. Cervo¹, G. Cuomo¹, M. Simion², A. Soffritti², L. Piermatteo³, S. D'Anna³, R. Salpini³, V. Svicher³, C. Mussini²
¹Infectious Diseases Unit, University Hospital Policlinico of Modena, Modena, Italy, ²Infectious Disease Clinic, Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Biology, University of Rome Tor Vergata, Rome, Italy
- P 73 Long-term outcomes and incidence of clinically significant events after HCV eradication in people with HIV: data from ICONA/HepalCO-NA cohorts**
M. Mazzei¹, N. Lentini², A. Cozzi-Lepri³, A. Tavelli⁴, V. Malagnino⁵, A. Giacomelli⁶, V. Mazzotta⁷, E. Quiros-Roldan⁸, A. Siribelli⁹, G. Lapadula¹⁰, A. Cingolani¹¹, R. Pastorino¹², M. Puoti¹³, A. d'Arminio¹⁴, R. Rossotti¹⁴ on behalf of Icona/Hepalcona Study Group
¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ²Section of Hygiene, University Department of Health Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy, ³Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ⁴ICONA Foundation, Milan, Italy, ⁵Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Policlinico Tor Vergata of Rome, Rome, Italy, ⁶III Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC Luigi Sacco, Università degli Studi di Milano, Milan, Italy, ⁷Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁸Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, ⁹Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁰Department of Infectious Diseases, IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy, ¹¹UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, Italy, ¹²Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹³Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, University of Milan-Bicocca, Milan, Italy, ¹⁴Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, Milan, Italy
- P 74 Optimizing hepatitis C treatment: the impact of patient reported measures in varied healthcare settings in a large Italian region**
E. De Vita, M.P. Tramonti Fantozzi, L. Tivoschi
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
- P 75 Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Euro-bioplex ebx071 and Altostar**
S. Uceda Renteria¹, M.P. Anolli², E. Degasperi², F. Facchetti², D. Sambarino², M. Borghi², R. Perbellini², R. Soffredini², S. Monico², A. Callegaro¹, P. Lampertico^{2,3}
¹Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ³CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
- P 76 The substantial burden of HDV chronic infection and the gaps in HDV screening across Europe rise the need to implement HDV diagnostics at pan-European level**
R. Salpini¹, I. Grossi¹, I. Alexiev², L. Baiocchi³, L. Bonica⁴, J. Begovac⁵, B. Benkoova⁶, S. Bopegamage⁶, C. Castelli⁷, C. Caudai⁷, S. D'Anna¹, T. Demir⁸, C. Devaux⁹, A. Di Lorenzo¹⁰, E. Heger¹¹, R. Kaiser¹¹, N. Kokkinos¹², G. Fernandez-Rivas¹³, K. Gazdikova⁶, A.M. Geretti^{12,10}, E. Golkocheva-Markova², Y. Gozlan¹⁴, G. Iserentant¹⁵, I. Lazarevic¹⁵, V. Lazareanu¹⁶, K. Leuzinger¹⁷, M. Lindh¹⁸, J.M. Llibre¹⁹, M.M. Lunar²⁰, J. Mihale⁶, O. Mor¹⁴, D. Nierhoff²¹, D. Otelea⁴, L. Piermatteo¹, M. Poljak²², A. Riccio¹, M. Ruzic²², L. Sarmati¹⁰, G. Torre¹, A.M. Tudor⁴, A. Vata²³, D. Yildiran⁸, M. Zazzi²⁴, A.M.J. Wensing²⁵, V. Svicher¹
¹Department of Biology, University of Rome Tor Vergata, Rome, Italy, ²National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria, ³Hepatology Unit, University Hospital Tor Vergata, Rome, Italy, ⁴National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania, ⁵University Hospital for Infectious Diseases, Zagreb, Croatia, ⁶Institute of Laboratory Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic, ⁷Microbiology and Virology Unit, AOU Senese, Siena, Italy, ⁸Ministry of Health, Public Health Institute, National Reference Laboratory for HIV/AIDS and Viral Hepatitis Department, Ankara, Turkey, ⁹Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg, ¹⁰Dept of System Medicine, University of Rome Tor Vergata, Rome, Italy, ¹¹Institute of Virology, University of Cologne, Cologne, Germany, ¹²Royal Free NHS Foundation Trust - North Mid Hospital, London UK, ¹³Microbiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona-Badalona, Spain, ¹⁴National Reference Laboratory for HIV and Viral Hepatitis, Sheba Medical Center of Tel Aviv, Israel, ¹⁵Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Serbia, ¹⁶The University of Medicine and Pharmacy Timisoara, Romania, ¹⁷Clinical Virology, University Hospital Basel, Basel, Switzerland, ¹⁸Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, ¹⁹Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²⁰Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ²¹Department of Gastroenterology and Hepatology, University of Cologne, Cologne, Germany, ²²Faculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Infectious Diseases, Serbia, ²³The University of Medicine and Pharmacy Iasi, Romania, ²⁴Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²⁵Translational Virology, Department of Global Health and Bioethics Julius Center for Health, Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
- P 77 Treatment of chronic HDV hepatitis with bulevirtide: preliminary results of a behavior-driven investigation on patients and clinicians**
L. Badia¹, A. Ciancio², M. Distefano³, A. Izzì⁴, A. Loglio⁵
¹Azienda Unità Sanitaria Locale, Imola, Italy, ²Ospedale Molinette, Torino, Italy, ³Azienda Sanitaria Provinciale, Siracusa, Italy, ⁴Ospedale Cotugno AORN dei Colli, Napoli, Italy, ⁵ASST Papa Giovanni XXIII, Bergamo, Italy
- P 78 Trends in the prevalence and epidemiological characteristics of HDV infection in HBsAg+ persons with or without HIV in Italy: is HIV still a key factor for HDV co-infection?**
M. Puoti¹, A. Tavelli^{2,3}, G. Brancaccio⁴, M.G. Quaranta⁵, M.E. Tosti⁵, G.B. Gaeta⁶, L. Kondili^{5,7}, A. d'Arminio Monforte² on behalf of PITER, MASTER and ICONA Study Groups
¹ASST Grande Ospedale Metropolitano, Department of Infectious Diseases, School of Medicine and Surgery, University Milano Bicocca, Milan, Italy, ²Icona Foundation, Milan, Italy, ³National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, ⁴Infectious Diseases, Link Campus University, Department of Life Sciences, Health and Health Professions, Rome, Italy, ⁵National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, ⁶Infectious Diseases, University L. Vanvitelli, Naples, Italy, ⁷UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy
- P 79 Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure**
A. Rugova¹, G. Ghilardi², E. Colella¹, N. Squillace¹, A. Cappelletti¹, F. Sabbatini¹, S. Limonta¹, P. Bonfanti², G. Lapadula², A. Soria¹
¹Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ²Università Milano-Bicocca, Monza, Italy
- P 80 Utility of the Fibrosis-4 Index for 10-Year Risk of All-Cause Mortality in People with HIV: A Retrospective Longitudinal Cohort Study**
C. Bertoni^{1,2}, N. Capra¹, R. Lolatto¹, H. Hasson¹, A. Siribelli^{1,2}, C. Muccini¹, V. Spagnuolo¹, G. Piromalli¹, A. Castagna^{1,2}, G. Morsica¹
¹Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy, ²Faculty of Medicine and Surgery, Vita-Salute University, San Raffaele, Milan, Italy

HIV: Antiretroviral therapy

- P 81 Acceptance rate and reasons for rejection of long-acting injectable CAB/RPV in an Italian center**
A. Vergori, R. Gagliardini, P. Borrelli, F. De Zottis, R. Bellagamba, G. Del Duca, A. Imeneo, E. Grilli, S. Ottou, I. Mastrorosa, V. Mazzotta, C. Pinnetti, A. Lener, M.M. Plazzi, M. Fusto, J. Paulicelli, A. Antinori
Clinical and Research Infectious Diseases Department, Viral Immunodeficiency Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
- P 82 Antiretroviral therapy in patients with swallowing disorders: an open issue**
N. Spalletta
Gay Center, Rome, Italy
- P 83 B/F/TAF as a switch therapy in a cohort of women living with HIV: a 24-months observational study on durability, effectiveness and metabolic profile**
A. Gasperin², G. Mancarella¹, V. Speciale², A. Carraro³, V. Kelmendi², A. Grimaldi², S. Corazza², S.G. De Maria^{1,2}, L. Ansaldo¹, T. Tieghi¹, V. Filippi³, F. Izzo², M. De Masi¹, A. Parente¹, B. Kertusha¹, C. Del Borgo¹, M. Lichtner⁴, R. Marocco¹
¹Infectious Disease Department, Santa Maria Goretti hospital, University of Rome "La Sapienza", Latina, Italy, ²Department of Public Health and Infectious Diseases, University of Rome "La Sapienza"; Italy, ³Infectious Disease Department, Sant'Andrea hospital, University of Rome "La Sapienza", Rome; Italy, ⁴Department of NESMOS, University of Rome "La Sapienza", Italy
- P 84 Bictegravir/tenofovir alafenamide/emtricitabine: a real-life experience in Women Living With HIV (WLWH)**
A. Gidari^{1,2}, S. Tordi¹, V. Gonzi¹, D. Francisci¹
¹Department of Medicine, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, ²Department of Medicine, Clinic of Infectious Diseases, "Santa Maria" Hospital, Terni, Italy
- P 85 Causes of discontinuation of co-formulated DOR/TDF/3TC in ART-experienced adults with HIV-1 after three years of follow-up: Real-world data from a single center in Florence, Italy**
G. Formica¹, G. Somma¹, J. Mencarini², C. Malcontenti², M. Pozzi², B. Borchini², C. Fiorelli², S. T. Kiros^{1,3}, M. Pittorru⁴, P. Corsi¹, G. Sterrantino¹, L. Zammarchi^{1,2}, A. Bartoloni^{1,2}, F. Lagi²
¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, ³Clinical Trial Center, Careggi University Hospital, Florence, Italy, ⁴Hospital Pharmacy, Careggi University Hospital, Florence, Italy
- P 86 Changes in body weight in people living with HIV switching therapy from TAF/FTC/RPV to TAF/FTC/BIC**
R.J. Steiner¹, C. De Vivo¹, P.F. Salvo¹, V. Iannone¹, A. Carbone¹, G. Lenzi¹, G. Cucinotta¹, F. Lombardi^{1,2}, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}, D. Farinacci²
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche – UOC Malattie Infettive, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy
- P 87 Dual versus triple as optimization antiretroviral therapy in people with HIV with stable virological suppression: long-term effectiveness from the MOSAICO Study**
D. Mengato¹, M. Mazzitelli², G. Berti³, S. Michielan⁴, L. Cappellazzo⁵, L. Agnoletto⁶, M. Chiumente⁷, A. Francavilla³, D. Gregori³, F. Venturini¹, A. Cattelan²
¹Hospital Pharmacy Unit, Azienda Ospedale-Università Padova, Italy, ²Infectious and Tropical Diseases Unit, Azienda Ospedale-Università Padova, Italy, ³Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padua, Italy, ⁴Hospital Pharmacy Unit, Ospedale Ramazzini Carpi, Modena, Italy, ⁵Hospital Pharmacy Unit, Bolzano General Hospital, Bolzano, Italy, ⁶Hospital Pharmacy Unit, AUSLSS5 Rovigo, Italy, ⁷Italian Society for Clinical Pharmacy and Therapeutics (SIFACT), Torino, Italy
- P 88 Effectiveness and durability of simplification strategies with oral dolutegravir/lamivudine vs long-acting injectable cabotegravir/rilpivirine in virologically suppressed people living with HIV**
A. Carbone¹, V. Iannone¹, P. F. Salvo¹, R. J. Steiner¹, D. Farinacci², G. Balzin², C. De Vivo¹, G. Cucinotta¹, G. Lenzi¹, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}, F. Lombardi^{1,2}
¹Dipartimento di Sicurezza e Bioetica, Sezione Malattie Infettive, Università Cattolica Del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, Italy
- P 89 Immunovirological efficacy of long-acting cabotegravir/rilpivirine therapy and perception of well-being in people living with HIV. Experience of the Infectious Diseases Clinic of Perugia**
E. Schiaroli, E. Baranello, M. Albagini, D. Veramonti, C. Ercolani, V. Gonzi, D. Francisci
Infectious Diseases Clinic, Department of Medicine and Surgery, University of Perugia, Italy
- P 90 Impact of 2 drug antiretroviral regimens on immune recovery**
R.J. Steiner¹, P.F. Salvo¹, G. Balzin², V. Iannone¹, G. Lenzi¹, A. Carbone¹, C. De Vivo¹, G. Cucinotta¹, C. Torti^{1,2}, F. Lombardi^{1,2}, S. Di Giambenedetto^{1,2}
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- P 91 Impact of baseline plasma HIV-1 RNA and viral subtype on the achievement of virological suppression in PWH treated with bictegravir/emtricitabine/tenofovir alafenamide in clinical practice**
L. Crupi¹, A. Parodi¹, G. Cenderello³, M. Muccio¹, S. Bianchi¹, B. Bruzzone², N. Randazzo², F. Stefanelli², A. Limongelli¹, G. Massobrio¹, D. Laurenda³, M. Nofri¹, S. Cardaci¹, A. Di Biagio¹, M. Bassetti¹, L. Taramasso¹
¹Infectious Disease Clinic, IRCCS Ospedale San Martino Hospital, University of Genoa, Genoa, Italy, ²Unit of Hygiene, IRCCS San Martino Hospital, University of Genoa, Genoa, Italy, ³Infectious Disease Department, ASL-1 Imperiese, Sanremo, Italy
- P 92 Implementation of a same-day ART start model in a real-life setting: experiences from a clinical centre in Italy**
G. Micheli, A. Caioli, R. Esvan, A. Giacinta, V. Barchi, I. Abbate, A. Lener, C. Pinnetti, L. Fabeni, G. Frate, G. Rozera, E. Girardi, F. Maggi, A. Antinori, V. Mazzotta
National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
- P 93 Lipid profile improvement among ART-experienced PLWH switching to Bictegravir/Emtricitabine/Tenofovir alafenamide according to prior INSTI exposure and latest ART regimen**
M. Poliseno¹, N. Colavito², A. Cianciaruso², M. Cibelli¹, N. De Gennaro¹, A. Vigna¹, F. Di Gennaro¹, A. Saracino¹
¹Clinic of Infectious Diseases, DiMePre-J, University of Bari "Aldo Moro", Bari, Italy, ²University of Bari "Aldo Moro", Bari, Italy
- P 94 Long-acting injectable antiretroviral therapy (LAI-ART) with cabotegravir (CAB) and rilpivirine (RPV) for the treatment of HIV infection: analysis nearly two years implementation in a university hospital**
F.S. Soave¹, C. Lanzillotta¹, L. Camisa², C. Di Castri², E.A. Gabor², L.B. Di Candia¹, F. Carli², A. Zanardi¹
¹Dipartimento Farmaceutico Interaziendale, Parma, Italy, ²UO Malattie Infettive ed Epatologia, Azienda Ospedaliero-Universitaria di Parma, Italy
- P 95 Metabolic and Immunological Outcomes After Switching to Long-Acting Cabotegravir + Rilpivirine: A 44-Week Multicenter Observational Study (LAHIV)**
F. Lagi¹, M. Fognani², G. Formica², G. Gasparro², M. Piccica³, G. Sarteschi⁴, A. Pampaloni⁵, B. Menichini⁶, B. Rossetti⁷, F. Panza⁸, S. Costarelli⁹, E. Riguccini¹⁰, M. De Gennaro¹¹, E. Francalanci¹¹, P. Corsi¹, M. Pozzi¹, L. Pisano¹², G. Sterrantino², M. Tumbarello⁸, C. Costa³, B. Adriani⁵, C. Nencioni⁷

D. Messeri⁶, D. Tacconi¹⁰, S. Sani⁹, A. Vincenti⁴, N. Pimpinelli¹², A. Bartoloni^{1,2}

¹SOD Malattie Infettive, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy, ²Dipartimento di medicina sperimentale e clinica, Università degli Studi di Firenze, Italy, ³SOC Malattie Infettive, Ospedale Santa Maria Annunziata, USL Toscana Centro, Italy, ⁴UO Malattie Infettive, Nuovo Ospedale Apuane, USL Toscana Nord-Ovest, Italy, ⁵UO Malattie Infettive, Azienda Ospedaliera Prato, USL Toscana Centro, Italy, ⁶SOS Malattie Infettive, Azienda Ospedaliera Pistoia, USL Toscana Centro, Italy, ⁷UO Malattie Infettive, Azienda Ospedaliera Grosseto, USL Toscana Sud-Est, Italy, ⁸Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena, Italy, ⁹UO Malattie Infettive, Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest, Italy, ¹⁰UOC Malattie Infettive, Azienda Ospedaliera Arezzo, USL Toscana Sud-Est, Italy, ¹¹UO Malattie Infettive, Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest, Italy, ¹²Section of Dermatology, Health Sciences Department, University of Florence, Florence, Italy

P 96 Minor revision: simplification therapy with dolutegravir, a retrospective observational study with 96 weeks follow-up

A. Pupo¹, A. Lazzaro², D. Giangiulio¹, V. Giunta¹, L. De Martino¹, G. Zacco¹, F. Alessi¹, N. Cavallari¹, M. Ridolfi¹, C. Mastroianni^{1,2}, G. d'Ettore^{1,2}

¹Università di Roma La Sapienza, Roma, Italy, ²A.O. Policlinico Umberto I, Roma, Italy

P 97 Next Generation Sequencing (NGS) of proviral HIV DNA and analysis of APOBEC-induced mutations to assess suitability for longacting cabotegravir/rilpivirine therapy

G. Massobrio¹, M. Giurco¹, A. Limongelli¹, M. Nofri¹, S. Cardaci¹, L. Taramasso¹, N. Randazzo², F. Stefanelli², B. Bruzzzone², M. Bassetti^{1,3}, A. Di Biagio^{1,3}

¹Department of Specialist Medicine, Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ²Hygiene Unit, IRCCS Ospedale Policlinico San Martino for Oncology and Neurosciences, Genoa, Italy, ³Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

P 98 Patient-reported outcomes in HIV: a study on quality of life in PLWH on long-acting antiretroviral therapy

A. Auricchio^{1,2}, G. Matarese², S. Scriffignano³, I. Di Filippo¹, L. Fusco¹, F. De Gregorio¹, A. Prozzo¹

¹Unit of Infectious Disease, PO "A. Cardarelli", Campobasso, Italy, ²University of Study of Molise UNIMOL, Campobasso, Italy, ³UOC Medicine, Foundation Institute "G. Giglio", Cefalù, Italy

P 99 Proximity-based long-acting therapy: a real-world model at a clinical center for HIV/AIDS care in Turin

G.C. Orofino¹, M.F. Bello², C. Bena³, P. Tettamanti³, G. De Santis⁴, M. Peretti⁴, T. De Blasi¹, M.C. Tettoni⁵, L. Trentini⁵, M. Guastavigna¹, G. Bo⁵, C. Bobba⁵, D. Arrue Diaz⁵, A. Crocetta⁵, D. Piccioni⁶, P. Crosasso⁶, G. Calleri¹

¹Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ²Home Health Care Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ³Home Health Care ASLTO4, Italy, ⁴Casa Giobbe Onlus, Turin, Italy, ⁵Medical Science Department, University of Turin, Turin, Italy, ⁶Pharmacy Department ASL Città di Torino, Italy

P 100 Real-life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with more than 50 years old

G. Moi¹, A. De Vito¹, G. Conti², B.M. Celesia², S. Spampinato², A. Marino², C. Calì³, M.A. Di Rosolini³, A. Colpani¹, R. Tala⁴, G. Sanna⁵, G. Angioni⁵, G. Nunnari², G. Madeddu¹

¹Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, ³Infectious and Tropical Diseases Unit, Modica Hospital, Ragusa, Italy, ⁴School of Medicine, University of Sassari, Sassari, Italy, ⁵Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy

P 101 Real-World Durability, Safety, and Changes in Lipid and Body Weight Profiles with B/F/TAF in ART- Naive Adults: A 24-Month Observational Study

G. Mancarella¹, A. Gasperin², V. Speciale¹, V. Kelmendi¹, A. Grimaldi², S. Corazza², S. De Maria^{1,2}, D. Di Trento^{1,2}, F. Izzo¹, L. Ansaldo¹, M. De Masi¹, D. Bello¹, A. Carraro³, S. Di Bari³, V. Filippi³, T. Tieghi¹, A. Parente¹, L. Fondaco¹, B. Kertusha¹, C. Del Borgo¹, M. Lichtner⁴, R. Marocco¹

¹Infectious disease department, Santa Maria Goretti hospital, Latina, Italy, ²La Sapienza, University of Rome, Italy, ³Infectious disease department, Sant'Andrea hospital, Rome, Italy, ⁴Department of NESMOS, La Sapienza, University of Rome, Italy

P 102 Sculpting long-term success in hiv therapy: the synergistic dynamics of dolutegravir and doravirine in a precision-driven dual regimen

F. Zimmerhofer¹, M. Trizzino², F. Di Figlia¹, C. Gioè², A. Cicero¹, A. Cascio¹

¹Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy, ²Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy

P 103 Switching boosted protease inhibitor-based antiretroviral therapy to fostemsavir plus an optimized background in people with HIV with limited therapeutic options: a case series from the FOST SWITCH Study

A. Calcagno¹, M. Nwanbila², L. Assoumou³, C. Antoniadis⁴, A. Winston⁴, J. Moody⁵, C. Fletcher⁶, G. Hilton-Smith⁷, M. Prakash⁷, A. Clark⁷, A. Pozniak^{2,8}, M. Boffito^{2,4}

¹A.S.L. Città di Torino, Torino, Italy, ²Chelsea and Westminster Hospital, London, UK, ³Sorbonne Université, Inserm, iPLESP, Paris, France, ⁴Imperial College Healthcare NHS Trust, London, UK, ⁵Central and North West London NHS Foundation Trust, London, UK, ⁶Research Organisation (Kings Cross), London, UK, ⁷ViiV Healthcare, London, UK, ⁸NEAT ID Foundation, Brussels, Belgium

P 104 Switching from 3 or 2-drug oral regimen to Long-Acting Cabotegravir and Rilpivirine in People With HIV: Real-World Experience from ASST Lecco

M. Bottonelli, V. Morena, F. Conti, L. Bradanini, A. Chiesa, M. Gatti, N. Gemignani, M. Gerbi, C. Molteni, A. Mulè, A. Pandolfo, S. Pontiggia, G. Valsecchi, S. Volpi, S. Piconi

Infectious diseases unit – Alessandro Manzoni Hospital, ASST Lecco, Italy

P 105 Treatment interruption among PWH on long-acting-injectable (LAI) Cabotegravir/Rilpivirine: Experience from an Italian HIV Outpatient clinic

G. Sangaletti, L. Pagnucco, S. Lerta, A. Celsi, A. Arcuri, C. Giuliani, M. Gerola, R. Gulminetti

Infectious Diseases Unit UOC, Department of Medical Science, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy

P 106 Up to half of geriatric people living with HIV are treated with 2-drug INSTI-based regimens

D. Ripamonti¹, L. Comi¹, T. Spaccalferro¹, A. Cargnelutti², D. Valenti³, A. Francavilla³, V.M. Cossu⁴, M. Galimberti⁴, L. Oreni⁴, A. Gori^{4,6}, S. Antinori^{4,6}, R. Gulminetti⁵, A. Celsi⁷, L. Pagnucco⁵, A. Giacomelli^{4,6}

¹Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ²School of Medicine and Surgery, University of Brescia, Brescia, Italy, ³Bergamo Hospital Research Foundation – ETS (FROM), Bergamo, Italy, ⁴Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy, ⁵Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy, ⁶Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, ⁷School of Medicine and Surgery, University of Pavia, Pavia, Italy

P 107 Use of prolonged-release injectable CAB/RPV in outpatients

N. Bobbio, E. Blasi Vacca, S. Boni, F. Del Puente, M. Feasi, A. Parisini, R. Prinapori, S. Tigano, A. Sarà, D. Fiorellino, S. Puppo, A. Zunino, F. Filauo, E. Pontali

E.E.O.O. Galliera, Genoa, Italy

P 108 Virological failures in a real-world cohort: a retrospective analysis of population characteristics and resistance mutations

I. Bon¹, C. Rigamonti², D. Marzolla², M. Giglia², A. Zuppiroli², L. Calza²

¹Microbiology Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ²Infectious Diseases Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy

Infections in the Immunocompromised Host

- P 109 Circulating autoantibodies targeting G-protein-coupled neurotransmitter receptors: reliable biomarkers for Long COVID diagnosis?**
M. Camici¹, M. Franco², L. Talamasca², E. Cimini¹, E. Tartaglia¹, S. Notari¹, M. Petino³, L. Scarnecchia⁴, A. Vergori¹, R. Baldelli⁴, P. Zuppi⁴, A. Antinori¹
¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²IMSB, D-BIOL, ETH Zürich, Switzerland, ³Azienda sanitaria ASL Roma 1, Rome, Italy, ⁴S. Camillo Forlanini Hospital, Rome, Italy
- P 110 Early management of COVID-19 infection in solid organ transplant recipients: our experience with antiviral treatments**
M. Abbott¹, S. Agrenzano¹, F. Guida Marascia¹, A. Gizzi¹, G. Ciusa¹, C. Imburgia¹, L. Moscarelli², P. Marrone², B. Buscemi³, P. Salis³, A. Mularoni⁴, G. Panarello⁵, C. Di Benedetto⁶, G. Li Cavoli⁷, A. Ferrantelli⁸, A. Cascio⁹, C. Iaria¹
¹Infectious and Tropical Diseases Unit - ARNAS Civico-Di Cristina - Benfratelli - Palermo, Italy, ²Pharmacy Unit - ARNAS Civico-Di Cristina-Benfratelli - Palermo, Italy, ³Department of Nephrology, IRCCS-ISMETT - Palermo, Italy, ⁴Department of Infectious Diseases, IRCCS-ISMETT - Palermo, Italy, ⁵Department of Anesthesiology and Intensive Care, IRCCS ISMETT - Palermo, Italy, ⁶Office of the Director of Health Care Activities, IRCCS-ISMETT - Palermo, Italy, ⁷Nephrology and Dialysis Unit - ARNAS Civico-Di Cristina - Benfratelli - Palermo, Italy, ⁸Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
- P 111 Long COVID: looking for a definition**
V. Cogliandro¹, N. Squillace¹, E. Rossi², M. C. Ferrara³, A. Monzani⁴, G. Ferrario¹, L. Bonaffini¹, F. Luppi^{3,5}, G. Bellelli^{3,5}, P. Bonfanti^{1,5}
¹Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ²Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, ³Acute Geriatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁴Respiratory Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁵School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
- P 112 Long-term neurological outcome in Progressive Multifocal Leukoencephalopathy survivors**
M.C. García Martarena¹, C. Pinnetti⁴, G. Catalano¹, R. Vercesi³, A. Antinori⁴, L. Moiola⁵, M. Filippi², A. Castagna^{1,2}, P. Cinque^{2,3}, I. Mainardi²
¹Vita-Salute San Raffaele University, Milan, Italy, ²Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Unit of Neurovirology Disease, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴National Institute of Infectious Diseases Lazzaro Spallanzani, Roma, Italy, ⁵Unit of Neurology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- P 113 Non-tuberculous mycobacteria (NTM) in people with HIV (PWH) in recent cART era: clinical presentation and mortality**
G. Baldin^{1,2}, F. Sanmartini¹, G. Oliva¹, G. Cucinotta¹, H. Morrone³, I. Palucci^{4,5}, M. Sal^{4,5}, G. Delogu^{4,6}, F. Raffaelli^{1,2}, E. Tamburrini^{1,2}, M. Sanguinetti^{4,5}, A. Cingolani^{1,2}, C. Torti^{1,2}
¹Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Sezione Malattie Infettive, Rome, Italy, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie infettive, Rome, Italy, ³Dipartimento di Scienze Mediche e Chirurgiche, Università "Magna Graecia", Catanzaro, Italy, ⁴Dipartimento di Scienze Biologiche di Base, Cliniche Intensivologiche e Perioperatorie-Sezione di Microbiologia, Università Cattolica del Sacro Cuore, Roma, Italy, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di laboratorio e Ematologiche, Roma, Italy, ⁶Mater Olbia Hospital, Olbia, Italy
- P 114 Prolonged clinical monitoring of cognitive performance and psychiatric symptoms among PACS**
G. Del Duca¹, I. Sperduti², A.C. Brita¹, M. Maresca¹, M. Camici¹, C. Pinnetti¹, I. Mastroianni¹, V. Mazzotta¹, A. Antinori¹
¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Regina Elena National Cancer Institute IRCCS, Rome, Italy
- P 115 SARS-CoV-2 infection in hospitalized oncohematological patients: a comparison between two years**
F. Izzo¹, G. Mancarella¹, S. Di Bari², L. Bresciani², D. Bello², A. Carraro², A. Gasperin¹, D. Di Trento¹, A. Grimaldi¹, S. Corazza¹, S.G. De Maria¹, S. Cacace¹, R. Marocco¹, A. Parente¹, B. Kertusha¹, T. Tieghi¹, L. Fondaco¹, P.G. Pace¹, M. Lichtner³, C. Del Borgo¹
¹Department of Public Health and Infectious Diseases, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy, ²Department of Public Health and Infectious Diseases, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy, ³Department of NESMOS, Sapienza University of Rome, Rome, Italy
- P 116 Specific T-cell response to CMV, EBV and VZV in people with multiple sclerosis under disease-modifying therapies**
F. Dominelli¹, M.A. Zingaropoli¹, P. Pasculli¹, M. Antonacci¹, M. Guardiani¹, F. Ciccone¹, Y.C. Fosso Ngangue¹, R. Campagna², A. Collura³, G. Ferrazzano³, O. Turriziani², M. Lichtner⁴, G. Antonelli², A. Conte^{3,5}, C.M. Mastroianni¹, M.R. Ciardi¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ³Department of Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy, ⁴Department of Neurosciences Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy, ⁵IRCCS Neuromed, Pozzilli, Italy
- P 117 Trajectories and Predictors of Post-COVID-19 Condition Persistence: a prospective evaluation in the EuCARE Study**
A. Santoro¹, C. Acampora¹, M.F. Greco¹, V. Sala¹, F. Ceccherini-Silberstein², I. Fanti³, F. Incardona^{3,4}, J.A. Pinto⁵, G.H. Rubio^{6,7}, C. Toscano⁸, A. Cozzi-Lepri⁹, C. Tincati¹, G. Marchetti¹ on behalf of EuCARE Study Group
¹Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Science, University of Milan, Milan, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³EuResist Network, Rome, Italy, ⁴IPRO-InformaPRO S.R.L., Rome, Italy, ⁵Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ⁶Infectology Department, Viral Safety Unit, Paul Ehrlich Institute, Langen, Germany, ⁷Infectious Diseases Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁸Hospital Egas Moniz, Lisbon, Portugal, ⁹Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK
- P 118 Unraveling the role of peripheral and mucosal SARS-CoV-2-specific CD8 T cell responses in shaping disease severity**
A. Vecchi¹, C. Tiezzi², M. Rossi², E.A. Gabor², P. Piscaro¹, F. Ferraglia¹, F. Carli¹, S. Sartori², M. Segovic², G. Russo², D. Laccabue², G. Missale^{1,2}, C. Ferrari^{1,2}, C. Boni^{1,2}
¹Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy, ²Department of Medicine and Surgery, University of Parma, Parma, Italy
- P 119 Varicella Zoster Virus Vaccination in patients with haematological diseases and primary immunodeficiencies. Assessment of specific T and B-cell responses**
L. Coppola^{1,2,3}, L. Benedetti¹, G. Montagnari¹, F. Meconi⁴, M. Sgrulletti⁵, V. Moschese⁵, M. Andreoni^{1,3}, L. Sarmati^{1,3}, M. Iannetta^{1,3}
¹Department of Systems Medicine, University of Tor Vergata, Rome, Italy, ²PhD Program in Microbiology, Immunology, Infectious Diseases and Transplants (MIMIT), Tor Vergata University, Rome, Italy, ³Infectious Diseases Unit, Policlinico Tor Vergata, Rome, Italy, ⁴Oncohaematological Diseases Unit, Policlinico Tor Vergata, Rome, Italy, ⁵Immunology and Allergology Unit, Policlinico Tor Vergata, Rome, Italy
- P 120 Viral respiratory infections in immunocompromised and immunocompetent patients: a case-control study**
M. Mastropasola¹, V.C. Di Maio², L. Colagrossi², G. Linardos², L. Colletta², S. Ranno², L. Gentile², A.C. Vittucci³, E. Galeno², S. Landi², P. Merli⁴, A. Bragaglia⁵, A. Villani³, C. Russo², C.F. Perno^{1,2}, R. Scutari¹
¹Multimodal Laboratory Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ²Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ³Hospital University Pediatrics Clinical Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ⁴Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ⁵Neonatal Sub-Intensive Care Unit and Follow-up, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- P 121 What remains of Long COVID after four years from hospitalization for severe COVID pneumonia**
V. Cogliandro¹, N. Squillace¹, E. Rossi², M. C. Ferrara³, A. Monzani⁴, G. Ferrario¹, L. Bonaffini¹, F. Luppi^{3,5}, G. Bellelli^{3,5}, P. Bonfanti^{1,5}
¹Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ²Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, ³Acute Geriatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁴Respiratory Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁵School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

PrEP

- P 122 Assessment and monitoring of psychological, sexual, and relational status in individuals accessing a Pre-Exposure Prophylaxis (PrEP) program**
G. Del Duca, A. Caioli, M. Maresca, R. Esvan, A.C. Brita, G. Micheli, A. Giacinta, A. Antinori, V. Mazzotta
National Institute for Infectious Disease Lazzaro Spallanzani IRCCS, Rome, Italy
- P 123 Exploring the attitude about using telehealth in persons on Pre-Exposure Prophylaxis (PrEP)**
F. Barbaro¹, L. Sasset¹, C. Cozzolino², M. Mazzitelli¹, A. Ferrari¹, S. Gardin¹, D. Leoni¹, M. Bolzonella², S. Cavinato¹, F. Colombo¹, A.M. Cattelan^{1,3}
¹Infectious and Tropical Diseases Unit, University Hospital of Padua, Italy, ²Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Italy, ³Department of Molecular Medicine, University of Padua, Italy
- P 124 HIV PrEP and STI Surveillance: insights from a Tertiary HIV Unit**
F. Barbaro, M. Mazzitelli, L. Sasset, A. Cattelan
Infectious Disease Unit, Azienda Ospedale Università Padova, Padova, Italy
- P 125 Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey**
S. Nozza¹, T. Masoero², A. Taveli², F. Leseri³, L. Taramasso⁴, D. Tesoro⁵, E. Caruso⁶, F.M. Fusco⁷, M. Menozzi⁸, E. Milano⁹, D. Moschese¹⁰, R. Rossotti¹¹, F. Barbaro¹², S. Cecere¹³, M. Giglia¹⁴, S. Venturini¹⁵, A. d'Arminio Monforte², M. Cernuschi¹⁶, A. Antinori¹⁶, A. Castagna¹, V. Mazzotta¹⁶
¹Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy, ²ICONA Foundation, Milan, Italy, ³PLUS Roma, Rome, Italy, ⁴Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ⁵Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy, ⁶Milano Checkpoint ETS, Milan, Italy, ⁷Infectious Diseases, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy, ⁸Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ⁹Infectious Diseases, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy, ¹⁰Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ¹¹School of Medicine and Surgery, Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹²Infectious Diseases, University Hospital of Padova, Padova, Italy, ¹³Bologna Checkpoint, Bologna, Italy, ¹⁴Infectious Diseases, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ¹⁵Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, ¹⁶National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
- P 126 Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified PrEP delivery**
P. Vinti¹, E. Caruso¹, R. Repossi¹, M. Cernuschi^{1,2}, N. Frattini¹
¹Milano Check Point ETS, Milano, Italy, ²IRCCS Ospedale San Raffaele, Milano, Italy
- P 127 PrEP - Where are we now? Understanding providers' perspectives on current practices and long-acting PrEP in Southern Italy**
M. Poliseni¹, E. Milano², G. Manca Cesari¹, E. De Vita¹, M. Allegrini², A. Auricchio³, G. Bruno⁴, S.R. Bruno⁵, G.B. Buccoliero⁴, S. Carbonara³, P. Congedo⁶, M. Fasano⁷, M. Federico⁷, M. Frontuto⁸, M. Gilio⁸, C. Grillo⁹, S. Lo Caputo⁹, A.M. Maci⁶, S. Minniti², G. Pietromatera¹⁰, A. Prozzo³, M.A. Purgatorio¹⁰, A. Tartaglia¹¹, F. Di Gennaro¹, A. Saracino¹
¹Clinic of Infectious Diseases, DiMePre-J, University of Bari "Aldo Moro", Italy, ²Infectious Diseases Unit, Ospedale Di Summa - Perrino, Brindisi, Italy, ³Infectious Diseases Unit, ASREM - Ospedale Cardarelli, Campobasso, Italy, ⁴Infectious Diseases Unit, Ospedale San Giuseppe Moscati, Taranto, Italy, ⁵Infectious Diseases Unit, Ospedale Vittorio Emanuele II, Bisceglie, Italy, ⁶Infectious Diseases Unit, Ospedale "Vito Fazzi", Lecce, Italy, ⁷Infectious Diseases Unit, ALS BA, Ospedale della Murgia, Altamura, Bari, Italy, ⁸Infectious Diseases Unit, AOR San Carlo, Potenza, Italy, ⁹Infectious Diseases Unit, A.O.U. Policlinico Foggia, Università di Foggia, Foggia, Italy, ¹⁰Ambulatorio Territoriale di Malattie Infettive, ASM Matera, Matera, Italy, ¹¹Ambulatorio di Malattie Infettive, ASL Foggia, Foggia, Italy
- P 128 The role of Ancona Checkpoint in counseling and facilitating PrEP access through tele-visits**
S. Caucci^{1,3}, L. Saracini^{2,3}, C. Canzi^{2,3}, P. Pauri³, A. Costantini⁴, L. Butini^{4,5}
¹Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy, ²Ass. Opere Caritative Francescane, ³Ancona Checkpoint, Ancona, Italy, ⁴Clinical Immunology Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁵Anlaids Marche APS, Italy

Social Science, PROs

- P 129 Acceptability and availability to change care for people living with HIV followed by home care assistance (HCA)**
V. Iannone¹, D. Farinacci², F. Lombardi², G. Baladin², A. D'Angelillo¹, P.F. Salvo¹, M. Petrucci², F. Onorati², E. Visconti², E. Tamburrini^{1,2}, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
- P 130 Analysis of the final data and future prospects of the "FRAGIL/mind" project**
A. Calluso, N. Catucci, M. Di Tullio, R. Giusto, M. Giannelli, G. Labianca
C.A.M.A. - Centro Assistenza Malati Aids - OdV ETS, Bari, Italy
- P 131 Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals**
L. Butini¹, V. De Falco², R. Galipò³, G. Notore⁴, A. Gori⁵, P. Castelli⁶, M. Longhi⁷, A. Costantini⁸, C.R. Santoro⁹, T. Prestileo¹⁰, G. Boero¹¹, M.C. Rossi¹², G. Gamboni¹³
¹Anlaids ETS, Italy, ²Anlaids Campania, Italy, ³Anlaids Lazio, Italy, ⁴Anlaids Liguria, Italy, ⁵Anlaids Lombardia, Italy, ⁶Anlaids Macerata, Italy, ⁷Anlaids Mantova, Italy, ⁸Anlaids Marche, Italy, ⁹Anlaids Puglia, Italy, ¹⁰Anlaids Sicilia, Italy, ¹¹Anlaids Torino, Italy, ¹²Anlaids Treviso, Italy, ¹³Anlaids Umbria, Italy
- P 132 Anlaids Forum challenges Artificial Intelligence: can algorithms act as a counsellor?**
A. Venturini, C. Balotta, R. Galipò, L. Butini
Anlaids Ets, Rome, Italy
- P 133 Assessing awareness of HIV and prevention strategies: a cross-sectional study from two free rapid testing events in Rome**
L. Bortolani, M. Ridolfi, F. Alessi, A. Lazzaro, E.N. Cavallari, E.A.I.B. Bruno, F. Romano, C.M. Mastroianni, G. d'Ettore
Policlinico Umberto I - Sapienza Università di Roma, Rome, Italy
- P 134 Beyond a standalone checkpoint: Three years of collaboration and growth at IOC'ENTRO, Genoa, Italy**
A. Ferrari^{1,2,3}, G. Notore^{1,4}, T. Cerisola^{1,5}, G. Manzi¹, I. Schenone^{1,6}, E. Pontali^{1,7}
¹ANLAIDS Sezione Liguria, Genoa, Italy, ²Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ³Social Epidemiology and Health Policy (SEHPO), University of Antwerp, Antwerp, Belgium, ⁴San Martino Polyclinic Hospital, Genoa, Italy, ⁵Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOEMI), University of Genoa, Genoa, Italy, ⁶Regional Health Agency of Liguria (A.Li.Sa.), Genoa, Italy, ⁷Department of Infectious Disease, Ente Ospedaliero Ospedali Galliera, Genoa, Italy
- P 135 Bridging gaps in HIV care: an outreach screening program for street-based sex workers**
A. Soria¹, G. Ghilardi², A. Rugova¹, M. Fava³, B. Monti², V. Brogna², V. Ferraro¹, A. Zaccaria¹, L. Villa¹, B. Di Malta¹, E. Beretta¹, L. Corsico¹, G. Sala⁴, G. Vercelli⁴, C. Mozzoni⁴, E. Bertaglio⁴, V. Impedovo⁴, P. Bonfanti
¹Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ²Università Milano-Bicocca, Monza, Italy, ³ASST di Lodi, Lodi, Italy, ⁴Cooperativa Lotta Contro l'Emarginazione, Monza, Italy

- P 136 Challenges on Recruiting for the HIV-CORE 007 Cure Trial: the perspective of Infectious Disease Doctors**
E. Bruzzesi¹, S. Dispinseri², S. Bagaglio³, A. Baglivi³, G. Annicchiarico³, S. Nozza^{1,3}, F. Sironi², M. Tolazzi², T. Trbos³, A. Soria⁴, F. Ciceri^{5,1}, C. Corti⁵, A. Crook⁶, N. Borthwick⁶, T. Hanke⁶, A. Castagna^{1,3}, G. Scarlatti², R. Dell'Acqua³
¹Vita-Salute San Raffaele University, Milan, Italy, ²Viral Evolution and Transmission Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, ⁵Hematology and Bone Marrow Transplant Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy, ⁶The Jenner Institute, University of Oxford, Oxford, United Kingdom
- P 137 Degree of appropriateness and organization of services dedicated to the administration of CAB+RPV: PWH opinions from an Italian multicenter cohort**
G. Cucinotta¹, V. Iannone¹, D. Farinacci², F. Lombardi², G. Baldin², M. Mena³, G. Cavazza⁴, N.B. Bana⁴, C.R. Bassoli³, S. Rusconi³, R. Rossotti⁴, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, ³Unità di Malattie Infettive, ASST Ovest Milanese, Legnano & DIBIC, Università di Milano, Milano, Italy, ⁴Dipartimento di Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- P 138 Degree of current knowledge and awareness regarding long-acting injectable antiretroviral therapy in people living with HIV who are undergoing oral therapy**
V. Iannone¹, D. Farinacci², G. Cucinotta¹, P.F. Salvo¹, F. Lombardi², G. Lenzi¹, G. Baldin², E. Visconti², M. Mena³, C.R. Bassoli³, S. Rusconi³, S. Di Giambenedetto^{1,2}
¹Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, ³Unità di Malattie Infettive, ASST Ovest Milanese, Legnano & DIBIC, Università di Milano, Milano, Italy
- P 139 Evolution of HIV Testing Access in the MSM Community: a Comparison of the 2005/2015 and 2015/2025 Decades with a Focus on the Use of the INSTI Test in Meeting Places (Outreach)**
M. Corda
GRUPPO SALUTE, CIG Arcigay Milano, Milano, Italy
- P 140 From screening to care: Strengthening linkage to services for marginalized populations in Genoa, Italy**
G. Notore^{1,2}, A. Ferrari^{1,3,4}, T. Cerisola^{1,5}, G. Manzi¹, I. Schenone^{1,6}, E. Pontali^{1,7}
¹ANLAIDS Sezione Liguria, Genoa, Italy, ²San Martino Polyclinic Hospital, Genoa, Italy, ³Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ⁴Social Epidemiology and Health Policy (SEHPO), University of Antwerp, Antwerp, Belgium, ⁵San Martino Polyclinic Hospital, Genoa, Italy; Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy, ⁶Regional Health Agency of Liguria (A.Li.Sa.), Genoa, Italy, ⁷Department of Infectious Disease, Ente Ospedaliero Ospedali Galliera, Genoa, Italy
- P 141 Getting to the first 95: introducing recommended best practices in national HIV testing guidelines**
P. Russo^{1,2}, E. Caruso¹, N. Frattini¹, A. Perugini², M. Stizoli^{2,3}, P. Vinti^{1,2}
¹Milano Checkpoint ETS, Milan, Italy, ²CIG Arcigay Milano, Milan, Italy, ³Brescia Checkpoint, Brescia, Italy
- P 142 HIV and STI testing beyond key populations: Brescia's first community-based experience**
M. Stizoli¹, M. Barracchia¹, A. Bergomi¹, P. Russo^{2,3}, A. Sala¹, P. Vinti²
¹Brescia Checkpoint ETS, Brescia, Italy, ²Milano Check Point ETS, Milano, Italy, ³CIG Arcigay Milano ODV, Milano, Italy
- P 143 LILA's virtual help desk: giving voice and empowering people with HIV through remote support**
G. Dessi¹, G. Giupponi¹, E. Mura²
¹LILA ONLUS Italian League Fighting AIDS, Como, Italy, ²LILA Cagliari ODV, Cagliari, Italy
- P 144 Multifactorial vulnerability and HIV: local response to health-care needs of key populations**
M. Falaguasta^{1,2,3,4}, G. Borgato^{1,2,3,4}, F. Sguotti^{1,2,3}, G. Giardina^{1,2,4}, A. Cattelan^{1,5}, F. Barbaro^{1,5}, L. Sasseti^{1,5}, M. Mazzitelli^{1,5}, A. Ferrari^{1,5}, D. Leoni^{1,5}, S. Cavinato^{1,5}, B. Cherchi⁴, M. Pillon⁴, S. Gardin⁵, M. Cola⁵, C. Braganolo³
¹Anlaids sez. Padova APS, Padova, Italy, ²PadovaCheckpoint, Padova, Italy, ³Progetto N.A.V.I.G.A.R.e, Veneto, Italy, ⁴CAD (Centro Anti Discriminazioni LGBT+) Spolato, Padova, Italy, ⁵UOC Malattie Infettive e Tropicali AOPD, Padova, Italy
- P 145 New challenges in the long-term management of people living with HIV (PLWH): introduction of Patient-Reported Outcomes (PROs) into routine clinical practice. A pilot study**
D. Segala¹, F. Facchini², R. Cultrera³
¹University of Ferrara-Az.Ospedaliera Universitaria di Ferrara, Ferrara, Italy, ²University of Ferrara, Ferrara, Italy, ³University of Ferrara-Azienda Unità Sanitaria Locale di Ferrara, Ferrara, Italy
- P 146 Patient-reported outcomes (PROs) in people living with HIV treated with long-acting injectable antiretroviral therapy (LAI-ART)**
S. Rapino¹, S. Arsuffi¹, C. Mazzi², S. Calza³, G. Tiecco¹, C. Anzoni¹, D. Minisci¹, B. Fioretti¹, I. Polesini¹, F. Castelli¹, E. Quiros-Roldan¹, E. Focà¹
¹Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy, ²Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Italy, ³Unità di Biostatistica e Biomatematica e Unità di Bioinformatica, Dipartimento di Medicina Molecolare e Traslaazionale, Università degli Studi di Brescia, Italy
- P 147 People living with HIV in treatment with long-acting therapy: what changes in terms of stigma?**
A. Romeo^{1,3}, V. Perutelli^{1,3}, M. Di Tella¹, L. Trentini^{2,3}, C. Tettini², S. Bonora²
¹Department of Psychology, University of Turin, Turin, Italy, ²Department of Medical Sciences, University of Turin, C/o Infectious diseases Unit, Amedeo di Savoia Hospital, Turin, Italy, ³Anlaids sezione Torino ODV, Italy
- P 148 PrEP is an obstacle race**
B. Mocci, A. Pontis, A. Loddo, S. Campus
LILA Cagliari, Cagliari Sardegna, Italy
- P 149 Promoting health through movement: fit-walking as an intervention to reduce cardiovascular and metabolic risk in people living with HIV/AIDS in Turin**
D. Penoncelli¹, G.C. Orofino², P.C. Durelli¹, M.N. Petrachi¹, M. Guastavigna², A. Ianniello³, G. Bo⁴, G.G. Parodi⁵, A. Pezzana, G. Caller²
¹S.C. Clinical Nutrition ASL Città di Torino, Italy, ²Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ³Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ⁴Medical Science Department, University of Turin, Turin, Italy, ⁵SSD Sports and Physical Exercise Medicine, ASL City of Turin, Turin, Italy
- P 150 Psychological outcomes and learning loss in students after the COVID-19 pandemic: findings from EuCARE's SCHOOL studies**
F. Bellerba¹, G. Doi¹, E. Tomezzoli¹, S. Raimondi¹, I. Cutica², D. Mazzone², I. Martins Alves³, A. Santos³, P.L. Lopalco⁴, V. Gabellone⁴, N. Bardeck⁵, G.H. Rubio Quintanares^{6,7}, C. Andreon¹, M. Mainetti¹, G. Tucci⁸, C. Mommo⁹, I. Fanti⁹, A. Abecasis³, R. Kaiser³, F. Incardona⁹, S. Gandini¹
¹European Institute of Oncology, Milan, Italy, ²University of Milan, Milan, Italy, ³Universidade Nova de Lisboa, Lisbon, Portugal, ⁴University of Salento, Lecce, Italy, ⁵University of Cologne, Cologne, Germany, ⁶Paul Ehrlich Institut, Langen, Germany, ⁷Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, ⁸Organising Bureau of European School Student Unions (OBESSU), Brussels, Belgium, ⁹EuResist Network, Rome, Italy
- P 151 School intervention for STIs prevention 2024-2025**
P.M. Testoni¹, C. Soligo¹, P.L. Vinti¹, F. Rossi¹, A. Bianchi¹, D. Zagato¹, M. Cernuschi^{1,2}
¹ASA Associazione Solidarietà AIDS ODV, Milano, Italy, ²San Raffaele Hospital, Milano, Italy

- P 152 Sexualized drug use and chemsex: exploring the link between addiction, sexual risk, and psychological well-being among MSM in Modena, Italy**
G. Cuomo¹, M. Menozzi¹, A. Cervo¹, L. Gozzi², C. Mussini²
¹Azienda Ospedaliero-Universitaria di Modena, Italy, ²Università degli Studi di Modena e Reggio Emilia, Italy
- P 153 Streethaart project: art as a tool to challenge Stigma and promote well-being among people living with HIV**
C. Oneto¹, V. Rizzo², M. Ricciardi³
¹Antinoo Arcigay Napoli, health department, Italy, ²Azienda Ospedali dei Colli, Cotugno, Quarta divisione U.O.C. Immunodeficienze e malattie infettive di genere, Italy, ³Università degli Studi di Salerno DISPS, Italy
- P 154 The impact of awareness-raising and screening initiatives on the migrant population living in Bergamo**
I. Mercurio¹, P. Meli¹, V. Gotti¹, D. Meli¹, E. Zanetti¹, C. Pellegris², R. Carissoli³, M. Rizzi⁴, M. Beretta⁴, M. Rizzi⁴
¹Cooperativa Don Giuseppe Monticelli, Italy, ²Associazione Comunità Emmaus OdV, Italy, ³Arcigay Bergamo Cives, Italy, ⁴Croce Rossa Italiana - Comitato di Bergamo, Italy
- P 155 The need and frequency of STI testing depends on the lifestyle of the people on PrEP. Data from the PrEP Point Plus (PPP) in Bologna**
S. Mattioli, S. Cecere
Plus aps/BLQ Checkpoint, Bologna, Italy
- P 156 Therapeutical group for chemsex addiction**
G. Fracca, M. Manfredini
ASA Associazione Solidarietà Aids ODV, Milan, Italy

STIs

- P 157 Doxycycline vs Penicillin for Late Latent Syphilis: Comparative Analysis of Efficacy data**
D. Farinacci¹, R.J. Steiner², P.F. Salvo², V. Iannone², G. Lenzi², C. De Vivo², G. Cucinotta², F. Lombardi¹, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Dipartimento di Scienze Mediche e Chirurgiche – UOC Malattie Infettive, Italy, ²Università Cattolica del Sacro Cuore, Roma, Dipartimento di Sicurezza e Bioetica sezione Malattie Infettive, Italy
- P 158 Dynamics of syphilis among HIV+: prevalence, incidence and serological results in 1669 PLWH, 2021-23, "D. Cotugno" hospital, Naples**
F.M. Fusco, N. Sangiovanni, R. Viglietti, O. Tambaro, F. Borrelli, C. Camaioni, N. Cuomo, R. Falanga, M.A. Carleo, V. Rizzo, P. Rosario, G. Palmiero, A. Guida, A. Gallicchio, A. Marocco, E. Manzillo, V. Esposito, V. Sangiovanni
Ospedale "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy
- P 159 Dynamics of vaccine-preventable anal HPV genotypes in individuals screened for HPV: a retrospective observational study**
A. Rizzo¹, D. Moschese², F. Salari¹, A. Giacomelli², S. Giubileo¹, M.V. Cossu², L. Morelli¹, C. Fusetti², D. Maddalena², G. Carrozzo², S. Lazzarin², S. Antinori^{2,3}, A. Dolci^{1,3}, A. Gori^{2,3}, A. Lombardi¹
¹Laboratory of Clinical Microbiology, Virology and Bioemergencies, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, ³Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- P 160 HPV and STIs screening in outpatient clinic. The multidisciplinary experience in AOUP- Pisa (preliminary data)**
L. Del Bono¹, L. Fralleone², T. Serra¹, I. Marchetti³, P. Mazzetti⁴, S. Esin⁵, V. Seccia⁶, A. Borghetti¹, R. Morganti⁷, G. Naccarato³, M. Falcone¹, M. Pistello⁴, C. Menconi²
¹Infectious Diseases Unit, Pisa University Hospital, University of Pisa, Italy, ²Proctology and Perineal Surgery Unit, Pisa University Hospital, University of Pisa, Italy, ³Pathological Anatomy I, Department of Oncology, Pisa University Hospital Pisa, Italy, ⁴Virology Unit, Pisa University Hospital, University of Pisa, Italy, ⁵Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Italy, ⁶Otorhinolaryngology, Audiology and Phoniatrics, Unit AOUP Pisa University, Italy, ⁷SOD Statistical Support for Clinical Studies, AOUP Pisa, Italy
- P 161 Impact of genotypic substitutions on treatment failure for Mycoplasma genitalium infection**
N.B. Bana^{1,2}, A. Nava³, D. Fanti³, C. Vismara³, G. Cavazza^{1,2}, E. Di Gennaro^{1,2}, F. Peracchi^{1,2}, L. Rezzonico¹, A. Mulè^{1,3}, L. Denti^{1,4}, M. Puoti^{1,2}, R. Rossetti¹
¹ASST Grande Ospedale Metropolitano Niguarda, UO Malattie Infettive, Milan, Italy, ²Università degli Studi di Milano Bicocca, Milan, Italy, ³ASST Grande Ospedale Metropolitano Niguarda, UO Microbiologia, Milan, Italy, ⁴Università degli Studi di Brescia, Italy, ⁵Università degli Studi di Sassari, Italy
- P 162 Investigation of Additional Risk Factors to Prioritize Anal Cancer Screening in MSM Living With HIV**
E.N. Cavallari¹, M. Ridolfi¹, F. Alessi¹, A. Lazzaro¹, C. Eberspacher², G. Zacco³, D. Mascagni², A. Pernazza⁴, O. Turriziani⁵, A. Pierangeli⁵, C.M. Mastroianni³, G. d'Ettore³
¹Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, ²Department of Surgical Sciences "Sapienza" University, Rome, Italy, ³Department of Public Health and Infectious Diseases "Sapienza" University, Rome, Italy, ⁴Department of Radiological Oncological and Pathological Sciences "Sapienza" University, Rome, Italy, ⁵Department of Molecular Sciences "Sapienza" University, Rome, Italy
- P 163 More Testing, More STDs? The paradox of follow-up in people on PrEP**
D. Farinacci¹, A. D'Angelillo², P.F. Salvo², V. Iannone², R.J. Steiner², G. Lenzi², C. De Vivo², G. Cucinotta², F. Lombardi¹, C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Dipartimento di Scienze Mediche e Chirurgiche – UOC Malattie Infettive, Italy, ²Università Cattolica del Sacro Cuore, Roma, Dipartimento di Sicurezza e Bioetica sezione Malattie Infettive, Italy
- P 164 Outcomes of Anal High Grade Dysplasia Treatment in MSM living with HIV and MSM living without HIV**
E.N. Cavallari¹, C. Eberspacher², A. Pernazza³, A. Lazzaro¹, F. Alessi¹, M. Ridolfi¹, A. Zingaropoli⁴, D. Mascagni², A. Pierangeli⁴, O. Turriziani⁵, C.M. Mastroianni³, G. d'Ettore³
¹Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, ²Department of Surgical Sciences "Sapienza" University, Rome, Italy, ³Department of Radiological Oncological and Pathological Sciences "Sapienza" University, Rome, Italy, ⁴Department of Molecular Medicine "Sapienza" University, Rome, Italy, ⁵Department of Public Health and Infectious Diseases "Sapienza" University, Rome, Italy
- P 165 Prevalence of syphilis among people living with HIV (PLWH), pre-exposure prophylaxis (PrEP) users and individuals screened for sexually transmitted disease (STD) attending Ferrara HIV/AIDS Section. A comparative observational study**
D. Segala¹, M. Chiapponi², R. Cultrera³
¹University of Ferrara-Az.Ospedaliera Universitaria di Ferrara, Ferrara, Italy, ²University of Ferrara, Ferrara, Italy, ³University of Ferrara-Azienda Unità Sanitaria Locale di Ferrara, Ferrara, Italy
- P 166 Scabies: not just a neglected disease, but a public health concern among key populations**
G. Lenzi¹, P.F. Salvo¹, V. Iannone¹, R.J. Steiner¹, F. Lombardi^{1,2}, A. Carbone¹, G. Cucinotta¹, C. De Vivo¹, D. Farinacci², E. Visconti², G. Baldin², C. Torti^{1,2}, S. Di Giambenedetto^{1,2}
¹Dipartimento di sicurezza e bioetica, sezione malattie infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di scienze mediche e chirurgiche, UOC malattie infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- P 167 Sexually transmitted infections, condom use and sexual behaviors in women: the WomanIST experience in an Italian reference center**
G. Canavesi^{1,2}, D. Bernacchia¹, G. Pagani¹, L. Pezzati¹, F. Bassani^{1,2}, M. Rigoni^{1,2}, M. Ticozzelli^{1,2}, C. Cassani³, S. Rusconi^{1,2}
¹Infectious Diseases Unit, ASST Ovest Milanese, Legnano (MI), Italy, ²DIBC, University of Milan, Milan, Italy, ³Trial Office, ASST Ovest Milanese, Legnano (MI), Italy

Vaccines

- P 168 A Rapid Fluorometric Approach for Evaluating ADCC Activity Against Different forms of HIV-1 Env Protein**
M. Martino¹, E. Torreggiani¹, B. Dallan¹, A. Tripiciano², V. Francavilla², F. Mancini², M. Campagna², O. Picconi², C. Sgadari², D. Proietto¹, M. De Laurentis¹, E. Tassani¹, A. Caputo¹, R. Gavioli¹, A. Cafaro², B. Ensoli², F. Nicoli¹
¹University of Ferrara, Ferrara, Italy, ²National HIV/AIDS Research Center (CNAIDS), Istituto Superiore di Sanità (ISS), Rome, Italy
- P 169 Comparison of STI burden and its predictors in people diagnosed with mpox or vaccinated with MVA-BN**
A. Giacinta¹, A. Caioli², G. Micheli³, D. Vincenti³, R. Esvan¹, G. Matusali¹, J. Paulicelli¹, V. Barchi¹, B. Bartolini³, R. Schiavone¹, A. Oliva¹, P. Piselli², I. Abbate⁴, C. Fontana³, E. Girardi⁵, F. Maggi⁴, M. Farinella⁶, A. Antinori¹, V. Mazzotta¹
¹Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Clinical Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ³Laboratory of Microbiology and Biobank, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁴Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁵Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁶Circolo di Cultura Omosessuale "Mario Mieli", Roma, Italy
- P 170 Current adherence and vaccine hesitancy to Herpes Zoster vaccination in northern Italy: a cumulative trend analysis at an HIV clinical center in Turin**
M. Guastavigna¹, G. Orofino¹, G. Bo², A. Ianniello³, F. Mollo⁴, C. Bobba², M. Quaranta², G. Calleri¹
¹Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, ²Medical Science Department, University of Turin, Turin, Italy, ³Laboratory of Microbiology and Virology, Amedeo Di Savoia Hospital, ASL Città di Torino, Turin, Italy, ⁴Pharmacy Department ASL Città di Torino, Italy
- P 171 Evaluating the long-term antibody response of MVA-BN in people living with HIV (PLWH): a two-year monocentric follow-up study**
P.F. Salvo¹, F. Lombardi^{1,2}, V. Iannone¹, G. Lenzi¹, R.J. Steiner¹, A. Carbone¹, D. Farinacci², E. Visconti², C. Torti^{1,2}, S. Di Giambenedetto^{1,2}, G. Balzin²
¹Dipartimento di Sicurezza e Bioetica, Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- P 172 Evaluation of virologic rebounds in people living with HIV (PLWH) after receiving MVA-BN vaccination for mpox**
P.F. Salvo¹, F. Lombardi^{1,2}, V. Campolattano¹, V. Iannone¹, A. Carbone¹, G. Lenzi¹, R.J. Steiner¹, S. Di Giambenedetto^{1,2}, C. Torti^{1,2}, G. Balzin¹
¹Dipartimento di Sicurezza e Bioetica, Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- P 173 Hepatitis B vaccine response in people living with HIV and with isolated anti-HBc serological profile: a retrospective study**
E. Guarise², P.M. Postma², L. Taramasso¹, M. Nofri¹, S. Cardaci¹, E. Massaro³, A. Di Biagio^{1,2}, L. Sticchi^{1,2}
¹IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ²Department of Health Sciences, University of Genoa, Italy, ³ASL3 Healthcare System of the Liguria Region, Genoa, Italy
- P 174 Multi-cytokine assessment of T-cell responses to Varicella Zoster Virus glycoprotein E after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatments**
L. Benedetti¹, I. Fato¹, L. Coppola^{1,2}, G. Montagnari¹, D. Landi², F. Napoli², G. Alessio¹, A. Di Lorenzo^{1,2}, A.C. Epifani¹, M.A. Zingaropoli³, P. Pasculli^{3,4}, C.M. Mastroianni^{3,4}, M.R. Ciardi^{3,4}, G.A. Marfia^{1,2}, L. Sarmati^{1,2}, M. Iannetta^{1,2}
¹"Tor Vergata" University of Rome; Rome, Italy, ²"Policlinico Tor Vergata"; Rome, Italy, ³"Sapienza" University of Rome; Rome, Italy, ⁴"Policlinico Umberto I"; Rome, Italy
- P 175 The impact of vaccination on presentation and clinical outcomes in patients hospitalized for COVID-19 Pneumonia in a Lombardy Tertiary Care Center**
N. Gemignani¹, S. Pontiggia¹, F. Branda², M. Bottanelli¹, L. Bradanini¹, A. Chiesa¹, F. Conti¹, C. Molteni¹, V. Morena¹, A. Pandolfo¹, S. Volpi¹, G. Valsecchi¹, S. Piconi¹
¹Infectious Diseases Unit, "Alessandro Manzoni" Hospital, ASST-Lecco, Lecco, Italy, ²Faculty of Medicine and Surgery, Campus Bio-medico University Rome, Rome, Italy

Virology and Pharmacology

- P 176 Evaluation of AD4SEQ HIV-1 Whole Genome for Drug Resistance Testing**
F. Stefanelli¹, N. Randazzo¹, G. Guarona², N. Nigro¹, S. Varesano¹, G. Massobrio³, A. Di Biagio³, B. Bruzzone¹
¹Hygiene Unit, IRCCS San Martino Hospital, Genoa, Italy, ²Department of Health Science (DISSAL), University of Genoa, Genoa, Italy, ³Infectious Disease, Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
- P 177 Exploring the relationship between HIV-DNA load and archived antiretroviral drug resistance in treated individuals with suppressed or low-level viremia**
D. Armenia¹, A. Bertoli^{2,3}, L. Piermatteo⁴, G. Torre², L. Carioti³, P. Paba², M. Compagno⁵, E. Teti⁵, V. Malagnino^{5,6}, M. Iannetta^{5,6}, A.M. Geretti⁶, L. Sarmati^{5,6}, F. Ceccherini-Silberstein³, M.M. Santoro³
¹Saint Camillus International University of Health Sciences, Rome, Italy, ²Virology Unit, Polyclinic of "Tor Vergata", Rome, Italy, ³Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ⁴Department of Biology, University of Rome "Tor Vergata", Rome, Italy, ⁵Infectious Diseases Unit, Polyclinic of "Tor Vergata", Rome, Italy, ⁶Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy
- P 178 HIV-1 Whole Genome Sequencing: comparative analysis of Illumina and Nanopore technologies**
F. Stefanelli¹, N. Randazzo¹, V. Ricucci¹, A. Limongelli², L. Taramasso², A. Orsi³, B. Bruzzone¹
¹Hygiene Unit, IRCCS San Martino Hospital, Genoa, Italy, ²Infectious Disease, Department of Health Science (DISSAL), University of Genoa, Genoa, Italy, ³Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
- P 179 HIV-DNA Analysis in PLWH with a complex treatment history: correlation with immunological and virological parameters**
R. Campagna¹, P. Roberto¹, L. Cinti¹, M.A. Zingaropoli², M. Antonacci³, G. Antonelli¹, I. Mezzaroma³, O. Turriziani¹
¹Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, ²Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy, ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
- P 180 In vitro characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degradator of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2**
M.G. Liturri¹, A. Bergna¹, A. Lai¹, C. Della Ventura¹, A. Gabrieli¹, I. Seravalli¹, S. Ciofi-Baffoni¹, E. Lenci², A. Trabocchi², S. Rusconi¹
¹Infectious Diseases Research Lab, DIBIC - University of Milan, Milan, Italy, ²Department of Chemistry "Ugo Schiff" (DICUS) - University of Florence, Florence, Italy
- P 181 Injection site pain and cabotegravir/rilpivirine trough plasma concentration in people with HIV**
C. Candela¹, E. Sabeta², P. Reali¹, A. Mattino², M. Garcia Martearena³, R. Lolatto¹, M. Locatelli², S. Nozza^{1,3}, A. Castagna^{1,3}, C. Muccini¹
¹Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Laboratory Medicine Service, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy

HIV e STI

- CC 4 A case of secondary cerebrospinal fluid HIV escape in a patient on long-acting cabotegravir/rilpivirine. A Case of Secondary Cerebrospinal Fluid HIV Escape in a Patient on Long-acting Cabotegravir/Rilpivirine**
L. Trentini¹, C. Ghione², S. Audagnotto¹, E. Vuaran², M. Tettoni¹, T. Alice³, A. Calcagno², S. Bonora²
¹Amedeo di Savoia Hospital, Infectious Diseases Unit, Department of Medical Sciences, University of Turin, Turin, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ³Laboratory of Microbiology and Virology, Ospedale Amedeo di Savoia, ASL 'Città di Torino', Torino, Italy
- CC 5 A peculiar case of persistent CPK elevation in a newly acutely diagnosed person with HIV**
L. Calandrino¹, S. Marinello¹, L. Dal Bello², E. Pegoraro², M. Mazzitelli¹, A. Cattelan¹
¹Infectious and Tropical Diseases Unit, Padova University Hospital, Padova, Italy, ²Department of Neurosciences DNS, Padova University Hospital, Padova, Italy
- CC 6 A rare case of Wells syndrome diagnosis in human immunodeficiency virus infection**
F. Todisco, A. Poma, D. Marzolla, I. Massari, M. D'Errico, G. Motta, C. Bertuzzi, V. Gaspari, A. Zuppiroli, L. Calza, P. Viale
Alma Mater Studiorum, Bologna, Policlinico Sant'Orsola Malpighi, Italy
- CC 7 Acute cholestatic hepatitis as the presenting manifestation of Syphilis in an HIV-infected patient**
E. Morelli^{1,2}, M. Sambo^{1,2}, F. Panza^{1,2}, M. Crispo^{1,2}, A. Bailoni^{1,2}, F. Montagnani^{1,2}, M. Tumbarello^{1,2}, M. Fabbiani^{1,2}
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy
- CC 8 Acute Polyradiculoneuritis in Advanced HIV: A Case of Immune Dysregulation Following ART Discontinuation**
V. Speciale¹, A. Carrara¹, V. Bleve¹, L. Napoleoni³, F. Talamoni¹, L. Bresciani¹, S. Di Bari¹, A.M. Ialungo², V. Filippi², G. Fiorentino², A. Negro³, C. Pasquazzi¹, V. Kelmendi¹, D. Bello¹, M. Lichtner¹
¹UOC Infectious Diseases, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy, ²UOC Infectious Diseases, Sant'Andrea University Hospital, Rome, Italy, ³UOC Internal Medicine, Sant'Andrea University Hospital, Rome, Italy
- CC 9 Atypical dermatological manifestations in advanced HIV: diagnostic challenges and clinical considerations**
F. Cesanelli¹, I. Scarvaglieri¹, G. Tiecco¹, I. Ghini², D. Minisci¹, C. Davoli¹, S. Rapino¹, E. Focà¹, F. Castelli¹, E. Quiros-Roldan¹
¹Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ²Department of Pathology, ASST Spedali Civili di Brescia, Brescia, Italy
- CC 10 Beneficial switch to long-acting injectable CAB/RPV for a woman living with HIV struggling with daily oral medication adherence: a case report**
A. Celsi, L. Pagnucco, G. Sangaletti, A. Arcuri, C. Giuliani, M. Gerola, R. Gulminetti
Infectious Diseases Unit UOC, Department of Medical Science; Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
- CC 11 Breakthrough HIV infection in a pre-exposure prophylaxis (PrEP) user: the role of the signal-to-cutoff (S/CO) ratio in early diagnosis**
I. De Angelis, M. Maiorano, L. Bortolani, M. Ridolfi, F. Alessi, A. Lazzaro, E.N. Cavallari, C.M. Mastroianni, G. d'Ettorre
Policlinico Umberto I - Sapienza Università di Roma, Rome, Italy
- CC 12 Breakthrough Monkeypox Infection in a Fully Vaccinated Individual: A Case Report and Clinical Insights**
M.S. Paternò Raddusa¹, R. Bruno², A. Marino², F. Tramuto³, N. Villari², B. Bellocchi², A. Franzò¹, C. Gullotta¹, G. Bruno¹, E. Pistrà², G. Pellicanò¹, B.M. Cesia², B.S. Cacopardo², G. Nunnari²
¹University of Messina, Unit of Infectious disease, Messina, Italy, ²Unit of Infectious Disease University of Catania A.R.N.A.S. Garibaldi, Catania, Italy, ³Policlinico University Hospital of Palermo "Paolo Giaccone", Palermo, Italy
- CC 13 CMV retinitis in HIV patient with good compliance to ART: case report**
G. Doro², S. Marinello¹, L. Sasseti¹, M. Brundu¹, C. Casarin², A. Leonardi¹, A. Cattelan^{1,2}
¹Department of Infectious and Tropical Diseases AOPD, Padua, Italy, ²School of Specialization in Infectious and Tropical Diseases University of Padua, Italy
- CC 14 Disseminated Cryptococcosis in an HIV-Positive Patient: A Case Report Highlighting Diagnostic Challenges and Therapeutic Approaches**
D. Veramonti
S. Maria della Misericordia, Perugia, Italy
- CC 15 Dolutegravir/lamivudine combination therapy in an antiretroviral-naïve pregnant woman living with HIV. Time to act?**
M. Lanzafame¹, A. Delama¹, G. Mori¹, A. Castelli¹, E. Lattuada¹, S. Vento²
¹Unit of Infectious Diseases, Ospedale Santa Chiara, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy, ²Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia
- CC 16 HPV-related anal squamous cell carcinoma in MSM- HIV patient: A case report**
R. Ferri, M. Conserva, C. Ucciferri, J. Vecchiet, K. Falasca
Università G. D'Annunzio, Chieti, Italy
- CC 17 Impact of HIV-1 Integrasi N155H and K156N mutation in a Clinical Isolate**
V. di Biase, M. Di Pietrantonio, L. Falconi Di Francesco, A. D'Alonzo
Infectious Disease Unit "G. Mazzini" Hospital, ASL of Teramo, Italy
- CC 18 Invasive infection caused by Talaromyces marneffei in a patient with HIV infection: a case report**
C. Rovelli¹, M.L. Balsamo¹, P.A. Grossi^{1,2}
¹Clinica di Malattie Infettive e Tropicali, Ospedale di Circolo – ASST Sette Laghi, Varese, Italy, ²Università degli Studi dell'Insubria, Varese, Italy
- CC 19 Lenacapavir as rescue therapy in a case of multidrug-resistant HIV-1 infection and previous virological failure with different antiretroviral regimens**
A. Gallicchio¹, A. Bianchi¹, V. Gentile¹, A. Marocco¹, M. Sardo¹, N. Cuomo², E. Manzillo¹
¹Infectious diseases of the immunocompromised host and immigration Unit, AO dei Colli Cotugno, Naples, Italy, ²Microbiology and virology Unit, AO dei Colli Cotugno, Naples, Italy
- CC 20 Opportunistic sexually transmitted infection in an immunocompromised patient with Crohn's Disease treated with adalimumab: a case report**
M. Rigoni, D. Bernacchia, G. Canavesi, C. Pavia, L. Vismara, P. Mirri, S. Rusconi, G. Pagani
Ospedale Nuovo di Legnano, ASST Ovest Milanese, Legnano, Italy
- CC 21 PML-IRIS: more shadows than lights—an ongoing challenge. Case report of PML-IRIS in an HIV patient and considerations on possible diagnostic and therapeutic strategies**
E.A. Gabor, G. Magagna, M. Donth, A. Scarati, G. Missale
University of Parma, Italy
- CC 22 Pulmonary nocardiosis in an AIDS-presenter patient: diagnostic and treatment challenges**
M. Pieruzzi¹, I. Faggion¹, A. Mainini¹, D. Moschese¹, A. Gori^{1,2}, S. Antinori^{1,2}, A. Giacomelli^{1,2}
¹Infectious Diseases Department, ASST Fatebenefratelli Sacco, Milan, Italy, ²Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy

- CC 23 Relapse of exceptional weight gain with CAB+RPV in former treatment with second generation integrase strand transfer inhibitors**
G. Bozzi¹, A. Pastena^{1,2}, A. Liparoti^{1,2}, V. Castelli¹, B. Mariani¹, A. Muscatello¹, A. Bandera^{1,2}
¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²UNIMI Università degli Studi di Milano, Milan, Italy
- CC 24 Successful Implementation of Long-Acting Antiretroviral Therapy in a Heavily Treatment-Experienced Patient with Vertical HIV Infection**
D. Piccioni¹, G. Maffei¹, F. Mollo², F. Donato¹, P. Crosasso¹, F. Barrera³, M. Ferrara³, L. Trentini³
¹S.D.S. Infectious Diseases Hospital Pharmacy, Amedeo di Savoia Hospital, Turin, Italy, ²Department of Drug Science and Technology, University of Turin, Turin, Italy, ³Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy
- CC 25 Switch from Ibalizumab to Lenacapavir in a rescue regimen for an MDR HIV patient**
S. Martini¹, N. Cuomo², A. Russo¹, R. Palladino¹, A. Raddi², M. Pisaturo¹, N. Coppola¹
¹UOC Malattie infettive Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²AORN dei COLLI, Unità di Malattie Infettive ospedale Cotugno, Napoli, Italy
- CC 26 The challenge of leishmaniasis in immunological non responders among people living with HIV**
A. Gallicchio, A. Bianchi, V. Gentile, A. Lanzardo, A. Marocco, M. Sardo, E. Manzillo
Infectious diseases of immunocompromised host and immigration Unit, AO dei colli Cotugno, Naples, Italy
- CC 27 The potential benefits of new pre-exposure prophylaxis (PrEP) regimens: a clinical case from the past**
N. Braccialarghe¹, R.A. Cavasio¹, D. Zaçe¹, A. Cekrezi¹, F. Nina¹, D. Pucci¹, E. Teti², L. Campogiani¹, L. Coppola¹, M. Iannetta^{1,2}, L. Sarmati^{1,2}
¹Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases Unit, Fondazione Policlinico Tor Vergata, Rome, Italy
- CC 28 Virological failure after two years of cabotegravir + rilpivirine long-acting treatment: case report**
A. Narducci, F.R.P. Ieva, R. Papale, C. Grillo, M. Niglio, F. De Gregorio, S. Ferrara, S. Lo Caputo
Division of Infectious Disease, AOU Policlinico di Foggia, Italy

Viral infections in the immunocompromised host

- CC 29 A case of atypical Pneumonia**
C. di Castri, G. Missale, C. Lanzillotta, F.S. Soave, M. Labruzzo, S. Sartori, F. Carli
U.O Malattie Infettive ed Epatologia, AOU Parma, Azienda Ospedaliera Universitaria di Parma, Italy
- CC 30 A case of Varicella Zoster Virus (VZV) encephalitis in a young immune-competent woman after mRNA COVID-19 vaccine**
R. Ligresti^{1,2}, C. Aloise², L. Gazzola², C. Tincati², G. Marchetti²
¹Università degli studi di Milano, Ospedale Luigi Sacco, Milano, Italy, ²Università degli studi di Milano, Ospedale San Paolo, Milano, Italy
- CC 31 Fulminant hepatitis due to Enterovirus systemic infection in a pediatric patient**
S. Garattini^{1,2}, L. Romani¹, G. Lorenzetti¹, M. Di Giuseppe¹, L. Cursi¹, M. De Luca¹, S. Bernardi¹, S. Chiurchiù¹, S. Mercadante¹, C. Tripiciano¹, A. Krzysztofak², F.I. Calò Carducci¹, L. Lancella¹
¹Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Università La Sapienza, Roma, Italy
- CC 32 HHV-6 DNA in cerebrospinal fluid of HIV patients with unrecognized non-Hodgkin cerebral lymphoma: True encephalitis or a diagnostic red herring? A case report**
A. Arcuri, L. Pagnucco, C. Giuliani, G. Sangaletti, A. Celsi, M. Gerola, R. Gulminetti
Infectious Diseases Unit UOC, Department of Medical Science, Pavia, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
- CC 33 Onset of Kaposi Sarcoma in a PLWH with undetectable HIV-RNA and high CD4+ count: a rare but possible event**
G. Picchi¹, A. Emiliozzi¹, R. Preziosi¹, F. Primi², S. Farinelli¹
¹Infectious Disease Department, S. Rosa Belcolle Hospital, Viterbo Italy, ²Oncology Department, S. Rosa Belcolle Hospital, Viterbo Italy
- CC 34 Safety and long-term immunological and virological outcomes of Lenacapavir plus Fostemsavir-based OBR in the treatment of a case of MDR HIV infection**
E. Zappulo¹, S. Mercinelli¹, G. Di Filippo¹, M. Cotugno¹, N. Cuomo², C.F. Perno^{3,4}, I. Gentile¹
¹Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University of Naples "Federico II", Naples, Italy, ²Microbiology and Virology Unit, Cotugno Hospital - Naples, Italy, ³Microbiology and Diagnostic Immunology, Bambino Gesù Paediatric Hospital - Rome, Italy, ⁴UniCamillus - Rome, Italy
- CC 35 The complexities of treating Visceral Leishmaniasis in vulnerable immunocompromised patients**
S. Vita, M.V. Tomassi, A. D'abramo, A. Corpolongo, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastri
National Institute of Infectious Diseases Lazzaro Spallanzani, Rome, Italy
- CC 36 Ventriculitis in AIDS-presenter patient: diagnostic dilemma between toxoplasmosis and miliary tuberculosis**
M. Gerola, L. Pagnucco, G. Sangaletti, C. Giuliani, A. Celsi, A. Arcuri, R. Gulminetti
Infectious Diseases Unit UOC, Department of Medical Science, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy



No boundaries in Infection Research and Care

GENERAL INFORMATION



Congress Venue

PADOVA CONGRESS

Via N. Tommaseo, 59
35131 Padova



Conference registration

To attend the Conference, you must submit the registration form through **MyICAR** on the Conference website www.icar2025.it. After completing the form, you will receive an email with a link to confirm the activation of your personal account.

Official languages

Italian and English. No simultaneous translation provided.

Press Office

Diessecom - Daniel Della Seta, diessecom@gmail.com - Daniele Toscano, studiodiessecomdue@gmail.com

Official Journal of the Conference

Sexually Transmitted Infections - <https://sti.bmj.com>

Pre-Conference advanced Courses and Congress dates

Pre-Conference advanced courses:

● **Wednesday, May 21** from 14.00 to 16.30

Conference:

● **Wednesday, May 21** from 14.00 to 20.10

● **Thursday, May 22** from 09.00 to 17.30

● **Friday, May 23** from 09.00 to 16.30

Exhibition Area opening times

● **Wednesday, May 21** from 15.00 to 20.45

● **Thursday, May 22** from 09.00 to 18.30

● **Friday, May 23** from 09.00 to 16.30

Conference Secretariat opening times

● **Wednesday, May 21** from 10.30 to 20.45

● **Thursday, May 22** from 08.00 to 19.30

● **Friday, May 23** from 08.00 to 17.00

Lunches

● **Thursday, May 22** from 12.30 to 14.30

● **Friday, May 23** from 12.30 to 14.30

In dedicated areas inside the **Padova Congress Centre**.

Instructions for Speakers and Presenting Authors

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Centre Room at least **2 hours before the session**. At the Slide Centre Room, Speakers will have the possibility of:

- Reviewing power point presentations
- Last minute changes of power point presentations
- Being supported by technical staff
- Uploading power point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

A slides template for Speakers' presentations is available for download on the Conference website **www.icar2025.it**

Instructions for Oral Sessions

Oral Communications

Time allotted for each oral presentation is 10 minutes + 2 minutes for discussion. A maximum of 8/10 slides are required, plus the additional slide with the "Declaration of Potential Conflicts of Interest".

Short Communications

Time allotted for each oral presentation is 7 minutes + 2 minutes for discussion. A maximum of 6/7 slides are required, plus the additional slide with the "Declaration of Potential Conflicts of Interest".

Grand Round Clinical Cases

Time allotted for each oral presentation is 20 minutes including discussion. A maximum of 7 slides are required in order to allow more time for discussion. An additional slide with the "Declaration of Potential Conflicts of Interest" is also required.



The ICAR Scientific Committee firmly believes that language is a powerful tool in shaping beliefs and influencing behaviours, particularly in the context of addressing the stigma surrounding chronic infections such as HIV and viral hepatitis. We urge conference attendees to prioritize person-centred language and be mindful of how their language and materials align with this principle. To assist in this effort, we recommend the adoption of UNAIDS-endorsed terminology, such as referring to people as "living with HIV" rather than "HIV-infected". Together, let us promote inclusivity and respect for all individuals affected by HIV and other chronic infections.

Digital Posters Exhibition and Poster Viewing

All posters can be viewed through dedicated multimedia areas, on the third floor of the Congress Centre, during all Conference days. On 22 and 23 May, from 13.20 to 14.00 there will be Poster Viewing with the Authors, as follows:

Multimedia area 1

- Clinical HIV
- Hepatitis and Liver Diseases

Multimedia area 2

- HIV: Antiretroviral therapy
- Infections in the Immunocompromised Host

Multimedia area 3

- Epidemiology
- Social Science, PROs

Multimedia area 4

- Ageing
- Basic Science - Immunology
- PrEP
- STIs
- Vaccines
- Virology and Pharmacology



Presenting Authors are requested not to exceed 5 minutes for the presentation of their work, to give everyone the opportunity to present their Poster. **Don't forget to pick up the USB poster pendrive at the Gilead Sciences booth!**

With an unrestricted educational grant from Gilead Sciences

Digital Abstract Book

Available on the official ICAR website www.icar2025.it. The Abstract Book contains all accepted abstracts and clinical cases.

With an unrestricted educational grant from Gilead Sciences



Quick test for HIV, HBV, HCV and Syphilis

● Padova, Lungargine del Piovego

Wednesday, May 21	from 18.30 to 24.00
Thursday, May 22	from 18.30 to 23.00
Friday, May 23	from 18.30 to 23.00

Healthcare personnel will perform free rapid testing for HIV, HBV, HCV and Syphilis at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.

*Promoted by Azienda Ospedaliera di Padova, Croce Rossa Italiana, Fondazione Carlo Foresta.
With the endorsement of Città di Padova. In collaboration with Abbott and Nal von Minden*



Official events

RaccontART - 11° Edition

Presentation of the finalist works and Winners'Awards:

● Sala Plenaria Mantegna, Padova Congress

Wednesday, May 21	from 14.00 to 16.30
-------------------	---------------------

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS and STIs through various forms of expression. The winners will be awarded by the Jury composed of leading representatives of the National cultural, scientific and technical world.



Exhibition "Medici con l'Africa CUAMM"

● Padova Congress, Third Floor

HIV in Africa is still a major health emergency: millions of people are living with the virus, but only a fraction have access to necessary treatment. Through images, testimonies and data, this exhibition tells the story of Doctors with Africa CUAMM's work in the fight against HIV/AIDS, from access to medicines to prevention strategies, from support for pregnant women to the active involvement of local communities. A touching and real journey that takes us to the villages and hospitals of sub-Saharan Africa, where every day prevention and treatment make the difference between life and death. Discover the stories of those who have decided not to give up, those who are fighting for a future without stigma and for a basic right: HEALTH FOR ALL.



Special Awards

TRIS Awards

ICAR and SIMIT will announce the **"TRIS Awards"**, n. 3 prizes for the best manuscripts published between January and December 2024 in international indexed scientific journals on HIV, Sexually Transmitted Infections and other viral infections in the following areas:

- **N. 1 Award** of € 3.000,00 for the best **Epidemiology and Social Science** manuscript
- **N. 1 Award** of € 3.000,00 for the best **Basic Science** manuscript
- **N. 1 Award** of € 3.000,00 for the best **Clinical Science** manuscript

Winners will be announced during the **"TRIS Awards" Session** on Thursday, **22 May 2025**, from **13.30** to **14.00** in Sala Plenaria Mantegna by ICAR President *Prof. Antonella Castagna*.



ICAR 2025 Scientific Committee Awards

The 17th ICAR Chairs and Scientific Secretariat will award prizes for the three best abstracts submitted to ICAR 2025:

- **N. 1 Award** of € 1.000,00 for the best **Basic Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Clinical Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Social Science** abstract

Winners will be announced during the **ICAR 2025 Awards and Closing remarks Session** in Sala Plenaria Mantegna on Friday, **23 May 2025**, from **16.10** to **16.30**.



The Editorial Prize at ICAR 2025

Sexually Transmitted Infections journal (BMJ Group)

Chaired by the Editor-in-Chief, *Professor Anna Maria Geretti*, a panel of four judges will award the **STI journal Editorial Prize** to the oral presentation that best reflects the scope, aims and themes of the journal.

The winner will receive a 1-year mentored position as an editorial member of Perspectives, a regular journal section, providing an excellent introduction to editorial responsibilities.

The prize will be presented during the **"ICAR 2025 Awards and Closing Remarks"** session on Friday, **23 May 2025**, from **16.10** to **16.30** (Sala Plenaria Mantegna) by *Anna Maria Geretti*.

Sexually Transmitted Infections



ICAR for Participants

Community Village

A specific area of the **Congress Centre** dedicated to the Community Village: a meeting point for all participants to visit the booths of patient associations and meet the Community activists. On the first floor of the Congress Centre.



Nice to ICAR YOU

The ICAR 2025 welcome point, near the Secretariat at Ground Floor.



POSTER 4 YOU

A free service for selected posters' Authors to create their own posters and record their comments. **ICAR Poster 4 You USB pendrive** can be requested showing the coupon at the Gilead Sciences booth.


With an unrestricted educational grant from Gilead Sciences



ICAR Web Repository

After the Congress, on the official website **www.icar2025.it** you will find: ICAR 2025 web repository of abstracts, presentations, oral communications, short communications, posters, clinical cases, podcasts and photo gallery.

With an unrestricted educational grant from ViiV Healthcare



ICAR SOCIAL

Direct links to ICAR 2025 Social.
Stay connect #ICAR2025

www.instagram.com/ICARcongress
www.twitter.com/ICARcongress
www.facebook.com/ICARcongress



Participants are hereby informed that in some spaces where the conference and ancillary activities will take place, photographs/video footage intended for online publication may be taken; participants will be notified through dedicated signage.

Registration fees

Pre-Conference advanced Courses

Free of charge (registrations available on a "first come, first served" basis). Included congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), CME registration and documentation.

Conference registration fees (22% VAT not included)

Over 35 years of age Physicians, Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 850,00
Under 35 years of age Physicians, Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 450,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free
Exhibitors	€ 350,00

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), coffee break, lunches at the congress on 22 and 23 May, CME registration, conference USB poster, Welcome Cocktail on the evening of May 22th.

Daily Conference registration fees (22% VAT not included)

Over 35 years of age Physicians, Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 400,00
Under 35 years of age Physicians, Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 250,00
Students/PhD and Post-graduate medical trainees	Free

The registration fee includes: attendance at the day's scientific session, congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), coffee break and lunch of the day, CME registration and documentation, Conference USB poster.

CME Accreditation

Conference

The 17th ICAR Conference has been accredited to the Italian Ministry of Health for 11,20 CME Credits.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professional figures
Wednesday, May 21 150-444841	2,1	Physicians: Allergology and Clinical Immunology; Anesthesia and Resuscitation; Clinical Biochemistry; Continuity of Care; Dermatology and Venereology; Hospital Presidium Medical Management; Hematology; Endocrinology; Epidemiology; Pharmacology and Clinical Toxicology; Gastroenterology; Medical Genetics; Geriatrics; Hygiene, Epidemiology and Public Health; Medical Genetics Laboratory; Infectious Diseases; Metabolic Diseases and Diabetology; Community Medicine; Acceptance and Emergency Medicine and Surgery; Physical Medicine and Rehabilitation; General Medicine (Family Physicians); Internal Medicine; Microbiology and Virology; Nephrology; Neurology; Oncology; Organization of Primary Health Care Services; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology); Psychiatry; Psychotherapy. Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Thursday, May 22 150-444908	4,9	
Friday, May 23 150-444962	4,2	

Pre-Conference advanced courses

The 17th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

ID ECM Number	Credits	Professional figures
Opportunistic Infections in HIV: Current Insights and Evolving Strategies 150-441399	2	Physicians: Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
From Data to Care: Redefining Patient-Reported Outcomes to Measure Well-Being 150-441440	2	Physicians: Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Navigating the complexities: clinical and diagnostic challenges in HTE 150-441459	2	Physicians: Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory
Stats don't lie! How to believe in numbers 150-441472	2	Physicians: Allergology and Clinical Immunology; Dermatology and Venereology; Pharmacology and Clinical Toxicology; Gastroenterology; Hygiene, Epidemiology and Public Health; Infectious Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology). Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Psychologist (Psychology and Psychotherapy), Medical Technician of Biomedical Laboratory

CME Accreditation

Obtaining credits

Participants

To obtain credits, registered participants are required to:

- Validate attendance by reading the bar-code placed on the badge, every day, before the start of the scientific work and in the evening, at the end of the scientific work
- Wear the identification badge during working sessions
- Fill in the assessment and approval questionnaires for each individual conference day within the **MyICAR reserved area** in the official website **www.icar2025.it**

Speakers

Speakers will be given 1 credit for each 20 minutes consecutive teaching.

Moderators will be given 1 credit for each moderation session.

Speakers, moderators and discussants can decide to obtain credits as participants (see participants).

Attendance Tracking

Attendance of individual participants will be measured **by reading the bar-code** placed on the badge at the beginning and end of the scientific papers or each individual course and filling out the **online** evaluation questionnaire (**only one attempt will be allowed**) and approval rating, within one's **MyICAR** restricted area. The questionnaire for each work day will be available at the end of each day and will remain available for the following three days.

CME certification

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

SVC Assobiomedica

The Pre-Conference advanced courses and the Congress were evaluated as **compliant with the Code of Ethics** by the **Conference Evaluation System** (SVC) of Assobiomedica (Event Code: 2024-0409182232).


CONGRESS MAP

17° CONGRESSO NAZIONALE
Italian Conference on **AIDS** and **Antiviral Research**

GROUND FLOOR



FIRST FLOOR



EXHIBITION AREA

- | | |
|----|---|
| 1 | |
| 2 | GILEAD
Creating Possible |
| 3 | MSD |
| 4 | TILLOTTS PHARMA
ZERA GROUP |
| 5 | ReAdfiles Fondazione Icona
ITALIA FONDATIONE ANTIVIRALE |
| | |
| A | |
| B | GILEAD
Creating Possible |
| C | |
| D | GILEAD
Creating Possible |
| | |
| 34 | nal
von minden |
| 35 | Abbott |
| 36 | |

MULTIMEDIA AREAS

AREAS 1-2-3-4
FOR POSTER EXHIBITION AND
VIEWING WITH AUTHORS

YOU CAN ALSO FIND:

- ABSTRACT AND POSTER COLLECTION
- SCIENTIFIC PROGRAMME
- PROGRAM AT A GLANCE
- PHOTO GALLERY




COMMUNITY VILLAGE

- | | | | |
|----|---------------|----|-------------------|
| 18 | CICA | 25 | ARCOBALENO |
| 19 | VILLA MARAINI | 26 | LILA |
| 20 | CUAMM | 27 | MARIO MIELI |
| 21 | EPAC | 28 | NPS |
| 22 | FTC | 29 | MILANO CHECKPOINT |
| 23 | FTC | 30 | ASA |
| 24 | PLUS | 31 | ANLAIDS |
| | | 32 | ARCIGAY |



THIRD FLOOR





Padova CENTRO CONGRESSI, PADOVA CONGRESS

ICAR 17°
CONGRESSO
NAZIONALE
Italian Conference
on AIDS and Antiviral
Research

No boundaries in Infection Research and Care

effetti

THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat, the ICAR Government Bodies and the CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

PLATINUM



GOLD



SILVER



OTHERS



Seguici su



www.icar2025.it

